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Background: Interferon gamma release assays (IGRAs) are blood tests recommended for the diagnosis of
tuberculosis (TB) infection. There is currently uncertainty about the role and clinical utility of IGRAs in the
diagnostic workup of suspected active TB in routine NHS clinical practice.
Objectives: To compare the diagnostic accuracy and cost-effectiveness of T-SPOT.TB® (Oxford Immunotec,
Abingdon, UK) and QuantiFERON® TB GOLD In-Tube (Cellestis, Carnegie, VIC, Australia) for diagnosis of
suspected active TB and to estimate the diagnostic accuracy of second-generation IGRAs.
Design: Prospective within-patient comparative diagnostic accuracy study.
Setting: Secondary care.
Participants: Adults (aged ≥ 16 years) presenting as inpatients or outpatients at 12 NHS hospital trusts in
London, Slough, Oxford, Leicester and Birmingham with suspected active TB.
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Interventions: The index tests [T-SPOT.TB and QuantiFERON GOLD In-Tube (QFT-GIT)] and new
enzyme-linked immunospot assays utilising novel Mycobacterium tuberculosis antigens (Rv3615c, Rv2654,
Rv3879c and Rv3873) were verified against a composite reference standard applied by a panel of clinical
experts blinded to IGRA results.
Main outcome measures: Sensitivity, specificity, predictive values and likelihood ratios were calculated to
determine diagnostic accuracy. A decision tree model was developed to calculate the incremental costs
and incremental health utilities [quality-adjusted life-years (QALYs)] of changing from current practice to
using an IGRA as an initial rule-out test.
Results: A total of 363 patients had active TB (culture-confirmed and highly probable TB cases), 439
had no active TB and 43 had an indeterminate final diagnosis. Comparing T-SPOT.TB and QFT-GIT, the
sensitivities [95% confidence interval (CI)] were 82.3% (95% CI 77.7% to 85.9%) and 67.3% (95% CI
62.1% to 72.2%), respectively, whereas specificities were 82.6% (95% CI 78.6% to 86.1%) and 80.4%
(95% CI 76.1% to 84.1%), respectively. T-SPOT.TB was more sensitive than QFT-GIT (relative sensitivity
1.22, 95% CI 1.14 to 1.31; p < 0.001), but the specificities were similar (relative specificity 1.02, 95% CI
0.97 to 1.08; p = 0.3). For both IGRAs the sensitivity was lower and the specificity was higher for human
immunodeficiency virus (HIV)-positive than for HIV-negative patients. The most promising novel antigen
was Rv3615c. The added value of Rv3615c to T-SPOT.TB was a 9% (95% CI 5% to 12%) relative increase
in sensitivity at the expense of specificity, which had a relative decrease of 7% (95% CI 4% to 10%).
The use of current IGRA tests for ruling out active TB is unlikely to be considered cost-effective if a QALY
was valued at £20,000 or £30,000. For T-SPOT.TB, the probability of being cost-effective for a willingness
to pay of £20,000/QALY was 26% and 21%, when patients with indeterminate test results were excluded
or included, respectively. In comparison, the QFT-GIT probabilities were 8% and 6%. Although the use of
IGRAs is cost saving, the health detriment is large owing to delay in diagnosing active TB, leading to
prolonged illness. There was substantial between-patient variation in the tests used in the diagnostic pathway.
Limitations: The recruitment target for the HIV co-infected population was not achieved.
Conclusions: Although T-SPOT.TB was more sensitive than QFT-GIT for the diagnosis of active TB, the
tests are insufficiently sensitive for ruling out active TB in routine clinical practice in the UK. Novel assays
offer some promise.
Future work: The novel assays require evaluation in distinct clinical settings and in immunosuppressed
patient groups.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and the NIHR Health Protection Research Unit in Respiratory Infections, Imperial
College London, London, UK.
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Plain English summary
Tuberculosis (TB) is one of the world’s most important infectious diseases. In 2014, 1.5 million deathswere caused by the disease – about one death every 25 seconds. Traditional diagnosis of TB is based
partly on the tuberculin skin test. Blood tests such as QuantiFERON GOLD In-Tube (QFT-GIT; Cellestis,
Carnegie, VIC, Australia) and T-SPOT.TB® (Oxford Immunotec, Abingdon, UK) are now available. However,
these two tests are not used as part of current NHS practice because of the lack of evidence about how
well the tests perform when diagnosing symptomatic (active) TB in routine clinical practice.
The purpose of our study was to compare the ability of QFT-GIT and T-SPOT.TB to differentiate people
with active TB from those without active TB in a population suspected of the disease. We also assessed
new blood tests that are currently being developed for diagnosis of active TB.
We recruited 1074 patients with suspected TB from 14 NHS hospitals in London, Slough, Oxford, Leicester
and Birmingham into our study. We found that T-SPOT.TB correctly detected more people with active TB
than QFT-GIT; T-SPOT.TB would miss about 18 people out of every 100, whereas QFT-GIT would miss
about 33 people out of every 100 with active TB.
For this reason, neither test is good enough for routine clinical use because the number of people with
active TB who are incorrectly diagnosed as not having active TB is unacceptably high. In addition, neither
test is good value for money. However, we did find that some of the newer blood tests performed better
than T-SPOT.TB and their usefulness should be further investigated.
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Scientific summary
Background
Interferon gamma release assays (IGRAs) are blood tests recommended for diagnosis of tuberculosis (TB)
infection. The two types of commercially available IGRAs are QuantiFERON GOLD In-Tube (QFT-GIT;
Cellestis, Carnegie, VIC, Australia), a whole-blood enzyme-linked immunosorbent assay (ELISA), and
T-SPOT.TB® (Oxford Immunotec, Abingdon, UK), an enzyme-linked immunospot assay (ELISpot). There is
currently uncertainty in the role and clinical utility of IGRAs in the diagnostic workup of suspected active TB
in routine NHS clinical practice.
Aim
To evaluate and compare the diagnostic accuracy and cost-effectiveness of IGRAs for the diagnosis of
active TB.
Objectives
Primary objectives
l To compare the diagnostic performance [sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV)] of T-SPOT.TB and QFT-GIT for the diagnosis of active pulmonary and
extrapulmonary TB in routine clinical practice.
l To develop an evidence-based optimal testing algorithm that defines the role of IGRAs in the diagnostic
workup of suspected active TB.
l To deliver the above objectives for a key subgroup: human immunodeficiency virus (HIV) co-infected
patients (the highest-risk subgroup of TB).
l To quantify and compare the cost-effectiveness of a range of possible testing strategies against the
present testing regime.
Secondary objectives
l To quantify the sensitivity, specificity, and PPV and NPV of T-SPOT.TB and QFT-GIT in a number of key
patient subgroups, such as patients with pre-existing diabetes mellitus, end-stage renal failure and
iatrogenic immunosuppression.
l To quantify the use of second-generation IGRAs compared with existing commercially available assays.
Methods
We used a within-patient (paired) design to compare test accuracy by applying all IGRAs to blood samples
from each patient. The final diagnosis of participants was verified using a composite reference standard
(based on the Dosanjh’s criteria) applied by a panel of clinicians blinded to local (routine) and study IGRA
results. The diagnostic accuracy of early secretory antigenic 6 kDa (ESAT-6) and culture filtrate protein 10
(CFP-10) (together these antigens constitute T-SPOT.TB) and four new ELISpot-based assays utilising novel
Mycobacterium tuberculosis antigens (Rv3615c, Rv2654, Rv3879c and Rv3873) were also evaluated, both
individually and in test combinations. The test combinations were compared with T-SPOT.TB.
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Statistical analysis
The main clinical utility of IGRAs in the assessment of suspected active TB is likely to be in their NPV, which
enables clinicians to reliably rule out TB from the differential diagnoses. This depends on the sensitivity of
the test and the prevalence of active TB in the tested population. To detect a 10% difference in sensitivity
between T-SPOT.TB and QFT-GIT (assuming a sensitivity of 85% for T-SPOT.TB and of 75% for QFT-GIT) at
the 5% significance level with 90% power, 855 participants were required, assuming a 40% prevalence of
active TB. To allow for missing data, indeterminate index test and reference standard results, withdrawal
of consent and possible logistical errors, we aimed to recruit 1012 patients. For the HIV-positive subgroup,
we computed sample size based on sensitivities of 85% and 65% for T-SPOT.TB and QFT-GIT, respectively.
We assumed a 20% prevalence of active TB and so required 390 participants to detect a 20% difference
with 80% power.
We estimated sensitivity, specificity, PPV and NPV and likelihood ratios for each test and combinations of
tests. For test comparisons, relative test performance was assessed by comparing the sensitivity and specificity
of one test relative to those of another test. The comparisons between different IGRAs were done using
generalised estimating equation models to exploit the paired nature of the data. Variation in the relative
performance of T-SPOT.TB and QFT-GIT with HIV infection status and other clinical characteristics was
investigated by including one covariate at a time in the models.
Economic evaluation
The economic analyses were based on the main study cohort. The diagnostic tests performed, their costs,
and time taken between decision points involving each test were considered in the economic analyses. The
analysis was undertaken from a NHS perspective. No discounting was required, as the diagnostic process
occurs over a relatively short time period. For preference estimates we followed the National Institute for
Health and Care Excellence (NICE) reference case, using quality-of-life weights obtained from the literature.
A decision tree model was developed to calculate the incremental costs and incremental health utilities
[quality-adjusted life-years (QALYs)] of changing from current practice to using an IGRA as an initial rule-out
test. The model was parameterised using the IGRAs for Diagnostic Evaluation of Active tuberculosis (IDEA)
study clinical patient records and relevant current literature.
Results
Between 25 November 2011 and 31 August 2013, the IDEA study recruited 1074 adults (aged ≥ 16 years)
presenting as inpatients or outpatients at 10 NHS hospital trusts in London, Slough, Oxford, Leicester and
Birmingham with suspected active TB. We refer to this group as the main study cohort. Owing to low
recruitment of HIV-positive patients, the study was extended to 31 December 2014 to recruit only this
group of patients. Two additional hospital trusts were added. A total of 263 HIV-positive patients were
recruited from 12 NHS trusts between 25 November 2011 and 19 December 2014. This is the HIV-positive
substudy cohort.
In the main cohort, the median age of the 845 patients included in the analyses was 38 (range 16–86) years.
Most (59.3%) were male, approximately half (48.2%) were of Indian ethnicity and 135 (16.0%) were HIV
positive. There were 88 (10.4%) patients with pre-existing diabetes mellitus, 12 (1.4%) patients with chronic/
end-stage renal failure and 105 (12.3%) patients who were on immunosuppressive therapy. In the HIV-positive
substudy cohort, the median age of the 201 patients included in the analyses was 43 (range 18–79) years.
The majority (67.7%) were male and a substantial number were of black (45.3%) or white (37.8%) ethnicity.
Principal findings of diagnostic accuracy in main study cohort
A total of 363 (43.0%) patients had a diagnosis of active TB (culture-confirmed and highly probable TB
cases), whereas active TB was excluded in 439 (52.0%) patients. The remaining 43 (5.1%) patients had
an indeterminate final diagnosis and were excluded from all analyses of diagnostic accuracy. The rate of
indeterminate IGRA results was higher for QFT-GIT (9.6%) than for T-SPOT.TB (7.0%). Indeterminate IGRA
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results were excluded from the main analyses. Comparing the two IGRAs, sensitivities were 82.3% [95%
confidence interval (CI) 77.7% to 85.9%] and 67.3% (95% CI 62.1% to 72.2%), whereas specificities
were 82.6% (95% CI 78.6% to 86.1%) and 80.4% (95% CI 76.1% to 84.1%) for T-SPOT.TB and QFT-GIT,
respectively. The sensitivity of T-SPOT.TB was superior to that of QFT-GIT [relative sensitivity 1.22, 95% CI
1.14 to 1.3; p < 0.001), but there was no statistical evidence of a difference in specificity [relative specificity
1.02, 95% CI 0.97 to 1.08; p = 0.3]. In sensitivity analyses with indeterminates included as test positives
(because only a negative result can rule out TB), conclusions about differences in the sensitivities and
specificities of T-SPOT.TB and QFT-GIT were unchanged.
The sensitivities of T-SPOT.TB and QFT-GIT were lower in patients with HIV co-infection than in the
HIV-negative subgroup. Similarly, the two IGRAs had lower sensitivities in patients with diabetes
mellitus than in patients without diabetes mellitus. Specificity was higher in HIV-positive patients than
in HIV-negative patients, but was lower in patients with diabetes mellitus than in those without diabetes
mellitus. Although there appeared to be differences in test performance between subgroups, there was
no statistical evidence of an effect of HIV infection status or diabetes mellitus on relative test performance.
The findings from these analyses should be taken with caution, as the number of test results in some
subgroups was small. Because data were few, subgroup analyses were not possible for the other two key
subgroups: those patients with end-stage renal failure and those on immune suppressants.
The most promising novel antigen was RV3615c, with a sensitivity that was higher than that of the other
antigens. Test combinations including Rv3615c showed higher sensitivity than T-SPOT.TB. The added value
of Rv3615c to T-SPOT.TB was a 9% (95% CI 5% to 12%) relative increase in sensitivity at the expense of
specificity, which showed a relative decrease of 7% (95% CI 4% to 10%). The combination of CFP-10
with Rv3615c (i.e. akin to replacing ESAT-6 in T-SPOT.TB) showed a relative increase of 7% (95% CI 3%
to 11%) in sensitivity and a relative decrease of 5% (95% CI 2% to 8%) in specificity.
Principal findings of diagnostic accuracy in the HIV-positive substudy cohort
A total of 32 (15.9%) patients had a diagnosis of active TB (culture-confirmed and highly probable TB
cases), whereas active TB was excluded in 165 (82.1%) patients. The remaining four (2.0%) patients had
an indeterminate final diagnosis and were excluded from all analyses. The indeterminate rate was 19.5%
for QFT-GIT and 23.1% for T-SPOT.TB. The difference of 3.6% (95% CI –4.5% to 11.6%) was not
significant (p = 0.4). Excluding indeterminate IGRA results, the sensitivities for T-SPOT.TB and QFT-GIT
were 62.8% (95% CI 44.1% to 78.3%) and 56.1% (95% CI 38.3% to 72.4%), respectively, and the
specificities were 83.4% (95% CI 75.7% to 88.9%) and 91.7% (95% CI 85.4% to 95.4%), respectively.
The sensitivity of T-SPOT.TB was higher than that of QFT-GIT, with a relative sensitivity of 1.12 (95% CI
0.87 to 1.44). There was no statistical evidence of a difference (p = 0.4). In contrast, the specificity of
T-SPOT.TB was significantly lower (p = 0.02) than that of QFT-GIT with a relative specificity of 0.91
(95% CI 0.84 to 0.99).
When indeterminate IGRA results were included in a sensitivity analysis, there was a small increase in the
sensitivity of QFT-GIT but a large increase in the sensitivity of T-SPOT.TB owing to the higher indeterminate
rate for T-SPOT.TB (18.2%) among active TB cases than that of QFT-GIT (5.9%). Nevertheless, there was
no statistical evidence of a difference in sensitivity (p = 0.1) or specificity (p = 0.1).
Main findings of economic evaluation
Tuberculosis diagnosis rarely followed the idealised diagnostic pathways and there was considerable
individual-level variability. This implies that costs of and time delays in diagnosis may be very different from
typical assumptions made in economic analyses. The number and order of diagnostic tests that were
performed varied between patients, as well as between final diagnosis categories. For instance, nearly all
active TB patients were given a culture test and sputum spear microscopy, whereas approximately 20%
and 25% of non-active TB patients were given a culture test and sputum spear microscopy, respectively.
The median cost of diagnosis was highest for unconfirmed diagnosis patients (£502) followed by the
non-culture-confirmed active TB patients (£476).
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The use of current IGRA tests for ruling out active TB would be unlikely to be considered cost-effective
if a QALY was to be valued at £20,000 or £30,000. T-SPOT.TB performed better than QFT-GIT in the
cost-effectiveness analysis. The probability of being cost-effective for a willingness to pay of £20,000/QALY
was 26% and 21% for T-SPOT.TB when patients with indeterminate test results were excluded or included,
respectively. In comparison, the QFT-GIT probabilities were 8% and 6%, respectively.
For the study cohort, the cost saving in these scenarios ranged from £65,120 to £86,850, but the health
detriment in QALYs was between –6.50 and –3.58.
Stratifying the main study cohort by HIV infection status, the HIV-negative group of patients had results
similar to those from the analyses of the entire cohort. However, cost-effectiveness results were worse for
the HIV-positive group, with the probability of being cost-effective at a willingness to pay of £20,000/
QALY of approximately 12% and 9% for T-SPOT.TB and QFT-GIT, respectively, when patients with
indeterminate IGRA results were excluded. When patients with indeterminate IGRA results were included,
the probability was 4% for both IGRAs. The HIV-positive group had ranges of cost savings and health
detriment of £42,110 to £106,090 and –7.86 to –5.91, respectively.
Although IGRAs are cost saving, the health detriment is large because of delay in diagnosing active TB
leading to prolonged illness. Whether there is a net health detriment or gain for the patient cohort as a
whole depends on the prevalence of active TB, the performance characteristics of the rule-out test and the
length of delay introduced by adding the initial rule-out test.
Conclusions
Implications for health care
Despite the significantly higher sensitivity of T-SPOT.TB over QFT-GIT, neither IGRA can be used routinely
as a reliable rule-out test for suspected active TB in this patient population in secondary care. Neither IGRA
was cost-effective in this setting. However, in patients in whom there is suspicion of TB, but the pre-test
probability is low, the NPV of a negative T-SPOT.TB result would be correspondingly higher. Hence, it
would not be unreasonable to use a negative T-SPOT.TB result to weigh the odds in favour of excluding TB
from the differential diagnosis as long as the test result is interpreted with an awareness of the limited
sensitivity as shown by this study.
The incorporation of novel antigens into T-SPOT.TB, in particular Rv3615c, provided high diagnostic
sensitivity values coupled with a modest reduction in specificity. Notably, replacing ESAT-6 with Rv3615c
also conferred higher sensitivity than T-SPOT.TB. This observation is relevant for TB control internationally
because one of the leading TB vaccine candidates in clinical trials, H56/IC31 [Statens Serum Institute,
Copenhagen, Denmark; Aeras, Rockville, MD, USA; formulated with Valneva’s IC31® proprietary adjuvant
(Lyon, France)] incorporates ESAT-6. The vaccine is protective in the non-human primate model and is likely
to be licensed if it proves to be protective in humans. If rolled out, vaccinated individuals are likely to develop
T-cell responses to ESAT-6 that would lead to false-positive IGRA results, akin to the current scenario with
bacillus Calmette–Guérin (BCG) vaccination inducing false-positive tuberculin skin test results. Replacing
ESAT-6 with Rv3615c may be a potential solution because a CFP-10- and Rv3615c-based IGRA would have
significantly higher sensitivity than existing IGRAs and specificity would not be compromised in H56/IC31-
vaccinated individuals.
Recommendations for research
The second-generation IGRAs evaluated in the IDEA study do not need to be re-evaluated in a UK routine
practice setting because this study provided an equally rigorous evaluation of these novel assays, as it did
for conventional IGRAs. However, the novel assays require evaluation in distinct clinical settings with much
lower or much higher prevalence of active TB and in immunosuppressed subgroups. A new generation of
QFT-GIT, QuantiFERON-TB Gold Plus (QFT®-Plus; Qiagen GmbH, Hilden, Germany), was recently launched.
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Although the QFT-GIT has been replaced by the QFT-GIT-Plus since our study was conducted, its diagnostic
accuracy does not appear to be significantly better than QFT-GIT and there is no evidence it is as sensitive
as T-SPOT.TB. A comparative accuracy study of the novel assays and QFT-Plus may be needed.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research (NIHR) and the NIHR Health Protection Research Unit in Respiratory Infections,
Imperial College London, London, UK.
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Chapter 1 Introduction
Background
In 2014, globally, an estimated 9.6 million cases of tuberculosis (TB) and 1.5 million deaths caused by the
disease were reported to the World Health Organization.1 Co-infection with TB and human immunodeficiency
virus (HIV) accounts for a significant proportion of cases globally (12%) and together these infections are the
biggest infectious causes of death. Health inequalities are exacerbated by the burden that TB places on the
most vulnerable and poor around the world. Over the past 20 years, worldwide TB incidence and mortality
have declined. However, despite this, the prevalence of TB still remains unacceptably high. Furthermore, there
is not yet evidence of a reduction in the number of cases in England, particularly in major cities such as
London and Birmingham.
In England, 6520 cases of TB were reported in 2014, with an incidence rate of 12.0 per 100,000.2 Of these,
2572 cases were in London, where the incidence rate was 30.1 per 100,000.2 Other urban high-incidence
areas include Leicester, Birmingham, Luton, Manchester and Coventry. The majority of cases in England
(72%) occurred in new entrants who were born outside the UK.2
Tuberculosis is caused by active infection with Mycobacterium tuberculosis (Mtb). Upon initial infection
with Mtb, a state of asymptomatic dormancy typically occurs. In most infected individuals this results in a
prolonged and perhaps lifelong latent TB infection (LTBI). In others, however, a breakdown of immune
control and activation of infection results in symptomatic disease, which can be fatal without treatment.
Co-infection with HIV dramatically increases the likelihood of progression from latent to active disease.
Active TB can manifest with pulmonary or extrapulmonary phenotypes. In its active pulmonary form, TB is
highly contagious. The diagnosis of active TB is central to preventing the spread of disease and thus
controlling the TB epidemic.3 However, the slow speed and poor sensitivity of existing diagnostic tools
often lead to delays diagnosis and treatment of the disease.4
Diagnosis of tuberculosis
Conventional methods of diagnosing active TB rely primarily on the identification of Mtb bacilli, as well as
imaging affected areas. Smear microscopy is quick and inexpensive, but typically lacks sensitivity. Although cell
culture is considered the ‘gold standard’ for diagnosis of active TB because of its higher sensitivity, it is often
slow, taking up to 6 or 8 weeks to give a result. Polymerase chain reaction (PCR)-based tests for Mtb, such as
the new GeneXpert Mtb/RIF® (Sunnyvale, Cepheid, CA, USA), can be quick and sensitive, but they are typically
expensive and require a high standard of infrastructure. Imaging techniques such as chest radiography and
computed tomography (CT) are quick and usually sensitive, but are not specific. Furthermore, they can be
expensive, and, again, require a high standard of infrastructure (for example in the case of CT). All of these tests
tend to be less accurate in cases of active TB with HIV co-infection, and also in cases of extrapulmonary TB.
Currently available tests for LTBI include the tuberculin skin test (TST) and interferon gamma release assays
(IGRAs). The TST measures the in vivo delayed-type hypersensitivity response to intradermal inoculation of a
crude mixture of mycobacterial antigens. Because this mixture contains antigens also present in bacillus
Calmette–Guérin (BCG), the test can be confounded by prior BCG vaccination. IGRAs, on the other hand,
detect ex vivo interferon gamma (IFN-γ) release from T cells (lymphocytes that play a key role in cell-mediated
immunity) in response to Mtb-specific antigens, early secretory antigenic 6 kDa (ESAT-6) and culture filtrate
protein 10 (CFP-10). These antigens are absent from the BCG vaccine and most environmental mycobacteria,
and thus IGRAs tend to be more specific than the TST.5 The two types of commercially available IGRAs are
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QuantiFERON GOLD In-Tube (QFT-GIT; Cellestis, Carnegie, VIC, Australia), a whole-blood enzyme-linked
immunosorbent assay (ELISA), and T-SPOT.TB® (Oxford Immunotec, Abingdon, UK), an enzyme-linked
immunospot assay (ELISpot); both IGRAs utilise peripheral blood mononuclear cells (PBMCs). These tests
have been recommended by the UK, European and North American guidelines for diagnosis of LTBI.6
Although typically used in the diagnosis of LTBI, TSTs and IGRAs actually detect Mtb infection in its entirety
(i.e. active or latent). The role of the tests within published guidelines for diagnostic evaluation of suspected
active TB to date has been limited because of their low specificity for the disease: they could never confirm
a diagnosis of active TB because they cannot differentiate latent and active infection. However, because
Mtb infection is a pre-requisite for TB disease, reliable determination of infection status could accelerate
diagnostic assessment by enabling rapid exclusion of TB (within 24 hours) when the result is negative.
In order for the IGRA or TST to reliably rule out a diagnosis of Mtb infection and thus TB disease, the
sensitivity of the test must be very high (> 95%). The sensitivity and specificity of IGRAs compared with the
TST in active TB have been examined in a number of studies, varying in size and quality.7 IGRAs are typically
more specific than the TST for diagnosing Mtb infection and T-SPOT.TB is more sensitive than the TST for
diagnosing TB. However, the diagnostic accuracy of T-SPOT.TB and QFT-GIT has not been compared directly
head to head in suspected active TB in the UK, nor comprehensively assessed in immunosuppressed
patients. Therefore, there is uncertainty in the role and clinical utility of IGRAs in the diagnostic workup of
suspected TB, as well as their cost-effectiveness in UK NHS practice.
Aim and study objectives
Aim
To evaluate and compare the diagnostic accuracy and cost-effectiveness of IGRAs with conventional testing
for diagnosis of active TB. Specifically, the study aimed to determine the sensitivity, specificity, positive
predictive values (PPVs) and negative predictive values (NPVs), and likelihood ratios of T-SPOT.TB and QFT-GIT
for diagnosis of active TB in routine NHS clinical practice. Second-generation IGRAs were also evaluated.
Study objectives
Primary objectives
1. To compare the diagnostic accuracy of T-SPOT.TB and QFT-GIT for the diagnosis of active pulmonary
and extrapulmonary TB in routine clinical practice.
2. To develop an evidence-based optimal testing algorithm that defines the role of IGRAs in the diagnostic
workup of suspected active TB.
3. To deliver the objectives above for a key subgroup: HIV co-infected patients (the highest-risk subgroup
of TB).
4. To quantify and compare the cost-effectiveness of a range of possible testing strategies against the
present testing regime.
Secondary objectives
1. To quantify the sensitivity, specificity, and positive and NPVs of T-SPOT.TB and QFT-GIT in a number of
key patient subgroups, such as patients with pre-existing diabetes mellitus, end-stage renal failure and
iatrogenic immunosuppression.
2. To quantify the use of second-generation IGRAs compared with existing commercially available assays.
INTRODUCTION
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Chapter 2 Methods
This chapter describes the study design and methods for the evaluation of the diagnostic accuracy ofIGRAs in active TB. Our report adheres to the Standards for the Reporting of Diagnostic Accuracy
Studies (STARD) guideline,8 as shown in Appendix 1. Methods for the health economic evaluation are
described separately in Chapter 6.
Overview of the study design
This prospective multicentre study comparing the accuracy of IGRAs was conducted in routine clinical
practice in the UK. Adults presenting with suspected active TB at NHS outpatient or inpatient services to
participating hospitals in London, Slough, Oxford, Leicester and Birmingham were recruited. We used a
within-patient design to compare test accuracy by performing all IGRAs on blood samples from each
patient with the presence or absence of active TB verified using the reference standard. This design
minimises between-patient variability while also allowing estimation of the accuracy of combinations of
IGRAs. Blood samples for IGRA testing were collected from patients at baseline and follow-up (2 and
6 months). If necessary, and when available, TST results were used as part of the composite reference
standard for verifying the final diagnosis of patients. The TST results were obtained from routine clinical
care and so the availability of TST results reflects local practice in participating hospitals.
Participants
Inclusion criteria
Adults (aged ≥ 16 years) presenting with suspected (pulmonary or extrapulmonary) active TB to NHS
outpatient or inpatient services were included. To replicate clinical practice, patients with a previous
diagnosis of TB and/or history of TB treatment were recruited. However, they were excluded from the
analyses on the basis that, when evaluating patients with suspected active TB, the clinician should not
perform an IGRA because any immunological biomarker would remain positive and thus affect test
accuracy. The study population was expected to be representative of the national TB burden in terms of
ethnic mix and range of comorbidities. A key subgroup was HIV-positive patients.
Exclusion criteria
Participants aged < 16 years or those unable to give informed consent were excluded.
Setting
Patients were recruited at the point of diagnostic workup from 14 hospitals in 10 NHS trusts in the UK.
Recruitment process
An overview of the recruitment process is shown in Figure 1. Potential participants presenting to
participating NHS centres were referred to a TB research nurse by the attending clinician. The nurse then
screened participants to ensure that they were eligible for the study according to the inclusion/exclusion
criteria stated above. Each potential participant was provided with an information sheet and a verbal
description of the study. Participants were included in the study if they were willing and informed consent
was obtained.
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Data collection and management
Follow-up
Participants were seen by research nurses for follow-up visits at 2 and 6 months after recruitment. Follow-up
visits were scheduled to be carried out at the same time as the patient’s routine clinic appointments. At these
visits blood was collected for IGRA testing and data on patient diagnosis were obtained. If patients were no
longer being seen as part of their routine NHS care, they were not required to attend study follow-up visits.
In such cases, information about a patient’s diagnosis was obtained from their medical notes. In addition to
following up patients at 2 and 6 months, a review of patient records was performed up to 1 year post
recruitment, if required, in order to obtain a final diagnosis.
Data management
A case report form (CRF) was used to collect patient data at each recruiting hospital after a patient
consented to participate in the IGRAs for Diagnostic Evaluation of Active tuberculosis (IDEA) study. Following
receipt of the CRFs, data were entered into an electronic password-protected database. The results of study
IGRAs and all other study laboratory tests were entered into a separate secure database. This laboratory
database was accessible only to specific laboratory staff. Thus, the Study Management Group (SMG)
responsible for day-to-day management of the IDEA study was blinded to the IGRA results. Furthermore,
NHS clinicians responsible for routine care and diagnosis of patients involved in the study were also blinded
to study IGRA results. To enable preparation of study reports for meetings of the independent oversight
committee [Study Steering Committee (SSC)], the study statistician was granted access to the clinical
database and excerpts of the laboratory database at specific periods during the study.
Sample collection
Blood samples
Blood sampling was done at three time points: at baseline and at follow-up at 2 and 6 months. Only blood
samples collected at baseline were used in the assessment of the index tests and for the reference standard.
Consecutive series of participants suspected of active TB
Screening process
Inclusion criteria met?
Exclude from study
No
(< 16 years old)
Yes
(> 16 years old)
Yes
No
Informed consent given?
Include in study
FIGURE 1 Overview of recruitment process.
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Samples taken at follow-up were used for further IGRA testing (but not analysed as part of the IDEA study)
and also stored for future research as consented by patients. Blood-taking (venepuncture) procedures were
carried out in accordance with local trust venepuncture guidelines. The baseline sample was obtained no
later than 14 days after the start of treatment for TB or within 7 days of consent, whichever was earlier,
depending on the patient’s diagnosis. For patients with a diagnosis of active TB, sarcoidosis or other non-TB
diagnosis, follow-up study blood samples were taken 2 and 6 months after the start of treatment. For
patients with a diagnosis of latent TB, when possible and if the patient returned to the same clinical team,
blood samples were taken 3 and 6 months after the initiation of treatment (if treatment was indicated
and given).
A 35-ml blood sample was taken at each time point. Blood was collected into heparinised collection tubes
and QFT-GIT collection tubes for T-SPOT.TB and QFT-GIT assays, respectively. Furthermore, heparinised
blood was collected for performance of second-generation IGRAs and to store plasma and PBMCs for
future research. In addition, blood was collected into uncoated collection tubes in order to store serum for
future research.
Blood samples were transported on the same day as sample collection either by a member of the research
team or by courier in the appropriate United Nations-type approved packaging to the TB Research Centre
for testing. All samples were processed within 6 hours of blood collection for London-based sites and within
8 hours for outer London sites. Excess PBMCs were stored in a liquid nitrogen tank, and serum and plasma
were stored in a –80 °C freezer at the TB Research Centre (led by Professor Ajit Lalvani) at Imperial College
London (St. Mary’s Hospital).
Diagnostic bronchoscopy samples
In patients with sputum smear-negative pulmonary TB, diagnostic bronchoscopies were performed and
bronchoalveolar lavage (BAL) was obtained as part of routine clinical care. When surplus BAL samples
were available and not required for diagnostic procedures, aliquots were cryopreserved and stored in the
research biorepository for subsequent testing by IGRA. The bronchoscopic procedure, along with collection
of surplus BAL samples, were applicable only for patients recruited at St. Mary’s Hospital, Imperial College
Healthcare NHS Trust, in accordance with set clinical practice guidelines. The BAL sample consent was
covered under the consent form as ‘tissue samples’. However, patients were informed if a surplus BAL
sample was kept for the IDEA study.
Index tests
Interferon gamma release assays
Two types of commercially available IGRAs, QFT-GIT and T-SPOT.TB, were evaluated. In addition, a new
ELISpot-based assay utilising novel antigens (Rv3615c, Rv2654, Rv3879c and Rv3873) was evaluated. The
performance of each antigen was evaluated individually and in combinations that included either ESAT-6
and CFP-10, the two antigens that constitute T-SPOT.TB, or both. IGRA testing is not standard practice
for HIV-negative patients suspected of having TB in the hospitals of our consortium and is not currently
recommended for HIV-positive patients suspected of having TB. However, if IGRAs were used locally at
participating hospitals as part of the routine diagnostic workup of patients, we recorded the tests done but
we did not analyse the test results as study results for the IDEA study. Thus, only from IGRAs performed in
our research laboratory specifically for this study were recorded and assessed. Laboratory staff performing
the IGRAs and recording the test results were blinded to clinical information and reference standard results.
Analysis of T-SPOT.TB and novel antigens
Peripheral blood mononuclear cells were isolated from heparinised whole blood using the Ficoll-Paque™
density centrifugation method (GE Healthcare Bio-Science, Uppsala, Sweden), as described by Whitworth
et al.6 In brief, whole blood was diluted in Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma-Aldrich,
Dorset, UK) and layered onto Ficoll-Paque™ Plus at a ratio of 2 : 1 in 50-ml Falcon® centrifuge tubes
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(Corning Science Mexico S.A. de C.V., Reynosa, USA). The tubes were centrifuged for 20 minutes at 18–25 °C
and the cloudy PBMC layer was aspirated into fresh RPMI 1640 medium. Cells were washed with fresh RPMI
1640 medium and counted using trypan blue stain for use with the Countess® Automated Cell counter
(Life Technologies, Eugene, OR, USA). T-SPOT.TB was applied to the freshly isolated PBMCs as per the
manufacturer’s instructions9 and as described by Whitworth et al.6
Cells were resuspended in AIM-V® Serum-Free Medium (Gibco by Life Technologies, Thermo Fisher Scientific,
Waltham, MA, USA) at a concentration of 2.5 million cells/ml and 250,000 cells per well were incubated
overnight (18 hours) at 37 °C with Mtb-specific antigens (ESAT-6, CFP-10, Rv3615c, Rv2654, Rv3879c and
Rv3873) individually, and positive (phytohaemagglutinin) and negative (RPMI 1640 medium) controls in a
96-well plate, pre-coated with IFN-γ-specific monoclonal capture antibodies (included in T-SPOT.TB kit).
Thus, a total of eight wells were used per patient and samples from 12 patients were included on a plate.
Overnight incubation of the cells with antigens allows for IFN-γ secretion from activated Mtb-specific effector
T cells present in the culture. Secreted IFN-γ binded to the pre-coated IFN-γ-specific monoclonal capture
antibodies on the membrane of each well. After incubation, wells were washed with phosphate-buffered
saline and an alkaline phosphatase-conjugated secondary IFN-γ-specific monoclonal antibody was added
to bind to any captured IFN-γ. For a visible representation of the spots on the membrane, an alkaline
phosphatase chromogen substrate was added.
Each spot formed on the membrane signifies IFN-γ release by a single activated Mtb antigen-specific T cell.
Spot-forming cells (SFCs) are expected to be detected in positive control wells and absent in negative
control wells. SFCs in TB antigen-stimulated wells indicate infection.
Spot-forming cells were counted using an automated ELISpot plate reader (AID ELISpot read system ELRIFL04;
Advanced Imaging Devices GmbH, Strasbourg, Germany), with saturation level set at 60%. For individual
antigens, test results were classified as negative, positive, borderline (equivocal) or indeterminate (invalid) by
subtracting the spot count in the negative control well from the spot count in each panel, according to the
algorithm illustrated in Figure 2 (based on the package insert for T-SPOT.TB).9 Panels A, B, C, D, E and F
correspond to ESAT-6, CFP-10, Rv3615c, Rv2654c, Rv3879c and Rv3873, respectively.
For T-SPOT.TB as well as other antigen combinations, if the positive control spot count was < 20, the result
was deemed indeterminate, unless the response to one of the Mtb antigens was positive (or borderline),
in which case the test result for the combination was deemed positive (or borderline). Thus, we applied an
‘OR’ rule (at least one antigen spot count deemed positive) for antigen combinations. For example, for
T-SPOT.TB, a result was positive if the negative-control spot count was ≤ 10 and either ‘panel A minus
negative control’ or ‘panel B minus negative control’ was ≥ 8 spots. This implies the T-SPOT.TB result
was negative if both ‘panel A minus negative control’ and ‘panel B minus negative control’ were negative
(≤ 4 spots). In the IDEA study, borderline test results (5–7 spots) were considered as positives.
Analysis of QuantiFERON GOLD In-Tube
The QFT-GIT assay was performed in two stages as per the manufacturer’s instructions10 and as described
in Whitworth et al.6 First, whole blood was collected from each participant into three QFT-GIT tubes
containing a negative control, mitogen-positive control and Mtb antigens [ESAT-6, CFP-10 and TB7.7
(also known as Rv2654c, a possible PhiRv2 prophage protein) combined], as provided by the manufacturer.10
The tubes were incubated at 37 °C for 16–24 hours to allow IFN-γ secretion from antigen-specific effector
T cells into the extracellular fluid (plasma). After incubation, tubes were centrifuged and 150 µl of plasma
was collected and stored in a 96-well plate for up to 4 weeks at 2–8 °C prior to performing the remainder of
the assay.
To perform the ELISA step, 50 µl of plasma from each of the QFT-GIT tubes (i.e. containing a mitogen
control, negative control and Mtb antigens) was transferred to wells of another 96-well plate pre-coated
with IFN-γ-specific monoclonal capture antibodies and incubated with a conjugate [an IFN-γ-specific antibody
conjugated to horseradish peroxidase (included in T-SPOT.TB kit)] for 2 hours at room temperature (22 °C).
Plasma samples in each well were mixed thoroughly using a microplate shaker (PMS-1000i Microplate Shaker;
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Grant Instruments Ltd, Shepreth, UK) for 1 minute to ensure that any IFN-γ was evenly distributed throughout
the sample. Secreted IFN-γ in the plasma will be sandwiched between the two antibodies.
After incubation and thorough washing with detergent, a photosensitive chromogen substrate solution
(3,3’,5,5’-tetramethylbenzidine; included in QFT-GIT kit) was added, which converted the sample to a
detectable form (blue colour signal). The reaction was stopped with a substrate stopping solution (sulphuric
acid; included in QFT-GIT kit). The intensity of the colour is directly proportional to the levels of IFN-γ present
in the plasma after activation of TB-specific T cells by Mtb antigens. Colour should develop in the positive
control well and not in the negative control well. Colour in the TB antigen well indicates infection.
The optical density of each well was measured using a microplate reader (Elx800 Absorbance Reader; BioTek,
Carnegie, VIC, Australia) with a 450-nm filter and a 620- to 650-nm reference filter. The concentration
(IU/ml) of IFN-γ for the plasma sample from each of the three tubes (negative, mitogen and Mtb antigen)
was determined against a series of standard concentrations (the standard curve). The test result (negative,
positive or indeterminate) was calculated from the concentration values using a US Food and Drug
Administration-approved algorithm (Figure 3) run on QuantiFERON-TB Gold In-Tube Analysis Software
version 2.62 (Cellestis) in accordance with the manufacturer’s instructions.10
Tuberculin skin test
A TST was performed as part of routine clinical care. Each recruiting centre has its own policy for TST use
based on National Institute for Health and Care Excellence (NICE) guidance.11 Patients eligible for the TST, as
defined by local or NICE guidance, received a single intradermal injection of two tuberculin units or 0.1 ml
of unlicensed tuberculin Mantoux test [Tuberculin PPD RT23 SSI (Statens Serum Institut, Copenhagen,
Denmark); this purified protein derivative (PPD) was used for the main site; however, other sites may have
Negative-control spot count
> 10 spots< 10 spots
IndeterminatePositive-control spot count
Positive
Panel X – negative-
control spot count
 > 8 spots
Positive
< 20 spots
> 20 spots or
saturation (TNTC)
Panel X – negative-
control spot count
 > 8 spots
Borderline
Panel X – negative-
control spot count
is 5, 6 or 7 spots
Borderline
Panel X – negative-
control spot count
is 5, 6 or 7 spots
Negative
Panel X – negative-
control spot count
 < 4 spots
Indeterminate
Panel X – negative-
control spot count
 < 4 spots
FIGURE 2 Algorithm for defining test positivity of antigens. Panel X indicates one of the six panels, A to F, which
correspond to the following antigens: A, ESAT-6; B, CFP-10; C, Rv3615c; D, Rv2654; E, Rv3879c; and F, Rv3873.
TNTC, too numerous to count.
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used other PPDs]. The test was administered by trained specialist TB nurses who were entitled to administer
medicines within the trust under a Patient Group Directive. The degree of skin induration was measured
48–96 hours later. Test results were obtained from centres and we determined test positivity using three
thresholds: ≥ 5 mm, ≥ 10 mm3,12 and a stratified threshold based on BCG vaccination status (≥ 6 mm for
unvaccinated and ≥ 15 mm for vaccinated participants).11 Patients were considered BCG vaccinated if they
reported they had been vaccinated and/or had a BCG scar.
Reference standard
Participating hospitals followed the minimum set of tests defined within the NICE guideline11 for diagnosing
active TB and in accordance with local routine practice. However, the final diagnosis of participants was
verified using the composite reference standard defined in Appendix 2. The reference standard was applied
by a panel of clinicians blinded to local (routine) and study IGRA results. The role of the clinical panel was
to assess anonymised patient clinical data without knowledge of the IGRA results in order to confirm the
diagnostic category of all study participants. The composition of the panel and the assessment process is
described in Composition of the clinical panel and Assessment of final diagnosis.
Composition of the clinical panel
Clinical panel members were appointed from among the principal investigators (PIs) and co-investigators by
the chief investigators. The panel included:
l an independent chairperson
l a chest physician
l a HIV physician with knowledge of HIV/TB infection
l an infectious disease physician.
All physicians had extensive TB expertise.
Structure of case panel meetings
Meetings were arranged and minutes were recorded by the study co-ordinator or a designated member
of the study team. The panel meetings were held quarterly and the schedule was decided by the SMG
depending on the number of data available for review. At each meeting, priority was given to assessment
of indeterminate (category 3) cases. Additional meetings were arranged to ensure that all patients in
categories 2 and 3, and some in category 4, were reviewed (see Assessment of final diagnosis). All panel
members had to attend the meeting in person.
TB antigen: nil > 0.35 IU/ml
AND
TB antigen: nil > 25% of nil
TB antigen: nil < 0.35 IU/ml
AND
TB antigen: nil < 25% of nil
Nil < 8.0 IU/ml
AND
Any mitogen
AND
Positive
Nil < 8.0 IU/ml
AND
Mitogen > 0.5 IU/ml
AND
Negative Indeterminate
Nil > 8.0 IU/ml
AND
Any mitogen
Nil < 8.0 IU/ml
AND
Mitogen < 0.5 IU/ml
AND
Any TB antigen: nil
AND
FIGURE 3 Determination of the test results for QFT-GIT. Reprinted from Methods, Vol. 61, Whitworth HS, Scott M,
Connell DW, Dongés B, Lalvani A. IGRAs – the gateway to T cell based TB diagnosis, pp. 52–62. © 2013, with
permission from Elsevier.6
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Assessment of final diagnosis
Diagnosis data (based on the Dosanjh categorisation3 outlined in Appendix 2) received from recruiting
centres were reviewed as follows:
l Category 1: all culture-confirmed cases were not reviewed, but were signed off at the end of the
clinical panel meeting by the chief or co-investigators.
l Category 2: all probable cases were reviewed.
l Category 3: all indeterminate cases were reviewed.
l Category 4: non-active TB cases with a confirmed alternative diagnosis were not reviewed by the panel.
Complicated category 4 patients were reviewed by the panel.
Reviewing cases in this way ensured consistent final diagnosis categorisation.
Data available to the panel
For each patient who was reviewed, the following information was presented to the panel:
l patient demographics
l TB symptoms, previous TB information, TB exposure history, current medication, patient medical
history, follow-up data, HIV infection status and relevant clinical information and travel data
l relevant clinical correspondence and test results during diagnosis and follow-up (excluding results of routine
and study IGRAs) such as culture, smear, PCR, TST, bronchoscopy, biopsy and/or radiological reports.
Documentation
Each panel member reviewed a patient’s documents and completed a form with the following information:
1. diagnosis category (based on the Dosanjh criteria)
2. body site of disease (only if final diagnosis was active TB)
3. method of diagnosis: included culture, PCR, imaging, smear microscopy, histology, clinical features,
response to treatment, multiple and other. For multiple and other, details were to be specified.
Confirmation of diagnosis
Final diagnosis decisions were made by a majority vote, with the chairperson having a casting vote, if
necessary. Final diagnoses were recorded by the study co-ordinator. If necessary, when a panel member
had treated a patient being reviewed, the member was asked to provide information (without disclosing
local or study IGRA results) and the member was excluded from final decision-making (their vote was
replaced with a vote from the chairperson) for the patient.
Outcomes
Sensitivity, specificity, PPVs and NPVs and likelihood ratios for each test and combinations of tests were
calculated to determine their diagnostic accuracy and clinical utility. The likely primary clinical utility of
immune-based testing is to exclude TB. Thus, when interpreting the analyses and drawing conclusions,
the focus was primarily on the sensitivities and NPVs. For test comparisons, relative test performance was
assessed by comparing the sensitivity and specificity of one test with those of another test. These results
were presented as relative sensitivities and relative specificities.
Statistical analyses
Sample size calculation
As stated in Outcomes, the primary clinical utility of IGRA results in the assessment of suspected active TB is
likely to be in their NPV, which may enable clinicians to reliably rule out TB from the differential diagnoses.
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This, in turn, depends on the sensitivity of the test and the prevalence of active TB in the tested population.
In a meta-analysis, the average sensitivity of T-SPOT.TB and QFT-GIT was 90% [95% confidence interval (CI)
86% to 93%] and 70% (95% CI 63% to 78%), respectively.7 However, the estimates were mainly based
on small studies and most studies included only patients without HIV infection. Furthermore, the estimates
were not based on head-to-head comparative accuracy studies. Two large studies (n = 194 active TB cases
diagnosed from n = 389 TB suspects;3 n = 216 active TB cases diagnosed from n = 413 TB suspects13) gave
more robust estimates for T-SPOT.TB of 85.1% (95% CI 79.2% to 89.9%) and 85.2% (95% CI 76.1% to
91.9%), respectively. The latter study compared T-SPOT.TB and QFT-GIT, and gave an estimate of 78.1%
(95% CI 70.7% to 84.3%) for QFT-GIT.13
Given the available evidence, we powered the IDEA study to detect a conservatively estimated 10%
difference in sensitivity between T-SPOT.TB and QFT-GIT, assuming a sensitivity of 85% for T-SPOT.TB and
of 75% for QFT-GIT. To detect this difference at the 5% significance level (two-tailed) with 90% power,
855 patients were required (each receiving both tests), assuming a 40% prevalence of active TB in the
study population. This calculation was done using a method that accounts for the paired nature of the
data (based on McNemar’s test).14 The method requires knowledge of the probability of positive T-SPOT.TB
and positive QFT-GIT results among cases of active TB (concordance probability). A positive correlation,
such as may be expected between both blood tests, would give a lower sample size than assuming
independence or a negative correlation of test errors. However, as no pilot data were available to inform
the choice of the concordance probability, we chose to be conservative and so assumed independence.
To allow for missing data, indeterminate index test and reference standard results, withdrawal of consent
and possible logistical errors, we aimed to recruit 1012 participants.
According to published evidence, the sensitivity of QFT-GIT decreases in HIV-positive subgroups, whereas
that of T-SPOT.TB is unaffected in some studies and decreased in others.15 Therefore, we computed
sample size for the HIV-positive subgroup based on sensitivities of 85% and 65% for T-SPOT.TB and
QFT-GIT, respectively. Assuming a 50% prevalence of active TB among these participants, we thus required
156 patients to detect a 20% difference between the IGRAs at the 5% significance level with 80% power.
We aimed to recruit 200 patients for similar reasons to those outlined above.
Revision of sample size calculation and study extension for recruitment of HIV-positive
participants
During the study recruitment period, the proportion of HIV-positive patients with a final diagnosis of active TB
was found to be substantially lower (20% rather than 50%) than originally anticipated when the study was
designed. This was attributed to a decrease in TB incidence in this population in recent years.16 In order to
answer a key objective regarding the utility of IGRAs in HIV-positive patients, the SSC and funder supported
an extension of recruitment of HIV-positive participants to ensure that the study was adequately powered.
The sample size calculation was revised to take into account the reduced prevalence of active TB in this
population. Given a prevalence of 20%, 390 HIV-positive participants will be required to detect a 20%
difference between the sensitivity of T-SPOT.TB and QFT-GIT with 80% power at the 5% significance level.
Thus, the sample size was increased from 156 to 390. Ethics approval was sought and an extension of
12 months was granted on 5 November 2014 to recruit and follow up only HIV-positive participants. Given
the purposive recruitment of additional HIV-positive participants, the results are presented separately for
the main cohort (including HIV-positive participants recruited during the first phase of the IDEA study prior
to the extension period) in Chapters 3 and 4, and for the entire HIV-positive cohort in Chapter 5.
Data analysis
Sensitivity, specificity, PPV, NPV and likelihood ratios for each test and combination of tests were calculated
to determine their diagnostic accuracy and clinical utility in the main cohort and within the key subgroups
outlined in the study objectives. For all proportions, 95% CIs were calculated using the Wilson method.17,18
CIs for positive and negative likelihood ratios were calculated using the method by Simel et al.19 Separate
analyses of the complete cohort of HIV-positive participants were also performed.
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Patients classified as having culture-confirmed (category 1) or highly probable (category 2) active TB
and those without active TB (category 4) were included in analyses of diagnostic accuracy (see definition of
categories in Appendix 2). However, despite not being included in the analysis, the proportion of patients
classified as clinically indeterminate (category 3) was reported. While borderline T-SPOT.TB results were
included as test positives in primary analyses of the main study cohort, we examined the impact of this by
excluding borderline test results in sensitivity analyses. For the primary analyses, patients with indeterminate
IGRA results were excluded from the analyses. In clinical practice, if an IGRA was used as a rule-out test for
active TB, then an indeterminate result would have the same implications as a positive result, that is, it could
not rule out a diagnosis of the disease (and thus TB would remain a differential diagnosis). The impact of
including indeterminate IGRA results as test positives (i.e. true positives and false positives depending on
final diagnosis of active TB or no active TB) was assessed in sensitivity analyses. Sensitivity analyses were
also conducted to investigate the impact of excluding category 2 patients on the sensitivity of IGRAs.
Comparisons between different IGRAs were performed using generalised estimating equation (GEE) models
to exploit the paired nature of the data. Our analysis was based on all available data (i.e. it included patients
who did not have a complete set of index test results). Separate GEE models were fitted for those with active
TB (Dosanjh categories 1 and 2) and those with no active TB (category 4) to determine differences in sensitivity
and specificity, respectively. The outcome variable in the GEE model was IGRA result (positive vs. negative) and
the explanatory variable was type of IGRA, for example T-SPOT.TB versus QFT-GIT. The natural outputs from
these models are odds ratios. For example, comparing the sensitivity of T-SPOT.TB to that of QFT-GIT, the
odds ratio is the odds of a positive T-SPOT.TB result compared with the odds of a positive QFT-GIT result in
patients with active TB. For the comparison of specificities, the odds ratio is the odds of a negative T-SPOT.TB
result compared with the odds of a negative QFT-GIT result in non-TB patients. As odds ratios do not have an
intuitive interpretation, we computed ratios of sensitivities (relative sensitivity) and ratios of specificities (relative
specificity) using a function (nlcom) that computes point estimates and CIs for non-linear combinations of
parameter estimates post estimation of the models. The CIs are computed using the delta method.
Variation in the relative performance of T-SPOT.TB and QFT-GIT with HIV infection status and other clinical
characteristics was investigated by including one covariate at a time in the GEE models.20 To assess the
effect of a covariate on relative test performance, an interaction term for test type and the covariate was
included in the model. In addition to these characteristics pre-specified in the protocol, we also investigated
the effect of smoking, because this has been associated with a twofold increase in the risk of developing
active TB.21 We included both inpatients and outpatients in all our analyses of diagnostic accuracy to allow
for generalisability of these tests as an initial test in any case of possible active TB. However, because disease
severity and spectrum can influence the diagnostic performance of a test, we also investigated the effect
of clinical setting (inpatients vs. outpatients) to determine if our approach was tenable. We were interested
in exploring the effect of vitamin D, as it is an important cofactor for the intracellular killing of TB. It is
associated with an increased resistance to TB infection, and with the phenotype of active TB. The value of
vitamin D supplementation in active TB to improve disease outcome is unclear. However, we were unable to
evaluate the effect of vitamin D status on IGRA performance because of variation between centres in the
definition of vitamin D status.
In the subset of patients presenting with a TST result as part of their clinical diagnostic workup, the
performance of the TST used in sequence with IGRAs was evaluated. The performance of this combination
was assessed using logistic regression models constructed in the same form as Bayesian updating (post-test
odds = pre-test odds × likelihood ratio) by including the log of the pre-test odds of prevalence (a constant
term of known value) as an offset in the model. A linear predictor was then used to estimate log-likelihood
ratios, rather than log-odds ratios, and bootstrap methods were used to obtain valid CIs.22 Model
parameterisations from Knottnerus23 were used to compute likelihood ratios for the additional diagnostic
value of each test in a testing sequence. Non-parametric, bias-adjusted CIs for parameter estimates from
1000 bootstrap samples were computed.
We performed all analyses using Stata®, version 13.0 (StataCorp LP, College Station, TX, USA).
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Patient and public involvement
Ms Nisha Karnani was our patient and public representative for the duration of the study. She was
consulted at key points during the study and was invited to SSC meetings and the IDEA study presentation
at the end of the study.
Study oversight and management arrangements
Study Management Group
The SMG included the chief investigators, study co-ordinator, lead research nurse and a post-doctoral
research associate. The day-to-day management of the study was carried out by the study co-ordinator,
with close support provided by the chief investigators and other members of the SMG. The SMG met
monthly to discuss study progress and oversight.
Data Management Group
The Data Management Group (DMG) consisted of members of the statistical team and members of the
SMG. The group met regularly to review data on recruitment and the prevalence of TB and HIV in the
study cohort. The DMG reported to the SSC (see Study Steering Committee).
Study Steering Committee
Independent oversight was provided by the SSC. The committee included an independent chairperson
(Professor Khalid Khan), three other independent members (Dr Stephen Gordon, Dr James Grey and
Dr Johannes B Reitsma) and a patient and public involvement (PPI) representative (Ms Nisha Karnani).
Ethics arrangements and regulatory approvals
Ethics approval for this study
This study received ethics approval from the London – Camden Kings Cross Research Ethics Committee
(REC) (reference number 11/H0722/8). The research study was submitted for site-specific assessment at
each participating NHS trust. The chief investigators required a copy of the research and development
(R&D) approval letter before accepting participants into the study. The study was conducted in accordance
with the recommendations for physicians involved in research on human subjects adopted by the 18th
World Medical Assembly, Declaration of Helsinki (1964) and later revisions.24
Consent and study withdrawal
Consent to enter the study was sought from each participant only after a full explanation had been given,
an information sheet offered and time allowed for consideration. Signed participant consent was then
obtained. The right of the participant to refuse to participate without giving reasons was respected. After a
participant was entered into the study the clinician remained free to give any treatment that he or she
considered necessary, or to refer onto an appropriate health-care professional, at any stage if it was
judged to be in the best interest of the participant. Reasons for such decisions were recorded. In such
cases, participants remained in the study for the purposes of follow-up and data analysis. All participants
were free to withdraw at any time from the study without giving reasons. Assurance was provided by the
person taking consent that withdrawal will not affect the patient’s care. In accordance with good clinical
practice guidance, participants who withdrew were not required to give a reason for withdrawal. Data
were collected on participant’s final diagnosis unless consent was withdrawn for any data to be used.
Confidentiality
The chief investigator and all members of the research team abided by the Data Protection Act25 and
preserved the confidentiality of participants involved in the study. Participants were allocated a unique
identifying code (anonymised) on recruitment, with no personal identifiers recorded on any sample or data.
METHODS
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Indemnity
The Imperial College London, as sponsor of this study, holds negligent and non-negligent harm insurance
policies that applied to this study. These were arranged through the Joint Research Office.
Protocol amendments
Between April 2011 and February 2015, the protocol underwent seven amendments as detailed in
Appendix 3, Table 53. Six of the seven amendments were deemed substantial amendments that required
ethics approval, whereas one was a minor amendment.
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Chapter 3 Participant characteristics
The results presented in this chapter are based on all participants recruited prior to the study extension,including those with HIV infection. Thus, the chapter excludes HIV-positive patients recruited during the
study extension period.
Recruitment of participants into main study cohort
A total of 1074 participants, including 177 (16.5%) who were HIV positive, were recruited from 10 NHS trusts
into the main study between 25 November 2011 and 31 August 2013. The number of patients recruited at
each centre is shown in Table 1. Over half of the study participants were recruited from two trusts: Imperial
College Healthcare NHS Trust (26.4%) and London North West Healthcare NHS Trust (27.8%).
The flow of patients through the study is shown in Figure 4. Of the 1074 patients recruited, 845 were included
in the analyses. Reasons for exclusion are shown in Figure 4. Forty patients from Frimley Health NHS Foundation
Trust were excluded because patients all had diagnoses of confirmed or highly probable TB (categories 1 and 2)
due to an error of implementation of recruitment criteria at this site (i.e. the natural spectrum of patients with
suspected TB was not being recruited). The decision to exclude these patients was approved by the SSC
following a SSC meeting during which the diagnosis of patients recruited at each centre was reviewed.
Table 2 shows the number of patients assigned to each diagnostic category. There were 43 (5.1%)
patients with a clinically indeterminate (category 3) diagnosis. Of the remaining 802 patients, there were
363 (45.3%) cases of active TB [based on those with culture-confirmed (category 1) and highly probable
(category 2) TB] and 439 (54.7%) in whom active TB was excluded (categories 4A to 4D). Of the 439
non-active TB cases, 117 (26.7%) were category 4D.
Baseline characteristics of participants
The main demographic characteristics of the 845 patients are given in Table 3. Most patients (64.4%)
were recruited from an outpatient setting, and the remaining were recruited from an inpatient setting.
The median age of patients was 38 (range 16–86) years and most (59.3%) of the patients were male.
TABLE 1 Recruitment by centre
Hospital trust Patients recruited, n (%)
Imperial College Healthcare NHS Trust 283 (26.4)
Heart of England NHS Foundation Trust 106 (9.9)
Chelsea and Westminster Hospital NHS Foundation Trust 52 (4.8)
Royal Free London NHS Foundation Trust 59 (5.5)
St George’s Healthcare NHS Trust 61 (5.7)
Frimley Health NHS Foundation Trust 44 (4.1)
University Hospitals of Leicester NHS Trust 116 (10.8)
London North West Healthcare NHS Trust 299 (27.8)
Oxford University Hospitals NHS Trust 4 (0.4)
Sandwell and West Birmingham Hospitals NHS Trust 50 (4.7)
Total 1074 (100)
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Almost half (48.2%) of the study population were of Indian origin. Altogether, 75 countries of birth were
represented in the study; 16 of the countries had at least 10 participants, with India (26.7%) and the UK
(22.8%) accounting for almost half of the study population. The complete list of countries is given in
Appendix 4, Table 54.
Table 4 shows the clinical characteristics of the patients. Of the 845 patients, 135 (16.0%) were HIV
positive. Out of the 135 patients, there were two (1.5%) with a clinically indeterminate diagnosis. Of the
remaining 133 patients, 25 (18.8%) were active TB cases and 108 (81.2%) were non-active TB cases.
Of the 845 patients, over half had other comorbidities: 300 (35.5%) patients had a single comorbidity,
127 (15.0%) had multiple comorbidities and the remaining 418 (49.5%) had none. There were 88
Patients with suspected TB 
recruited from 10 sites
(n = 1074)
Eligible for analyses
(n = 845)
Highly
probable TB
(n = 102)
Culture-confirmed 
TB
(n = 261)
Active TB
excluded
(n = 439)
Clinically
indeterminate
(n = 43)
T-SPOT.TB, n = 99
QFT-GIT, n = 101
T-SPOT.TB, n = 246
QFT-GIT, n = 252
T-SPOT.TB, n = 423
QFT-GIT, n = 425
T-SPOT.TB, n = 41
QFT-GIT, n = 42
Reasons for exclusion
• Previous TB diagnosis, n = 99a
• Exclusion by investigators, n = 80b
• Loss to follow-up, n = 39
• Withdrawal of consent, n = 8 
• Death, n = 3
FIGURE 4 Study flow diagram of patients with suspected active TB. The final four boxes show the number of patients
with available IGRA results. a, Patients with previously diagnosed TB were excluded from analyses because IGRA
results cannot be reliably interpreted in previously treated patients. The decision to exclude was taken by the expert
diagnostic panel and study management group in consultation with the independent Study Steering Committee before
unblinding of IGRA and next-generation IGRA results. b, On advice from the Study Steering Committee, and following
consultation between the study management group and data management groups, 80 patients were excluded from
analyses. Patients recruited from Frimley Health NHS Foundation Trust (n= 40) were excluded because they all had
diagnoses of confirmed or highly probable TB (categories 1 and 2) due to an error of implementation of the recruitment
criteria at this site, i.e. the natural spectrum of patients with suspected TB was not being recruited. A further subset of
patients (n= 27) were, on review, considered by the expert diagnostic panel to be ineligible (before unblinding IGRA
results) on the basis that they were being investigated for TB (due to an incidental abnormal chest X-ray, known contact
with active TB, or screening for anti-TNF treatment), but did not present with symptoms or signs suggestive of TB. An
additional 13 patients were excluded due to invalid consent forms. Republished with permission of Elsevier Science and
Technology Journals, from Clinical utility of existing and second-generation interferon-γ release assays for diagnostic
evaluation of tuberculosis: an observational cohort study, The Lancet Infectious Diseases, Whitworth HS, Badhan A,
Boakye AA, Takwoingi Y, Rees-Roberts M, Partlett C, et al., vol. 19, pp. 193–202, copyright 2019;27 permission conveyed
through Copyright Clearance Center, Inc.
PARTICIPANT CHARACTERISTICS
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TABLE 2 Reference standard results according to Dosanjh categories
Diagnostic category Criteria
Number of
patients
1: Culture-confirmed TB Microbiological culture of Mtb AND suggestive clinical and
radiological findings
261
2: Highly probable TB Clinical and radiological features highly suggestive of TB and unlikely
to be caused by other disease AND a decision to treat made by a
clinician AND appropriate response to therapy AND histology
supportive (if available)
102
3: Clinically indeterminate Final diagnosis of TB neither highly probable nor reliably excluded 43
4: Active TB excluded
4A: inactive TB Stable CXR changes AND TST positivea (if done) AND bacteriologically
negative (if done) AND no clinical evidence of active disease
7
4B: one or more risk factors for
TB exposure,b TST positivea
TST positivea AND bacteriologically negative (if done) AND no clinical
evidence of active disease
48
4C: one or more risk factors for
TB exposure,b TST negative
History of TB exposure AND TST negative (if done) 267
4D: no risk factors for TB
exposure,b TST negative
No history of TB exposure AND TST negative (if done) 117
Total 845
CXR, chest radiography.
a A TST using the Mantoux test with a threshold of ≥ 15mm considered positive.
b Risk factors for TB exposure: recent exposure to active TB patient, born in country of high prevalence or belonging to an
ethnic group with a high prevalence of TB (incidence > 100/100,00026).
Note
Diagnostic categories adapted from Dosanjh et al.3
TABLE 3 Demographics
Characteristic
Dosanjh category
Total
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
Clinical setting, n (%)
Inpatient 90 (34.5) 30 (29.4) 11 (25.6) 170 (38.7) 301 (35.6)
Outpatient 171 (65.5) 72 (70.6) 32 (74.4) 269 (61.3) 544 (64.4)
Age (years), median
(range)
32 (16–81) 36 (18–76) 38 (16–79) 44 (17–86) 38 (16–86)
Male, n (%) 177 (67.8) 53 (52.0) 21 (48.8) 250 (56.9) 501 (59.3)
Ethnic origin, n (%)
Asian 16 (6.1) 6 (5.9) 5 (11.6) 14 (3.2) 41 (4.9)
Black 50 (19.2) 22 (21.6) 10 (23.3) 102 (23.2) 184 (21.8)
Hispanic 1 (0.4) 0 (0.0) 0 (0.0) 7 (1.6) 8 (0.9)
Indian subcontinent 167 (64.0) 61 (59.8) 16 (37.2) 168 (38.3) 412 (48.8)
Middle Eastern 4 (1.5) 0 (0.0) 0 (0.0) 12 (2.7) 16 (1.9)
Mixed 1 (0.4) 4 (3.9) 0 (0.0) 8 (1.8) 13 (1.5)
White 22 (8.4) 9 (8.8) 12 (27.9) 126 (28.7) 169 (20.0)
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.5) 2 (0.2)
continued
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TABLE 3 Demographics (continued )
Characteristic
Dosanjh category
Total
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
Years in the UK, median
(range)
4.9 (0.1–52.9) 6.1 (0.3–59.7) 10.5 (0.4–56.9) 13.2 (0.0–60.3) 8.3 (0.0–60.3)
Profession, n (%)a
Paid employment 130 (49.8) 52 (51.0) 21 (48.8) 214 (48.7) 417 (49.3)
Unpaid employment 62 (23.8) 24 (23.5) 16 (37.2) 164 (37.4) 266 (31.5)
Student 50 (19.2) 13 (12.7) 3 (7.0) 26 (5.9) 92 (10.9)
Health-care/laboratory
worker
16 (6.1) 9 (8.8) 2 (4.7) 24 (5.5) 51 (6.0)
Social/prison worker 1 (0.4) 1 (1.0) 0 (0.0) 2 (0.5) 4 (0.5)
Sex worker 0 (0.0) 1 (1.0) 0 (0.0) 2 (0.5) 3 (0.4)
Unknown 2 (0.8) 2 (2.0) 1 (2.3) 7 (1.6) 12 (1.4)
a Some patients had more than one profession.
Note
Republished with permission of Elsevier Science and Technology Journals, from Clinical utility of existing and second-
generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort study, The Lancet
Infectious Diseases, Whitworth HS, Badhan A, Boakye AA, Takwoingi Y, Rees-Roberts M, Partlett C, et al., vol. 19,
pp. 193–202, copyright 2019;27 permission conveyed through Copyright Clearance Center, Inc.
TABLE 4 Clinical characteristics
Characteristic
Dosanjh category
Total
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
Height (m), median (range) 1.7 (1.4–2.0) 1.7 (1.5–1.9) 1.6 (1.5–1.8) 1.7 (1.3–2.0) 1.7 (1.3–2.0)
Weight (kg), median
(range)
63 (35–127) 64 (40–116) 71 (37–110) 68 (38–157) 65 (35–157)
BMI (kg/m2), median
(range)
22 (14–48) 22 (16–42) 24 (13–45) 24 (15–47) 23 (13–48)
BCG vaccinated, n (%) 194 (74.3) 79 (77.5) 36 (83.7) 340 (77.4) 649 (76.8)
BCG scar visible, n (%)
Yes 172 (65.9) 72 (70.6) 29 (67.4) 283 (64.5) 556 (65.8)
No 12 (4.6) 3 (2.9) 3 (7.0) 19 (4.3) 37 (4.4)
Unsure 16 (6.1) 8 (7.8) 6 (14.0) 44 (10.0) 74 (8.8)
Missing 61 (23.4) 19 (18.6) 5 (11.6) 93 (21.2) 178 (21.1)
Known TB contact, n (%) 70 (26.8) 25 (24.5) 12 (27.9) 83 (18.9) 190 (22.5)
HIV positive, n (%) 13 (5.0) 12 (11.8) 2 (4.7) 108 (24.6) 135 (16.0)
Other pre-existing conditions/comorbidities, n (%)a
None 169 (64.8) 61 (59.8) 19 (44.2) 169 (38.5) 418 (49.5)
Diabetes 22 (8.4) 5 (4.9) 8 (18.6) 53 (12.1) 88 (10.4)
Hepatitis B 5 (1.9) 1 (1.0) 0 (0.0) 5 (1.1) 11 (1.3)
Hepatitis C 1 (0.4) 1 (1.0) 0 (0.0) 10 (2.3) 12 (1.4)
PARTICIPANT CHARACTERISTICS
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TABLE 4 Clinical characteristics (continued )
Characteristic
Dosanjh category
Total
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
Chronic/end-stage
renal failure
5 (1.9) 1 (1.0) 2 (4.7) 4 (0.9) 12 (1.4)
Cancer 1 (0.4) 1 (1.0) 0 (0.0) 12 (2.7) 14 (1.7)
Organ transplantation 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.5) 2 (0.2)
Asthma 12 (4.6) 5 (4.9) 4 (9.3) 50 (11.4) 71 (8.4)
Sarcoidosis 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1)
Other 74 (28.4) 37 (36.3) 20 (46.5) 228 (51.9) 359 (42.5)
Vitamin D deficiency,b n (%)
Deficient 106 (40.6) 35 (34.3) 12 (27.9) 59 (13.4) 212 (25.1)
Insufficient 49 (18.8) 14 (13.7) 7 (16.3) 65 (14.8) 135 (16.0)
Normal 13 (5.0) 8 (7.8) 5 (11.6) 34 (7.7) 60 (7.1)
Not known 93 (35.6) 45 (44.1) 19 (44.2) 281 (64.0) 438 (51.8)
BMI, body mass index.
a Some patients had multiple comorbidities and so the numbers do not add up to 845.
b For the definition of the thresholds used for categorising vitamin D status, see Appendix 5.
Note
Republished with permission of Elsevier Science and Technology Journals, from Clinical utility of existing and second-
generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort study, The Lancet
Infectious Diseases, Whitworth HS, Badhan A, Boakye AA, Takwoingi Y, Rees-Roberts M, Partlett C, et al., vol. 19,
pp. 193–202, copyright 2019;27 permission conveyed through Copyright Clearance Center, Inc.
TABLE 5 Medication history
Medication
Dosanjh category, n (%)a
Total, n (%)
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
None 63 (24.1) 35 (34.3) 13 (30.2) 203 (46.2) 314 (37.2)
Chemotherapy 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2) 1 (0.1)
Corticosteroids ≥ 15mg/day 20 (7.7) 5 (4.9) 5 (11.6) 20 (4.6) 50 (5.9)
Corticosteroids < 15mg/day 13 (5.0) 7 (6.9) 1 (2.3) 19 (4.3) 40 (4.7)
Corticosteroids unknown 1 (0.4) 1 (1.0) 0 (0.0) 0 (0.0) 2 (0.2)
Ciclosporin, tacrolimus or
everolimus
0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2) 1 (0.1)
Other immune
suppressants
0 (0.0) 0 (0.0) 0 (0.0) 5 (1.1) 5 (0.6)
Methotrexate 1 (0.4) 0 (0.0) 0 (0.0) 5 (1.1) 6 (0.7)
Other 191 (73.2) 64 (62.7) 30 (69.8) 233 (53.1) 518 (61.3)
Unknown 1 (0.4) 0 (0.0) 0 (0.0) 1 (0.2) 2 (0.2)
a Some patients had multiple medications and so the numbers do not add up to 845.
Note
Republished with permission of Elsevier Science and Technology Journals, from Clinical utility of existing and second-
generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort study, The Lancet
Infectious Diseases, Whitworth HS, Badhan A, Boakye AA, Takwoingi Y, Rees-Roberts M, Partlett C, et al., vol. 19,
pp. 193–202, copyright 2019;27 permission conveyed through Copyright Clearance Center, Inc.
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(10.4%) patients with pre-existing diabetes mellitus, 12 (1.4%) patients with chronic/end-stage renal
failure and 105 (12.4%) patients were on immunosuppressive therapy (Table 5). These were the three
key subgroups that we had planned to investigate in the subgroup analyses. The thresholds used to
categorise vitamin D status varied between hospital trusts, as detailed in Appendix 5, Table 55. Although
vitamin D measurements were missing for a large number of patients (49.1%), when the results were
available, many patients were categorised as either vitamin D deficient (26.5%) or insufficient (16.9%),
with few (7.5%) having normal results (see Table 4).
The social history of participants is outlined in Table 6. Smoking history was missing for two patients;
about two-thirds of the patients had never smoked, and the remaining patients were current or
ex-smokers. Most (58.6%) patients also had no history of alcohol use. Almost all patients (97.6%) had
no history of homelessness and a few patients (27/845, 3.2%) had a history of imprisonment.
TABLE 6 Social history
Characteristic
Dosanjh category
Total
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
Smoking history, n (%)
Never smoked 181 (69.3) 81 (79.4) 26 (60.5) 248 (56.5) 536 (63.4)
Ex-smoker 31 (11.9) 8 (7.8) 6 (14.0) 93 (21.2) 138 (16.3)
Current smoker 49 (18.8) 13 (12.7) 11 (25.6) 96 (21.9) 169 (20.0)
Unknown 0 0 0 2 (0.5) 2 (0.2)
Pack years if current smoker, n (%)
≤ 10 11 (22.4) 6 (46.2) 4 (36.4) 27 (28.1) 48 (28.4)
11–20 1 (2.0) 2 (15.4) 1 (9.1) 6 (6.3) 10 (5.9)
21–50 1 (2.0) 1 (7.7) 0 7 (7.3) 9 (5.3)
> 51 1 (2.0) 0 0 1 (1.0) 2 (1.2)
Unknown 35 (71.4) 4 (30.8) 6 (54.5) 55 (57.3) 100 (59.2)
History of alcohol use, n (%)
Non-drinker 163 (62.5) 80 (78.4) 27 (62.8) 225 (51.3) 495 (58.6)
Ex-drinker 10 (3.8) 2 (2.0) 1 (2.3) 35 (8.0) 48 (5.7)
Current drinker 88 (33.7) 20 (19.6) 15 (34.9) 175 (39.9) 298 (35.3)
Unknown 0 0 0 4 (0.9) 4 (0.5)
Units/week if current drinker,
median (range)
4 (0–250) 5 (1–35) 2 (0–140) 5 (0–210) 4 (0–250)
History of alcohol misuse, n (%) 9 (3.4) 0 1 (2.3) 20 (4.6) 30 (3.6)
History of recreational drug use, n (%)
Non-user 21 (8.0) 10 (9.8) 1 (2.3) 18 (4.1) 50 (5.9)
Ex-user 2 (0.8) 0 1 (2.3) 5 (1.1) 8 (0.9)
Current user 5 (1.9) 3 (2.9) 1 (2.3) 13 (3.0) 22 (2.6)
Unknown 233 (89.3) 89 (87.3) 40 (93.0) 403 (91.8) 765 (90.5)
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Table 7 summarises the frequency of presenting symptoms for 827 patients. The main symptoms recorded
were cough, fever, night sweats, weight loss, haemoptysis and lethargy. Patients generally presented with
multiple symptoms, but a cough was often present (576/827, 69.6%). The median number of symptoms
was four (range 1–10).
TABLE 6 Social history (continued )
Characteristic
Dosanjh category
Total
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
History of homelessness, n (%)
None 256 (98.1) 101 (99.0) 43 (100.0) 425 (96.8) 825 (97.6)
Previously homeless 2 (0.8) 1 (1.0) 0 11 (2.5) 14 (1.7)
Currently homeless 3 (1.1) 0 0 3 (0.7) 6 (0.7)
Years homeless if currently or
previously homeless, median
(range)
4 (0–6) 12 – 6 (0–24) 6 (0–24)
History of imprisonment, n (%) 4 (1.5) 2 (2.0) 0 21 (4.8) 27 (3.2)
Note
The percentages are column percentages for each characteristic.
TABLE 7 Symptoms at presentation
Symptom
Diagnosis as per reference standard1
Total
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
Cough, n (%) 174 (68.0) 53 (53.5) 23 (53.5) 326 (76.0) 576 (69.6)
Fever, n (%) 126 (49.2) 49 (49.5) 14 (32.6) 195 (45.5) 384 (46.4)
Night sweats, n (%) 129 (50.4) 53 (53.5) 20 (46.5) 215 (50.1) 417 (50.4)
Weight loss, n (%) 154 (60.2) 54 (54.5) 21 (48.8) 211 (49.2) 440 (53.2)
Haemoptysis, n (%) 31 (12.1) 8 (8.0) 3 (7.0) 65 (15.2) 107 (12.9)
Lethargy, n (%) 133 (52.0) 56 (56.6) 23 (53.5) 222 (51.7) 434 (52.5)
Other, n (%) 163 (63.7) 59 (59.46) 25 (58.1) 202 (47.1) 449 (54.3)
Number of symptoms, median
(range)
4 (1–10) 4 (1–8) 3 (1–7) 3 (1–10) 4 (1–10)
Eighteen participants were recruited on the basis of abnormal clinical signs rather than symptoms. The percentages are
column percentages for each symptom.
Note
Republished with permission of Elsevier Science and Technology Journals, from Clinical utility of existing and second-
generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort study, The Lancet
Infectious Diseases, Whitworth HS, Badhan A, Boakye AA, Takwoingi Y, Rees-Roberts M, Partlett C, et al., vol. 19,
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Final diagnosis
Table 8 shows the diagnostic tests performed during the diagnostic workup of patients. Chest radiography
and culture were often performed (in 89.4% and 86.5% of patients, respectively), but cerebrospinal fluid
testing and magnetic resonance imaging (MRI) were uncommon (in 3.6% and 12.0%, respectively). The
number of T-SPOT.TB, QFT-GIT and TST tests performed as part of routine care at each centre is shown in
Appendix 6, Table 56. However, for the purpose of the IDEA study, IGRAs were not used in determining
the final diagnosis of patients. TSTs were performed in only 336 patients across the nine centres and
results were available for 322 patients. Most of these 336 patients were recruited at London North West
Healthcare NHS Trust (57%) and Imperial College Healthcare NHS Trust (26%).
The final diagnosis of active TB patients is detailed in Table 9. Of the 363 patients with active TB, 237 (65.3%)
had smear-negative TB. Forty-five (12.4%) active TB cases had both pulmonary and extrapulmonary TB.
Approximately half (189/363, 52.1%) had only extrapulmonary TB. This occurred more often among those
diagnosed as having highly probable TB (75/102, 73.5%) relative to culture-confirmed cases (114/261,
43.7%). In 129 (35.5%) active TB cases, patients had only pulmonary TB. In contrast to extrapulmonary TB,
pulmonary TB was more common among culture-confirmed cases (110/261, 42.15%) than in highly probable
TB cases (19/102, 18.6%). The most common sites of TB infection were the lungs (174/363, 47.9%) and
lymph nodes (154/363, 42.4%). The drug sensitivity profile shows that of the 351 culture tests performed,
239 (65.8%) were fully sensitive and 22 (6.3%) were drug resistant.
Table 10 shows the final diagnosis of non-active TB patients. A patient may have multiple conditions.
Of the seven conditions listed in the table, pneumonia was the most frequent diagnosis, with 104 of 439
(23.7%) patients having the condition. A higher proportion of inpatients were diagnosed with cancer
(14.1%) or pneumonia (38.8%) than outpatients (4.5% and 14.1%, respectively). In contrast, a higher
proportion of outpatients were diagnosed with chest infections, latent TB infection and sarcoidosis.
TABLE 8 Diagnostic tests performed during diagnostic workup
Test
Dosanjh category, n (%)
Total, n (%)
Culture-
confirmed TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
BAL investigation 51 (19.5) 20 (19.6) 7 (16.3) 108 (24.6) 186 (22.0)
CXR 231 (88.5) 95 (93.1) 38 (88.4) 391 (89.1) 755 (89.3)
CSF investigation 7 (2.7) 6 (5.9) 3 (7.0) 14 (3.2) 30 (3.6)
CT 142 (54.4) 69 (67.6) 26 (60.5) 273 (62.2) 510 (60.4)
Culture 261 (100) 90 (88.2) 29 (67.4) 351 (80.0) 731 (86.5)
Histology or biopsy 72 (27.6) 42 (41.2) 15 (34.9) 101 (23.0) 230 (27.2)
MRI 29 (11.1) 17 (16.7) 8 (18.6) 47 (10.7) 101 (12.0)
PCR 85 (32.6) 20 (19.6) 6 (14.0) 66 (15.0) 177 (20.9)
Smear test 232 (88.9) 75 (73.5) 24 (55.8) 335 (76.3) 666 (78.8)
CSF, cerebrospinal fluid; CXR, chest radiography.
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TABLE 9 Final diagnosis of patients with active TB
Characteristic
Category of TB, n (%)
Total, n (%)1 2
All TB 261 (71.9) 102 (28.1) 363 (100)
Smear-positive TB 67 (25.7) 3 (2.9) 70 (19.3)
Smear-negative TB 165 (63.2) 72 (70.6) 237 (65.3)
Pulmonary TB 110 (42.1) 19 (18.6) 129 (35.5)
Extrapulmonary TB 114 (43.7) 75 (73.5) 189 (52.1)
Pulmonary and extrapulmonary TB 37 (14.2) 8 (7.8) 45 (12.4)
Site of infectiona
Abdomen 6 (2.3) 3 (2.9) 9 (2.5)
Bones 5 (1.9) 0 5 (1.4)
Brain 2 (0.8) 4 (3.9) 6 (1.7)
Chest wall 1 (0.4) 1 (1.0) 2 (0.6)
Lungs 147 (56.3) 27 (26.5) 174 (47.9)
Lymph node 105 (40.2) 49 (48.0) 154 (42.4)
Miliary TB (disseminated) 11 (4.2) 0 11 (3.0)
Pericardium 4 (1.5) 2 (2.0) 6 (1.7)
Pleura 15 (5.7) 11 (10.8) 26 (7.2)
Spine 10 (3.8) 6 (5.9) 16 (4.4)
Other 15 (5.7) 16 (15.7) 31 (8.5)
Drug sensitivity profileb
Fully sensitive 239 (91.6) 0 239 (68.1)
Drug resistant 21 (8.1) 0 21 (6.0)
MDR 1 (0.4) 0 1 (0.3)
Not tested 0 90 (100) 90 (25.6)
MDR, multidrug resistant.
a Some patients had TB at multiple sites and so percentages do not add up to 100%.
b Available where culture tests were performed during diagnostic work up (n= 351).
Note
Republished with permission of Elsevier Science and Technology Journals, from Clinical utility of existing and second-
generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort study, The Lancet
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TABLE 10 Final diagnosis of patients without active TB
Diagnosis
Non-active TB patients, n (%)
Total, n (%) (N= 439)Inpatients (n= 170) Outpatients (n= 269)
Cancer 24 (14.1) 12 (4.5) 36 (8.2)
Chest infection 1 (0.6) 15 (5.6) 16 (3.6)
Lower respiratory tract infection 10 (5.9) 13 (4.8) 23 (5.2)
Pneumonia 66 (38.8) 38 (14.1) 104 (23.7)
Sarcoidosis 5 (2.9) 33 (12.3) 38 (8.7)
Upper respiratory tract infection 0 (0.0) 13 (3.0) 13 (3.0)
Other 70 (41.2) 153 (56.9) 223 (50.8)
Note
Some patients had multiple diagnoses and so percentages represent the number of patients with that particular diagnosis
out of the total number.
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Chapter 4 Diagnostic accuracy results
Overview
Estimates of the accuracy of IGRAs presented in this chapter are for the main cohort of patients (including
HIV-positive patients recruited prior to the extension period). Estimates of the accuracy of T-SPOT.TB and
QFT-GIT are presented individually, followed by comparisons of test accuracy (T-SPOT.TB vs. QFT-GIT). The
results of subgroup analyses are then presented for T-SPOT.TB and QFT-GIT. Finally, test accuracy estimates
are provided for ESAT-6, CFP-10 and second-generation IGRAs (Rv3615c, Rv2654, Rv3879c and Rv3873)
individually and in combinations; the diagnostic accuracy of the test combinations were then compared
with that of T-SPOT.TB. For completeness, we also briefly address the accuracy of the TST.
Completeness of interferon gamma release assay results
Of the 845 patients, T-SPOT.TB and QFT-GIT results were available for 809 (96%) and 820 (97%) patients,
respectively. All 809 patients with T-SPOT.TB results also had results for the second-generation IGRAs
(Rv3615c, Rv2654, Rv3879c and Rv3873). Table 11 shows the results for T-SPOT.TB and QFT-GIT by
diagnostic category. For 805 patients, results were available for both IGRAs; reasons for missing T-SPOT.TB
and QFT-GIT results are shown in Table 12. The cross-classified results of the two tests are given in
Appendix 7 (see Table 57) for the 805 patients.
TABLE 11 Results for T-SPOT.TB and QFT-GIT by diagnostic category
Index test result
Dosanjh category
Total1 2 3 4A 4B 4C 4D 4A–D
T-SPOT.TB
Positive 185 68 15 0 18 27 6 51 319
Negative 33 25 23 6 26 200 87 319 400
Borderline 16 1 0 0 1 14 1 16 33
Indeterminate 12 5 3 1 1 18 17 37 57
Missing 15 3 2 0 2 8 6 16 36
Total 261 102 43 7 48 267 117 439 845
Median SFCs
ESAT-6 (range)
13
(0–387)
13
(0–492)
0
(0–325)
0
(0–1)
2
(0–274)
0
(0–210)
0
(0–147)
0
(0–274)
1
(0–492)
Median SFCs
CFP-10 (range)
17
(0–465)
13
(0–437)
1
(0–315)
0
(0–3)
1
(0–160)
0
(0–166)
0
(0–148)
0
(0–166)
1
(0–465)
QFT-GIT
Positive 163 57 14 0 19 49 6 74 308
Negative 68 39 22 7 25 187 85 304 433
Indeterminate 21 5 6 0 2 26 19 47 79
Missing 9 1 1 0 2 5 7 14 25
Total 261 102 43 7 48 267 117 439 845
Median IFN-γ
levels (range)
0.69
(0–10)
0.64
(0–10)
0.15
(0–6.69)
0.02
(0–0.34)
0.15
(0–10)
0.03
(0–10)
0.01
(0–7.58)
0.03
(0–10)
0.12
(0–10)
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Diagnostic accuracy of T-SPOT.TB and QuantiFERON GOLD In-Tube
Table 13 shows the cross-tabulation of T-SPOT.TB and QFT-GIT results against active TB status (i.e. active
TB or not). The proportion of indeterminate test results was 7.0% (57/809) for T-SPOT.TB and 9.6%
(79/820) for QFT-GIT. The difference between the two proportions was 2.6% (95% CI –0.1% to 5.3%;
p = 0.06). Based on all culture-confirmed and highly probable active TB cases and excluding indeterminate
IGRA results, sensitivity was 82.3% (95% CI 77.8% to 86.1%) for T-SPOT.TB and 67.3% (95% CI 62.0%
to 72.1%) for QFT-GIT. Among those in whom active TB was excluded, specificity was 82.6% (95% CI
78.6% to 86.1%) for T-SPOT.TB and 80.4% (95% CI 76.1% to 84.1%) for QFT-GIT (Table 14). The PPVs
for T-SPOT.TB and QFT-GIT were 80.1% (95% CI 75.5% to 84.0%) and 74.8% (95% CI 69.6% to
79.5%), respectively, and the NPVs were 84.6% (95% CI 80.6% to 87.9%) and 74.0% (95% CI 69.5%
to 78.0%), respectively. For T-SPOT.TB, 4.1% (33/809) of the test results were borderline (see Table 13).
When these borderline results were excluded from the T-SPOT.TB analysis, sensitivity (95% CI) was 81.4%
(76.6% to 85.3%), specificity (95% CI) was 86.2% (82.3% to 89.4%), PPV (95% CI) was 83.2% (78.6%
to 87.0%) and NPV (95% CI) was 84.6% (80.6% to 87.9%). The full results of the analysis are shown in
Appendix 7, Table 58.
Using only culture-confirmed active TB cases, the sensitivities of T-SPOT.TB and QFT-GIT increased slightly
to 85.9% (95% CI 80.9% to 89.8%) and 70.6% (95% CI 64.4% to 76.1%), respectively. The sensitivity
of T-SPOT.TB was 7.0% lower in patients diagnosed with pulmonary TB than in those with extrapulmonary
TB [77.0% (95% CI 68.4% to 83.8%) vs. 84.0% (95% CI 77.9% to 88.7%)]. In contrast, although the
difference was small (2.3%), the sensitivity of QFT-GIT was higher in patients who had pulmonary TB
(68.4%, 95% CI 59.4% to 76.2%) than in those with extrapulmonary TB (66.1%, 95% CI 58.7% to
72.8%). Using only category 4D patients without active TB gave much higher specificities than using all
patients without active TB (see Table 14).
In the sensitivity analyses with indeterminate test results included as test positives, the sensitivity of T-SPOT.TB
was 83.2% (95% CI 78.9% to 86.8%) and 69.7% (95% CI 64.7% to 74.2%) for QFT-GIT. The specificity
of T-SPOT.TB was 75.4% (95% CI 71.1% to 79.3%) and 71.5% (95% CI 67.1% to 75.6%) for QFT-GIT.
Full results are provided in Appendix 7, Table 59.
Sensitivity, specificity and predictive values are presented as percentages. For TSPOT.TB, there were 69 test
positives out of 94 highly probable TB cases, with sensitivity (95% CI) of 73.4% (63.7% to 81.3%). For
QFT-GIT, there were 57 test positives out of 96 highly probable TB cases, with sensitivity (95% CI) of 59.4%
(49.4% to 68.7%). Note that in the primary analyses of T-SPOT.TB, borderline test results were included as
test positives. Sensitivity analyses were performed with borderline T-SPOT.TB results excluded and the
results are shown in Appendix 7, Table 58. Indeterminate IGRA results were excluded from all analyses.
See Appendix 7 for sensitivity analyses using all IGRA results with indeterminates included as test positives.
TABLE 12 Reasons for missing IGRA results
Reason
Test, n
QFT-GIT T-SPOT.TB
No sample could be taken 1 0
Sample destroyed for laboratory reasons 2 11
Sample unsuitable for testing 6 8
Unable to obtain sample from patient 16 17
Total 25 36
Note
The same reason applied to both test results for 20 participants.
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TABLE 13 Cross-tabulation of T-SPOT.TB and QFT-GIT against final diagnosis27
T-SPOT.TB, n
Active TB positive (categories 1 and 2) Active TB negative (category 4)
Positive Negative Borderline Indeterminate Missing Total Positive Negative Borderline Indeterminate Missing Total
QFT-GIT
Positive 187 13 6 9 5 220 37 30 3 3 1 74
Negative 49 41 8 7 2 107 12 250 12 26 4 304
Indeterminate 16 4 3 1 2 26 2 36 1 8 0 47
Missing 1 0 0 0 9 10 0 3 0 0 11 14
Total 253 58 17 17 18 363 51 319 16 37 16 439
Note
Republished with permission of Elsevier Science and Technology Journals, from Clinical utility of existing and second-generation interferon-γ release assays for diagnostic evaluation of
tuberculosis: an observational cohort study, The Lancet Infectious Diseases, Whitworth HS, Badhan A, Boakye AA, Takwoingi Y, Rees-Roberts M, Partlett C, et al., vol. 19, pp. 193–202,
copyright 2019;27 permission conveyed through Copyright Clearance Center, Inc.
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Comparison of diagnostic accuracy of T-SPOT.TB and QuantiFERON GOLD
In-Tube
Excluding indeterminate IGRA results, there were 714 T-SPOT.TB results and 705 QFT-GIT results. Based on
analyses using GEE models, the sensitivity of T-SPOT.TB was superior to that of QFT-GIT (relative sensitivity
1.22, 95% CI 1.14 to 1.31; p < 0.001), but there was no statistical evidence of a difference in specificity
(relative specificity 1.02, 95% CI 0.97 to 1.08; p = 0.3) (Table 15). Excluding the 33 borderline T-SPOT.TB
results (see Appendix 7, Table 60), the results for relative sensitivity were similar to those from the main
analysis but there was statistical evidence of a difference in specificity; the relative sensitivity (95% CI) was
1.20 (1.12 to 1.29; p < 0.001) and the relative specificity (95% CI) was 1.07 (1.02 to 1.12; p = 0.004).
TABLE 14 Diagnostic accuracy of T-SPOT.TB and QFT-GIT for diagnosis of active TB
Test performance
T-SPOT.TB QFT-GIT
n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
All TB 270/328 82.3 (77.8 to 86.1) 220/327 67.3 (62.0 to 72.1)
Culture-positive TB 201/234 85.9 (80.9 to 89.8) 163/231 70.6 (64.4 to 76.1)
Culture-negative TB 59/83 71.1 (60.6 to 79.7) 48/84 57.1 (46.5 to 67.2)
Smear-positive TB 50/60 83.3 (72.0 to 90.7) 42/56 75.0 (62.3 to 84.5)
Smear-negative TB 179/216 82.9 (77.3 to 87.3) 148/222 67.7 (60.2 to 72.5)
Pulmonary TB 87/113 77.0 (68.4 to 83.8) 78/114 68.4 (59.4 to 76.2)
Extrapulmonary TB 147/175 84.0 (77.9 to 88.7) 113/171 66.1 (58.7 to 72.8)
Specificity for a diagnosis of active TB
Active TB excluded 319/386 82.6 (78.6 to 86.1) 304/378 80.4 (76.1 to 84.1)
Active TB excluded, TST
negative, no risk factors for LTBI
87/94 92.3 (85.4 to 96.4) 85/91 93.4 (86.4 to 96.9)
Predictive values
PPV 270/337 80.1 (75.5 to 84.0) 220/294 74.8 (69.6 to 79.5)
NPV 319/377 84.6 (80.6 to 87.9) 304/411 74.0 (69.5 to 78.0)
Likelihood ratios
Positive likelihood ratio – 4.74 (3.79 to 5.93) – 3.44 (2.76 to 4.27)
Negative likelihood ratio – 0.21 (0.17 to 0.27) – 0.41 (0.35 to 0.48)
TABLE 15 Comparison of diagnostic accuracy of T-SPOT.TB and QFT-GIT
Test
Number of
test resultsa Sensitivity (95% CI)
Number of
test resultsb Specificity (95% CI)
T-SPOT.TB 328 82.2 (77.7 to 85.9) 386 83.0 (78.9 to 86.4)
QFT-GIT 327 67.3 (62.1 to 72.2) 378 81.0 (76.8 to 84.6)
Ratio (95% CI);c p-value – 1.22 (1.14 to 1.31); < 0.001 – 1.02 (0.97 to 1.08); 0.3
a Number of test results among those with active TB.
b Number of test results among those without active TB.
c The ratio of the sensitivity (or specificity) of T-SPOT.TB to that of QFT-GIT. The natural outputs from GEE models are odds
ratios. Ratios of sensitivities (relative sensitivity) and ratios of specificities (relative specificity) were computed post
estimation of the models. CIs were obtained using the delta method.
Note
Sensitivity and specificity values are presented as percentages.
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When all IGRA results were analysed and indeterminate IGRA results were included as test positives in a
sensitivity analysis, the analysis included 768 T-SPOT.TB results and 778 QFT-GIT results. Similar to the
primary analysis, there was statistical evidence of a difference in sensitivity (relative sensitivity 1.19, 95% CI
1.12 to 1.28; p < 0.001) and no evidence of a difference in specificity (relative specificity 1.05 95% CI 0.98
to 1.13; p = 0.1) (see Appendix 7, Table 61).
Subgroup analyses for T-SPOT.TB and QuantiFERON GOLD In-Tube
Human immunodeficiency virus-positive and -negative patients
Human immunodeficiency virus co-infected patients are the highest-risk subgroup for TB. In this section
we briefly present results for the 135 HIV-positive patients in the main cohort and address the primary
objectives related to this subgroup in Chapter 5 using all HIV-positive patients recruited into the IDEA
study. Appendix 8 (see Table 62) shows the results for T-SPOT.TB and QFT-GIT against active TB status.
Appendix 8 (see Table 63) shows the cross-tabulation of T-SPOT.TB and QFT-GIT results in HIV-positive
patients. For 134 patients, results were available for both T-SPOT.TB and QFT-GIT.
The number of test results for active TB and non-active TB patients who were available for the analyses of
test performance in HIV-positive patients was small (see Appendix 8, Table 62). Using culture-confirmed
and highly probable active TB cases and excluding indeterminate IGRA results, sensitivity was 63.2%
(95% CI 41.0% to 80.9%) for T-SPOT.TB and 56.5% (95% CI 36.8% to 74.4%) for QFT-GIT. Among
all non-active TB patients, specificity was 89.9% (95% CI 81.3% to 94.8%) for T-SPOT.TB and 92.0%
(95% CI 84.3% to 96.1%) for QFT-GIT (Table 16). For T-SPOT.TB and QFT-GIT, the PPVs were 60.0%
TABLE 16 Diagnostic accuracy of T-SPOT.TB and QFT-GIT in HIV-positive patients
Test performance
Test
T-SPOT.TB QFT-GIT
n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
All TB 12/19 63.2 (41.0 to 80.9) 13/23 56.5 (36.8 to 74.4)
Culture-positive TB 7/11 63.6 (35.4 to 84.8) 8/13 61.5 (35.5 to 82.3)
Culture-negative TB 5/8 62.5 (30.6 to 86.3) 5/9 55.6 (26.7 to 81.1)
Smear-positive TB 1/4 25.0 (4.6 to 69.9) 3/5 60.0 (23.1 to 88.2)
Smear-negative TB 7/11 63.6 (35.4 to 84.8) 7/14 50.0 (26.8 to 73.2)
Pulmonary TB 3/5 60.0 (23.1 to 88.2) 5/8 62.5 (30.6 to 86.3)
Extrapulmonary TB 7/10 70.0 (39.7 to 89.2) 6/12 50.0 (25.4 to 74.6)
Specificity for a diagnosis of active TB
Active TB excluded 71/79 89.9 (81.3 to 94.8) 80/87 92.0 (84.3 to 96.1)
Active TB excluded, TST
negative, no risk factors for LTBI
28/29 96.6 (82.8 to 99.4) 36/38 94.7 (82.7 to 98.5)
Predictive values
PPV 12/20 60.0 (38.7 to 78.1) 13/20 65.0 (43.3 to 81.9)
NPV 71/78 91.0 (82.6 to 95.6) 80/90 88.9 (80.7 to 93.9)
Likelihood ratios
Positive likelihood ratio – 6.24 (2.97 to 13.1) – 7.03 (3.17 to 15.6)
Negative likelihood ratio – 0.41 (0.22 to 0.74) – 0.47 (0.30 to 0.76)
Note
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA results were excluded from
these analyses. See Appendix 8, Table 64, for the sensitivity analyses with indeterminates included as test positives.
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(95% CI 38.7% to 78.1%) and 65.0% (95% CI 43.3% to 81.9%), respectively, and the NPVs were
91.0% (95% CI 82.6% to 95.6%) and 88.9% (95% CI 80.7% to 93.9%), respectively.
For HIV-negative patients (Table 17), results were generally similar to those of the entire cohort that
included both HIV-negative and -positive patients (see Table 14). For both subgroups, inclusion of
indeterminate IGRA results in sensitivity analyses led to higher sensitivities, lower specificities and no
change in NPVs, which is as expected because of the inclusion of indeterminates as test positives
(see Appendix 8, Tables 64 and 65).
Other key patient subgroups
For our secondary objective of quantifying test accuracy in three key patient subgroups (patients with
pre-existing diabetes mellitus, end-stage renal failure and iatrogenic immunosuppression), numbers of
participants in the subgroups were small but, nonetheless, we evaluated the performance of IGRAs in
patients with diabetes (see Table 4). The results for T-SPOT.TB and QFT-GIT against active TB status are
shown in Appendix 9, Table 66. Owing to the limited number of data for the TST, only the performance of
T-SPOT.TB and QFT-GIT is presented below (see Table 18). Table 67 in Appendix 9 shows the cross-tabulation
of T-SPOT.TB and QFT-GIT results in the 88 patients with diabetes mellitus. For 86 patients, the results were
available for both T-SPOT.TB and QFT-GIT.
TABLE 17 Diagnostic accuracy of T-SPOT.TB and QFT-GIT in HIV-negative patients
Test performance
Test
T-SPOT.TB QFT-GIT
n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
All TB 258/309 83.5 (79.0 to 87.2) 207/304 68.1 (62.7 to 73.1)
Culture-positive TB 194/223 87.0 (81.9 to 90.8) 155/218 71.1 (64.8 to 76.7)
Culture-negative TB 54/75 72.0 (61.0 to 80.9) 43/75 57.3 (46.1 to 67.9)
Smear-positive TB 49/56 87.5 (76.4 to 93.8) 39/51 76.5 (63.2 to 86.0)
Smear-negative TB 172/205 83.9 (78.3 to 88.3) 141/208 67.8 (61.2 to 73.8)
Pulmonary TB 84/108 77.8 (69.1 to 84.6) 73/106 68.9 (59.5 to 76.9)
Extrapulmonary TB 140/165 84.8 (78.6 to 89.5) 107/159 67.3 (59.7 to 74.1)
Specificity for a diagnosis of active TB
Active TB excluded 248/307 80.8 (76.0 to 84.8) 224/291 77.0 (71.8 to 81.4)
Active TB excluded, TST
negative, no risk factors for LTBI
59/65 90.8 (81.3 to 95.7) 49/53 92.5 (82.1 to 97.0)
Predictive values
PPV 258/317 81.4 (76.7 to 85.3) 207/274 75.6 (70.1 to 80.3)
NPV 248/299 82.9 (78.3 to 86.8) 224/321 69.8 (64.6 to 74.6)
Likelihood ratios
Positive likelihood ratio – 4.35 (3.44 to 5.49) – 2.96 (2.37 to 3.70)
Negative likelihood ratio – 0.20 (0.16 to 0.26) – 0.42 (0.35 to 0.49)
Note
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA results were excluded from
these analyses. See Appendix 8, Table 65, for sensitivity analyses with indeterminates included as test positives.
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Excluding indeterminate IGRA results, sensitivity was 68.0% (95% CI 48.4% to 82.8%) for T-SPOT.TB and
55.6% (95% CI 37.3% to 72.4%) for QFT-GIT among patients with culture-confirmed and highly probable
active TB. Based on all non-active TB patients, specificity was 77.6% (95% CI 64.1% to 87.0%) for T-SPOT.TB
and 78.7% (95% CI 65.1% to 88.0%) for QFT-GIT (Table 18). The PPVs were 60.7% (95% CI 42.4% to
76.4%) and 60.0% (95% CI 40.7% to 76.6%), and the NPVs were 82.6% (95% CI 69.3% to 90.9%) and
75.5% (95% CI 61.9% to 85.4%) for T-SPOT.TB and QFT-GIT, respectively. These analyses were based on
limited data and so should be interpreted with caution. Appendix 9 (see Table 68) shows the performance of
both tests when indeterminate IGRA results were included as test positives in sensitivity analyses.
Variation in relative performance of T-SPOT.TB and QuantiFERON-TB Gold Plus
We explored the effect of HIV co-infection, diabetes mellitus, smoking and clinical setting on the relative
test performance of T-SPOT.TB and QFT-GIT. Each covariate was investigated in a separate regression
model. The sensitivities of both tests were superior in HIV-negative patients than in HIV-positive patients.
However, there was no statistical evidence of an effect of HIV infection status on relative sensitivity
(p = 0.2). In contrast, specificities were superior in HIV-positive patients than in HIV-negative patients,
but there was no statistical evidence of an effect of HIV infection status on relative specificity (p = 0.2).
Although the sensitivities and specificities of both tests were higher in those without diabetes mellitus than
in those with diabetes mellitus, there was no statistical evidence of an effect on relative test performance
(Table 19). Although the p-value from the Wald test of the interaction between test type and smoking
TABLE 18 Diagnostic accuracy of T-SPOT.TB and QFT-GIT in patients with diabetes mellitus
Test performance
Test
T-SPOT.TB QFT-GIT
n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
All TB 17/25 68.0 (48.4 to 82.8) 15/27 55.6 (37.3 to 72.4)
Culture-positive TB 14/21 66.7 (45.4 to 82.8) 12/22 54.5 (34.7 to 73.1)
Culture-negative TB 3/4 75.0 (30.1 to 95.4) 3/5 60.0 (23.1 to 88.2)
Smear-positive TB 7/9 77.8 (45.3 to 93.7) 6/9 66.7 (35.4 to 87.9)
Smear-negative TB 9/14 64.3 (38.8 to 83.7) 7/16 43.8 (23.1 to 66.8)
Pulmonary TB 4/8 50.0 (21.5 to 78.5) 5/9 55.6 (26.7 to 81.1)
Extrapulmonary TB 10/13 76.9 (49.7 to 91.8) 8/14 57.1 (32.6 to 78.6)
Specificity for a diagnosis of active TB
Active TB excluded 38/49 77.6 (64.1 to 87.0) 37/47 78.7 (65.1 to 88.0)
Active TB excluded, TST
negative, no risk factors for LTBI
6/7 85.7 (48.7 to 97.4) 4/5 80.0 (37.6 to 96.4)
Predictive values
PPV 17/28 60.7 (42.4 to 76.4) 15/25 60.0 (40.7 to 76.6)
NPV 38/46 82.6 (69.3 to 90.9) 37/49 75.5 (61.9 to 85.4)
Likelihood ratios
Positive likelihood ratio – 3.03 (1.69 to 5.44) – 2.61 (1.37 to 4.98)
Negative likelihood ratio – 0.41 (0.23 to 0.75) – 0.57 (0.36 to 0.88)
Note
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA results were excluded from
these analyses. See Appendix 9, Table 68 for sensitivity analyses with indeterminates included as test positives.
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TABLE 19 Effect of comorbidities, smoking and clinical setting on relative test performance of T-SPOT.TB and QFT-GIT
Covariate NTD NQD
Sensitivity (95% CI)
p-value NTND NQND
Specificity (95% CI)
p-valueT-SPOT.TB QFT-GIT T-SPOT.TB QFT-GIT
None 328 327 82.2 (77.7 to 85.9) 67.3 (62.1 to 72.2) N/A 386 378 83.0 (78.9 to 86.4) 81.0 (76.8 to 84.6) N/A
HIV infection status
Negative 309 304 83.5 (79.0 to 87.3) 68.2 (62.8 to 73.2) – 307 291 80.8 (76.0 to 84.8) 77.5 (72.4 to 81.9) –
Positive 19 23 60.1 (38.0 to 78.7) 56.1 (36.1 to 74.35) 0.2 79 87 90.0 (81.2 to 94.7) 92.3 (84.7 to 96.3) 0.2
Diabetes
No 303 300 83.3 (78.7 to 87.1) 68.3 (62.9 to 73.3) – 337 331 83.8 (79.6 to 87.3) 81.2 (76.7 to 85.0) –
Yes 25 27 67.8 (47.8 to 82.9) 55.6 (36.9 to 72.8) 0.5 49 47 76.9 (63.2 to 86.6) 79.8 (66.0 to 88.8) 0.4
Smoking statusa
Never smoked 238 239 83.8 (78.6 to 87.9) 65.3 (59.1 to 71.1) – 220 216 83.0 (77.5 to 87.3) 78.0 (72.1 to 83.0) –
Previous smoke 34 29 77.0 (60.2 to 88.1) 82.2 (64.5 to 92.2) 0.01 82 77 81.0 (71.1 to 88.0) 80.4 (70.2 to 87.8) 0.4
Current smoke 56 59 78.5 (66.0 to 87.3) 68.3 (55.6 to 78.8) 0.2 82 83 84.3 (75.0 to 90.6) 88.8 (80.2 to 94.0) 0.06
Clinical setting
Inpatient 104 96 77.7 (69.0 to 84.6) 64.3 (54.5 to 73.1) – 140 132 86.8 (80.2 to 91.5) 90.0 (83.6 to 94.1) –
Outpatient 224 231 84.2 (78.8 to 88.4) 68.7 (62.4 to 74.3) 0.4 246 246 80.6 (75.2 to 85.0) 76.0 (70.3 to 80.9) 0.09
N/A, not applicable; NQD, number of QFT-GIT results in active TB cases; NQND, number of QFT-GIT results in non-active TB patients; NTD, number of T-SPOT.TB results in active TB cases;
NTND, number of T-SPOT.TB results in non-active TB patients.
a The global effect of smoking status on the relative performance of T-SPOT.TB and QFT-GIT was not significant for sensitivity (p= 0.7) or for specificity (p= 0.4).
Note
Sensitivity and specificity are presented as percentages. The p-values are from the Wald tests of the interaction between test type and the covariate.
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gave a p-value of 0.01 for the difference in relative sensitivity between the group that had never smoked
and the group of previous smokers, the global test of whether or not relative test performance varied
across smoking subgroups was not statistically significant for sensitivity (p = 0.7) or for specificity (p = 0.4).
The sensitivities of T-SPOT.TB and QFT-GIT were lower in inpatients than in outpatients; the converse was
the case for their specificities.
Diagnostic accuracy of second-generation interferon gamma release assays
The diagnostic accuracy of ESAT-6, CFP-10 and four second-generation IGRAs (Rv3615c, Rv2654, Rv3879c
and Rv3873) is presented in the following sections as individual tests and as test combinations. The accuracy
of different test combinations was compared with that of T-SPOT.TB.
Individual antigens
The results of the six antigens cross-tabulated against active TB status are shown in Table 20 and their
diagnostic accuracy in Table 21. Based on all culture-confirmed and highly probable active TB cases and
excluding indeterminate IGRA results, the three antigens with the highest sensitivities were Rv3615c,
ESAT-6 and CFP-10. The sensitivities were 78.0% (95% CI 73.1% to 82.1%), 69.4% (95% CI 64.1% to
74.1%) and 71.6% (95% CI 66.5% to 76.2%), and the specificities were 82.7% (95% CI 78.7% to
86.1%), 87.8% (95% CI 84.2% to 90.7%) and 86.3% (95% CI 82.5% to 89.4%) for Rv3615c, ESAT-6
and CFP-10, respectively. The performance of the remaining three antigens was very poor with sensitivities
of 34.2% (95% CI 29.2% to 39.5%), 37.4% (95% CI 33.3% to 42.9%) and 38.2% (95% CI 33.1% to
43.7%) for Rv3873, Rv2654 and Rv3879c, respectively. However, their specificities were high: 95.1%
(95% CI 92.4% to 96.8%), 91.7% (95% CI 88.5% to 94.0%) and 93.3% (95% CI 90.3% to 95.4%) for
Rv3873, Rv2654 and Rv3879c, respectively. Table 21 also shows the performance of the tests in different
clinical groups. For each antigen, sensitivity was higher in those with culture-confirmed active TB than in
those with culture-negative active TB.
TABLE 20 Results of second-generation IGRAs by diagnostic category
IGRA result
Dosanjh category, n
Total, n1 2 3 4A 4B 4C 4D 4A–D
Rv3615c
Positive 171 53 13 0 13 35 6 54 291
Negative 38 33 24 6 28 200 86 320 415
Borderline 21 6 1 0 5 6 2 13 41
Indeterminate 16 7 3 1 0 18 17 36 62
Missing 15 3 2 0 2 8 6 16 36
Total 261 102 43 7 48 267 117 439 845
SFCs, median
(range)
25 (0–642) 19 (0–450) 1 (0–102) 0 (0–4) 1 (0–134) 0 (0–493) 0 (0–406) 0 (0–493) 2 (0–642)
Rv3873
Positive 59 23 3 0 2 11 3 16 101
Negative 146 64 34 6 43 225 92 366 610
Borderline 22 5 0 0 0 3 0 3 30
Indeterminate 19 7 4 1 1 20 16 38 68
Missing 15 3 2 0 2 8 6 16 36
continued
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TABLE 20 Results of second-generation IGRAs by diagnostic category (continued )
IGRA result
Dosanjh category, n
Total, n1 2 3 4A 4B 4C 4D 4A–D
Total 261 102 43 7 48 267 117 439 845
SFCs, median
(range)
2 (0–178) 1 (0–181) 0 (0–145) 0 (0–0) 0 (0–30) 0 (0–64) 0 (0–71) 0 (0–71) 0 (0–181)
Rv2654
Positive 74 27 6 0 5 13 5 23 130
Negative 138 61 29 6 36 222 88 352 580
Borderline 14 4 2 0 4 4 1 9 29
Indeterminate 20 7 4 1 1 20 17 39 70
Missing 15 3 2 0 2 8 6 16 36
Total 261 102 43 7 48 267 117 439 845
SFCs, median
(range)
2 (0–260) 1 (0–395) 1 (0–55) 0 (0–1) 1 (0–44) 0 (0–370) 0 (0–57) 0 (0–370) 0 (0–395)
Rv3879c
Positive 66 30 4 0 3 13 3 19 119
Negative 138 59 32 6 41 222 90 359 588
Borderline 23 3 1 0 1 4 2 7 34
Indeterminate 19 7 4 1 1 20 16 38 68
Missing 15 3 2 0 2 8 6 16 36
Total 261 102 43 7 48 267 117 439 845
SFCs, median
(range)
2 (0–241) 1 (0–225) 0 (0–154) 0 (0–3) 0 (0–42) 0 (0–83) 0 (0–58) 0 (0–83) 0 (0–241)
ESAT-6
Positive 149 54 9 0 14 16 5 35 247
Negative 63 36 27 6 29 217 87 339 465
Borderline 18 3 1 0 2 8 2 12 34
Indeterminate 16 6 4 1 1 18 17 37 63
Missing 15 3 2 0 2 8 6 16 36
Total 261 102 43 7 48 267 117 439 845
SFCs, median
(range)
14 (0–642) 13 (0–492) 0 (0–325) 0 (0–1) 2 (0–274) 0 (0–210) 0 (0–147) 0 (0–274) 1 (0–642)
CFP-10
Positive 157 57 11 0 14 24 4 42 267
Negative 57 35 26 6 29 208 90 333 451
Borderline 17 1 1 0 2 9 0 11 30
Indeterminate 15 6 3 1 1 18 17 37 61
Missing 15 3 2 0 2 8 6 16 36
Total 261 102 43 7 48 267 117 439 845
SFCs, median
(range)
18 (0–642) 13 (0–437) 1 (0–315) 0 (0–3) 1 (0–160) 0 (0–166) 0 (0–148) 0 (0–166) 1 (0–642)
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TABLE 21 Diagnostic accuracy of individual second-generation IGRAs, ESAT-6 and CFP-10
Test performance
Antigen
Rv3615c Rv3879c Rv3873 Rv2654 ESAT-6 CFP-10
n/N
Estimate
(95% CI) n/N
Estimate
(95% CI)
Estimate
(95% CI) n/N
Estimate
(95% CI) n/N
Estimate
(95% CI) n/N
Estimate
(95% CI) n/N
Sensitivity for a diagnosis of active TB
All TB 251/322 78.0
(73.1 to 82.1)
122/319 38.2
(33.1 to 43.7)
224/323 69.4
(64.1 to 74.1)
224/323 69.4
(64.1 to 74.1)
224/323 69.4
(64.1 to 74.1)
232/324 71.6
(66.5 to 76.2)
Culture-positive TB 192/230 83.5
(78.1 to 87.7)
89/227 39.2
(33.1 to 45.7)
167/230 72.6
(66.5 to 78.0)
167/230 72.6
(66.5 to 78.0)
167/230 72.6
(66.5 to 78.0)
174/231 75.3
(69.4 to 80.4)
Culture-negative
TB
51/82 62.2
(51.4 to 71.9)
28/82 34.1
(24.8 to 44.9)
48/83 57.8
(47.1 to 67.9)
48/83 57.8
(47.1 to 67.9)
48/83 57.8
(47.1 to 67.9)
50/82 61.0
(50.2 to 70.8)
Smear-positive TB 48/58 82.8
(71.1 to 90.4)
22/57 38.6
(27.1 to 51.6)
39/58 67.2
(54.4 to 77.9)
39/58 67.2
(54.4 to 77.9)
39/58 67.2
(54.4 to 77.9)
43/59 72.9
(60.4 to 82.6)
Smear-negative TB 162/212 76.4
(70.3 to 81.6)
86/212 40.6
(34.2 to 47.3)
151/213 70.9
(64.5 to 76.6)
151/213 70.9
(64.5 to 76.6)
151/213 70.9
(64.5 to 76.6)
155/215 72.1
(65.7 to 77.7)
Pulmonary TB 85/111 76.6
(67.9 to 83.5)
35/111 31.5
(23.6 to 40.7)
71/111 64.0
(54.7 to 72.3)
71/111 64.0
(54.7 to 72.3)
71/111 64.0
(54.7 to 72.3)
75/113 66.4
(57.3 to 74.4)
Extrapulmonary TB 133/172 77.3
(70.5 to 83.0)
71/170 41.8
(34.6 to 49.3)
124/173 71.7
(64.5 to 77.9)
124/173 71.7
(64.5 to 77.9)
124/173 71.7
(64.5 to 77.9)
127/172 73.8
(66.8 to 79.8)
Specificity for a diagnosis of active TB
Active TB excluded 320/387 82.7
(78.7 to 86.1)
359/385 93.3
(90.3 to 95.4)
339/386 87.8
(84.2 to 90.7)
339/386 87.8
(84.2 to 90.7)
339/386 87.8
(84.2 to 90.7)
333/386 86.3
(82.5 to 89.4)
Active TB
excluded, TST
negative, no risk
factors for LTBI
86/94 91.5
(84.1 to 95.6)
90/95 94.7
(88.3 to 97.7)
87/94 92.6
(85.4 to 96.3)
87/94 92.6
(85.4 to 96.3)
87/94 92.6
(85.4 to 96.3)
90/94 95.7
(89.6 to 98.3)
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TABLE 21 Diagnostic accuracy of individual second-generation IGRAs, ESAT-6 and CFP-10 (continued )
Test performance
Antigen
Rv3615c Rv3879c Rv3873 Rv2654 ESAT-6 CFP-10
n/N
Estimate
(95% CI) n/N
Estimate
(95% CI)
Estimate
(95% CI) n/N
Estimate
(95% CI) n/N
Estimate
(95% CI) n/N
Estimate
(95% CI) n/N
Predictive values
PPV 251/318 78.9
(74.1 to 83.1)
122/148 82.4
(75.5 to 87.7)
224/271 82.7
(77.7 to 86.7)
224/271 82.7
(77.7 to 86.7)
224/271 82.7
(77.7 to 86.7)
232/285 82.4
(77.3 to 86.8)
NPV 320/391 81.8
(77.7 to 85.4)
359/556 64.6
(60.5 to 68.4)
339/492 77.4
(73.3 to 81.1)
339/492 77.4
(73.3 to 81.1)
339/492 77.4
(73.3 to 81.1)
333/425 78.4
(74.2 to 82.0)
Likelihood ratios
Positive likelihood
ratio
4.50
(3.59 to 5.64)
5.66
(3.81 to 8.42)
5.70
(4.32 to 7.52)
5.70
(4.32 to 7.52)
5.70
(4.32 to 7.52)
5.22
(4.02 to 6.76)
Negative likelihood
ratio
0.27
(0.22 to 0.33)
0.66
(0.61 to 0.73)
0.35
(0.30 to 0.41)
0.35
(0.30 to 0.41)
0.35
(0.30 to 0.41)
0.33
(0.28 to 0.39)
Note
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA results were excluded from these analyses. See Appendix 10, Table 69, for sensitivity analyses
with indeterminates included as test positives.
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The results of the sensitivity analyses in which indeterminate test results were included as test positives are
given in Appendix 10, Table 69. The results show slight increases in sensitivity with reductions in specificities.
Combinations of antigens
Various combinations of the antigens are shown cross-tabulated against diagnostic category in Table 22.
Table 23 shows the diagnostic accuracy of the combinations. The sensitivity of the four-antigen (CFP-10,
ESAT-6, Rv3615c and Rv3879c) and three-antigen (CFP-10, ESAT-6 and Rv3615c) combinations containing
both CFP-10 and ESAT-6 were identical irrespective of whether all active TB cases or different subgroups
were analysed, as shown in Table 23. For this three-antigen combination, the sensitivity was 89.9%
(95% CI 86.2% to 92.7%) among all active TB cases and the specificity was 76.5% (95% CI 72.0% to
TABLE 22 Results of combinations of IGRAs against diagnostic category
IGRA combination result
Dosanjh category, n
Total, n1 2 3 4A 4B 4C 4D 4A–D
CFP-10 + Rv3615c
Positive 197 66 15 0 19 44 7 70 348
Negative 15 23 23 6 22 188 86 302 363
Borderline 22 4 1 0 5 9 1 15 42
Indeterminate 12 6 2 1 0 18 17 36 56
Missing 15 3 2 0 2 8 6 16 36
Total 261 102 43 7 48 267 117 439 845
CFP-10 + Rv3615c + Rv3879c
Positive 197 66 15 0 19 49 8 76 354
Negative 14 22 23 6 22 184 84 296 355
Borderline 23 5 1 0 5 8 3 16 45
Indeterminate 12 6 2 1 0 18 16 35 55
Missing 15 3 2 0 2 8 6 16 36
Total 261 102 43 7 48 267 117 439 845
ESAT-6 + CFP-10 + Rv3615c
Positive 203 70 15 0 20 46 8 74 362
Negative 13 20 23 6 22 184 84 296 352
Borderline 18 4 1 0 4 11 2 17 40
Indeterminate 12 5 2 1 0 18 17 36 55
Missing 15 3 2 0 2 8 6 16 36
Total 261 102 43 7 48 267 117 439 845
ESAT-6 + CFP-10 + Rv3615c + Rv3879c
Positive 203 70 16 0 20 49 9 78 367
Negative 13 20 22 6 22 180 82 290 345
Borderline 18 4 1 0 4 12 4 20 43
Indeterminate 12 5 2 1 0 18 16 35 54
Missing 15 3 2 0 2 8 6 16 36
Total 261 102 43 7 48 267 117 439 845
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TABLE 23 Diagnostic accuracy of combinations of second-generation IGRAs
Test performance
Antigen combination
ESAT-6+ CFP-10+ Rv3615c+
Rv3879c ESAT-6+ CFP-10+ Rv3615 CFP-10+ Rv3615c+ Rv3879c CFP-10+ Rv3615c
n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
All TB 295/328 89.9 (86.2 to 92.7) 295/328 89.9 (86.2 to 92.7) 291/327 89.0 (85.1 to 91.9) 289/327 88.4 (84.5 to 91.4)
Culture-positive TB 221/234 94.4 (90.7 to 96.7) 221/234 94.4 (90.7 to 96.7) 220/234 94.0 (90.2 to 96.4) 219/234 93.6 (89.7 to 96.1)
Culture-negative TB 63/83 75.9 (65.7 to 83.8) 63/83 75.9 (65.7 to 83.8) 61/82 74.4 (64.0 to 82.6) 60/82 73.2 (62.7 to 81.6)
Smear-positive TB 57/60 95.0 (86.3 to 98.3) 57/60 94.9 (86.1 to 98.3) 57/60 95.0 (86.3 to 98.3) 57/60 95.0 (86.3 to 98.3)
Smear-negative TB 192/216 88.9 (84.0 to 92.4) 192/216 88.9 (84.0 to 92.4) 189/215 87.9 (82.9 to 91.6) 187/215 87.0 (81.8 to 90.8)
Pulmonary TB 101/113 89.4 (82.4 to 93.8) 101/113 89.4 (82.4 to 93.8) 101/113 89.4 (82.4 to 93.8) 100/113 88.5 (81.3 to 93.2)
Extra pulmonary TB 156/175 89.1 (83.7 to 92.9) 156/175 89.1 (83.7 to 92.9) 152/174 87.4 (81.6 to 91.5) 151/174 86.8 (80.9 to 91)
Specificity for a diagnosis of active TB
Active TB excluded 290/388 74.7 (70.2 to 78.8) 296/387 76.5 (72.0 to 80.4) 296/388 76.3 (71.8 to 80.3) 302/387 78.0 (73.7 to 81.9)
Active TB excluded,
TST negative, no risk
factors for LTBI
82/95 86.3 (78.0 to 91.8) 84/94 89.4 (81.5 to 94.1) 84/95 88.4 (80.4 to 93.4) 86/94 91.5 (84.1 to 95.6)
Predictive values
PPV 295/393 75.1 (70.6 to 79.1) 295/386 76.4 (71.9 to 80.4) 291/383 76.0 (71.5 to 80.0) 289/374 77.3 (72.8 to 81.2)
NPV 290/323 89.8 (86.0 to 92.6) 296/329 90.0 (86.3 to 92.8) 296/332 89.2 (85.4 to 92.1) 302/340 88.8 (85.0 to 91.8)
Likelihood ratios
Positive likelihood
ratio
3.56 (2.99 to 4.24) 3.83 (3.18 to 4.59) 3.75 (3.13 to 4.51) 4.02 (3.32 to 4.88)
Negative likelihood
ratio
0.14 (0.10 to 0.19) 0.13 (0.10 to 0.18) 0.14 (0.11 to 0.20) 0.15 (0.11 to 0.20)
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80.4%) in all non-active TB patients. Another three-antigen combination (CFP-10, Rv3615c and Rv3879c)
gave a similar sensitivity and specificity of 89.0% (95% CI 85.1% to 91.9%) and 76.3% (95% CI
71.8% to 80.3%). Reducing this combination to a two-antigen combination of CFP-10 and Rv3615c
gave a sensitivity of 88.4% (84.5% to 91.4%) and a specificity of 78.0% (95% CI 73.7% to 81.9%).
See Appendix 10, Table 70, for sensitivity analyses with borderline test results excluded as test positives.
For the results of the sensitivity analyses including indeterminate test results, see Appendix 10, Table 71.
Sensitivity, specificity and predictive values are presented as percentages. For both the four-antigen
(ESAT-6, CFP-10, Rv3615c and Rv3879c) and three-antigen (ESAT, CFP-10, Rv3615), there were 74 test
positives out of 94 highly probable TB cases, with a sensitivity (95% CI) of 78.7% (69.4% to 85.8%). For the
other three-antigen (CFP-10, Rv3615c, Rv3879c), there were 71 test positives out of 93 highly probable TB
cases, with a sensitivity (95% CI) of 76.3% (66.8% to 83.8%). For the two-antigen combination of CFP-10
and Rv3615, there were 70 test positives out of 93 highly probable TB cases, with a sensitivity (95% CI) of
75.3% (65.6% to 82.9%). Note that in the primary analyses of combinations of next-generation IGRAs,
borderline test results were included as test positives. Sensitivity analyses were performed with borderline
IGRA results excluded and the results are shown in Appendix 10, Table 70. Indeterminate IGRA results were
excluded from these analyses. See Appendix 10, Table 71, for the sensitivity analyses with indeterminates
included as test positives.
Comparison of novel antigen combinations with T-SPOT.TB
The results of individual antigens classified against those of T-SPOT.TB show few discordant results between
Rv3615c and T-SPOT.TB, unlike those of the other three novel antigens (Rv3873, Rv2654 and Rv3879c),
which are not components of T-SPOT.TB (Table 24).
TABLE 24 Cross-tabulation of individual IGRA results against T-SPOT.TB results
T-SPOT.TB, n
IGRA result Positive Negative Borderline Indeterminate Missing Total
Rv3615c
Positive 247 36 8 0 0 291
Negative 48 351 16 0 0 415
Borderline 18 13 8 2 0 41
Indeterminate 6 0 1 55 0 62
Missing 0 0 0 0 36 36
Total 319 400 33 57 36 845
Rv3873
Positive 95 4 1 1 0 101
Negative 187 393 30 0 0 610
Borderline 27 3 0 0 0 30
Indeterminate 10 0 2 56 0 68
Missing 0 0 0 0 36 36
Total 319 400 33 57 36 845
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Tables 25 and 26 show comparisons of the sensitivity and specificity of the different test combinations versus
those of T-SPOT.TB. Indeterminate test results were excluded from these analyses (see Appendix 10, Tables 72
and 73 for the results of sensitivity analyses with indeterminates included). The sensitivity of T-SPOT.TB
was lower than those of any of the four test combinations (see Table 25), but had higher specificity
(see Table 26). The sensitivity of the two-antigen combination of CFP-10 and Rv3615c was 7% higher than
that of T-SPOT.TB, with a relative sensitivity of 1.07 (95% CI 1.03 to 1.11). However, the specificity of the
combined CFP-10 and Rv3615c was 5% lower than that of T-SPOT.TB, with a relative specificity of 0.95
(95% CI 0.92 to 0.98).
TABLE 24 Cross-tabulation of individual IGRA results against T-SPOT.TB results (continued )
T-SPOT.TB, n
IGRA result Positive Negative Borderline Indeterminate Missing Total
Rv2654
Positive 118 9 3 0 0 130
Negative 169 384 27 0 0 580
Borderline 21 7 1 0 0 29
Indeterminate 11 0 2 57 0 70
Missing 0 0 0 0 36 36
Total 319 400 33 57 36 845
Rv3879c
Positive 109 6 3 1 0 119
Negative 170 390 28 0 0 588
Borderline 30 4 0 0 0 34
Indeterminate 10 0 2 56 0 68
Missing 0 0 0 0 36 36
Total 319 400 33 57 36 845
ESAT-6
Positive 247 0 0 0 0 247
Negative 46 400 19 0 0 465
Borderline 21 0 13 0 0 34
Indeterminate 5 0 1 57 0 63
Missing 0 0 0 0 36 36
Total 319 400 33 57 36 845
CFP-10
Positive 267 0 0 0 0 267
Negative 41 400 10 0 0 451
Borderline 8 0 22 0 0 30
Indeterminate 3 0 1 57 0 61
Missing 0 0 0 0 36 36
Total 319 400 33 57 36 845
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Evaluation of the tuberculin skin test
The TST was not performed as part of the IDEA study. We did not aim to evaluate the accuracy of the TST
and so we did not impose a standard protocol for the conduct of TSTs; each centre followed local trust
policy. Five of the nine hospital trusts included in the analyses performed TSTs, but only on a subset of
patients, ranging between 20% and 74% of those recruited. We do not know why certain patients were
selected for the TST and others were not but the reasons may involve a mix of patient- and clinician-specific
factors. Altogether, the TST results were available for only 38% of the study population. The TST was mainly
performed at two centres (London North West Healthcare NHS Trust and Imperial College Healthcare NHS
Trust), and these centres together accounted for 83% (266/322) of the available TST results. Furthermore,
practice varied across the centres in the IDEA study.
Nonetheless, for completeness we estimated the diagnostic accuracy of the TST alone. In addition, because
one of our primary objectives was to develop an evidence-based optimal testing algorithm that defines the
role of IGRAs in the diagnostic workup of suspected active TB, we considered combinations with T-SPOT.TB
or QFT-GIT. The results are presented in Appendix 13.
The sensitivity of the TST was evaluated at each of the three prespecified thresholds (≥ 5 mm, ≥ 10 mm
and the stratified threshold). The findings presented in Appendix 13 should be interpreted cautiously given
the limited number of data and variation in practice between centres. Moreover, the findings may be
TABLE 26 Comparison of specificity of IGRA combinations and T-SPOT.TB
Test na Specificity, % (95% CI) Relative specificityb (95% CI) p-value
T-SPOT.TB (ESAT-6 + CFP-10) 386 82.5 (78.4 to 86.0) – –
CFP-10 + Rv3615c 387 78.0 (73.6 to 81.9) 0.95 (0.91 to 0.98) 0.001
CFP-10 + Rv3615c+ Rv3879c 388 76.3 (71.8 to 80.3) 0.93 (0.89 to 0.96) < 0.001
ESAT-6+ CFP-10 + Rv3615c 387 76.5 (72.0 to 80.5) 0.93 (0.90 to 0.96) < 0.001
ESAT-6+ CFP-10 + Rv3615c + Rv3879c 388 74.7 (70.2 to 78.8) 0.91 (0.88 to 0.94) < 0.001
a Number of test results.
b Sensitivity of combination test divided by sensitivity of T-SPOT.TB.
Note
Indeterminate test results were excluded in these analyses. See Appendix 10 for the results of the sensitivity analyses with
indeterminates included as test positives.
TABLE 25 Comparison of sensitivity of IGRA combinations and T-SPOT.TB
Test na Sensitivity, % (95% CI) Relative sensitivityb (95% CI) p-value
T-SPOT.TB (ESAT-6 + CFP-10) 328 82.3 (77.7 to 86.1) – –
CFP-10 + Rv3615c 327 88.4 (84.5 to 91.5) 1.07 (1.03 to 1.12) < 0.001
CFP-10 + Rv3615c+ Rv3879c 327 89.0 (85.1 to 92.0) 1.08 (1.04 to 1.12) < 0.001
ESAT-6+ CFP-10 + Rv3615c 328 89.9 (86.2 to 92.8) 1.09 (1.06 to 1.13) < 0.001
ESAT-6+ CFP-10 + Rv3615c + Rv3879c 328 89.9 (86.2 to 92.8) 1.09 (1.06 to 1.13) < 0.001
a Number of test results.
b Sensitivity of combination test divided by sensitivity of T-SPOT.TB.
Note
Indeterminate test results were excluded in these analyses. See Appendix 10 for the results of the sensitivity analyses with
indeterminates included as test positives.
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subject to bias. The final diagnosis of patients was verified using a composite reference standard applied
by a panel of clinicians to anonymised patient clinical data. The panel were blinded to routine and study
IGRA results. However, if TSTs were performed, then the results were available thus creating a potential for
incorporation bias in the evaluation of the diagnostic accuracy of the TST.
Discussion
This large prospective study of the diagnostic accuracy of T-SPOT.TB, QFT-GIT, TSTs and second-generation
IGRAs was conducted in secondary care in a population representative of clinical practice. The differences
observed between inpatients and outpatients reflect the case mix of acute admissions, in which, for instance,
pneumonia-like illnesses and advanced malignancy presentations are more common. However, the final TB
diagnosis in these two groups was broadly similar and allows for generalisability of our findings. Figure 5
summarises the sensitivities of T-SPOT.TB, QFT-GIT, TSTs, and combinations of TSTs and IGRAs. Figure 5 also
shows the sensitivities of combinations of novel antigens. T-SPOT.TB showed higher sensitivity than QFT-GIT,
a relative increase of 22% (95% CI 14% to 31%), thus indicating greater utility as a rule-out test.
Literature searches in PubMed were regularly conducted during the IDEA study to update the SSC on
developments in the field. Appendix 11, Table 74, gives a summary of 31 IGRA studies and one systematic
review published between 1 January 2013 and 16 March 2016. To the authors’ knowledge, the IDEA
study is the largest prospective and most recent comparative evaluation of the accuracy of T-SPOT.TB and
QFT-GIT for diagnosis of active TB in a high-income setting. None of the studies in Appendix 11 compared
T-SPOT.TB and QFT-GIT either prospectively or retrospectively. QFT-GIT was compared with the TST in
14 (45.2%) studies and T-SPOT.TB was compared with the TST in four (12.9%) studies; the remaining
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DIAGNOSTIC ACCURACY RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
42
13 (41.9%) studies evaluated only T-SPOT.TB or QFT-GIT. According to the systematic review of pleural
TB published in 2015,28 there was only one good-quality study out of the 21 studies and two small studies
compared QFT-GIT and T-SPOT.TB. The authors of the review pooled results across all QuantiFERON and
T-SPOT.TB assays and so results are not comparable with the findings of the IDEA study.
The rate of indeterminate IGRA results was higher for QFT-GIT (9.6%) than for T-SPOT.TB (7.0%). For both
IGRAs, most of the indeterminate results were among patients without active TB, with 59% (47/79) and
65% (37/57) occurring for QFT-GIT and T-SPOT.TB. Appendix 12 (see Table 75) summarises some key
characteristics of patients with indeterminate IGRA results. Indeterminates were excluded from the main
analyses and the impact on findings was investigated in sensitivity analyses by including indeterminate
IGRA results as test positives, that is, as true positives for those with culture-confirmed or highly probable
active TB and as false positives for those without active TB. Based on this rule, an increase in sensitivities,
a decrease in specificities and no change in NPVs was expected. Generally, small increases were seen in
sensitivity accompanied by decreases in specificity.
Human immunodeficiency virus-positive patients were a key subgroup in which analyses of T-SPOT.TB and
QFT-GIT were planned. However, the number of patients (n = 135) recruited in the main cohort was small.
The IDEA study was extended to facilitate recruitment of additional patients. The results for the entire HIV
cohort (i.e. including patients recruited during the extension period) are presented in Chapter 5. For the
main study cohort, the sensitivities of T-SPOT.TB and QFT-GIT were lower in those with HIV co-infection
than the HIV-negative subgroup. Similarly, the two IGRAs had lower sensitivities in those patients with
diabetes mellitus than those without. Specificity was higher in HIV-positive patients than HIV-negative
patients but was lower in those with diabetes mellitus than those without diabetes mellitus. Although
there appeared to be differences in test performance between subgroups, there was no statistical evidence
of an effect of HIV infection status or diabetes mellitus on relative test performance. The findings from
these analyses should be taken with caution, as the number of test results in some subgroups was small.
Subgroup analyses were not possible for the other two key subgroups: those with end-stage renal failure
and those on immune suppressants.
The most promising novel antigen was RV3615c, with a sensitivity that was higher than that of the other
five antigens, including CFP-10 and ESAT-6 (the two antigens that constitute T-SPOT.TB). Test combinations
including Rv3615c showed higher sensitivity than T-SPOT.TB, with limited gains in sensitivity when more
antigens were added to a combination. Thus, the two-antigen combination of CFP-10 and Rv3615c or the
three-antigen combination of ESAT-6, CFP-10 and Rv3615c seem promising. The latter combination had a
sensitivity and specificity of 90.5% (95% CI 86.9% to 93.2%) and 70.0% (95% CI 65.4% to 74.2%),
compared with 83.2% (95% CI 78.9% to 86.8%) and 75.4% (95% CI 71.1% to 79.3%) for T-SPOT.TB.
The added value of Rv3615c to T-SPOT.TB was a 9% (95% CI 5% to 12%) relative increase in sensitivity at
the expense of specificity with a relative decrease of 7% (95% CI 4% to 10%). The incremental gain in
sensitivity to 90% is likely to be clinically useful and warrants further investigation.
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Chapter 5 Substudy of human immunodeficiency
virus-positive participants
Recruitment of human immunodeficiency virus-positive patients
Following the closure of the main study to recruitment, two additional NHS trusts (King’s College
Healthcare NHS Foundation Trust and Barts Health NHS Trust) were invited to participate in the study to
facilitate the recruitment of HIV-positive patients. A total of 263 patients were recruited from 12 NHS
trusts between 25 November 2011 and 19 December 2014. The number of patients recruited at each
centre is shown in Table 27. Over half of the patients were recruited from two trusts: Royal Free London
NHS Foundation Trust (29.3%) and Imperial College Healthcare NHS Trust (25.9%).
The flow of patients through the study is shown in Figure 6. Of the 263 HIV-positive patients recruited,
201 were included in the analyses. Reasons for exclusion are shown in Figure 6. Two patients from Frimley
Health NHS Foundation Trust were excluded, as mentioned earlier in Chapter 3 (see Recruitment of
participants into main study cohort).
The final diagnosis of four (2.0%) patients was clinically indeterminate (Figure 6 and Table 28). Among the
remaining 197 patients, there were 32 (16.2%) cases of active TB and 165 (83.8%) cases of non-active TB.
Of the 165 non-active TB cases, 68 (41.2%) were category 4D.
Baseline characteristics of the human immunodeficiency virus-positive
cohort
The demographic characteristics of the 201 patients are given in Table 29. The median age of patients was
43 years (range 18–79 years) and the majority (67.7%) were male. A substantial number of HIV-positive patients
were of black (45.3%) or white (37.8%) ethnicity. A total of 53 countries of birth were represented; countries
with at least three participants are shown in Table 29. Many patients (97/201, 48.3%) were in paid employment.
TABLE 27 Recruitment of HIV-positive patients by centre
Hospital trust Patients recruited, n (%)
Imperial College Healthcare NHS Trust 68 (25.9)
Heart of England NHS Foundation Trust 7 (2.7)
Chelsea and Westminster Hospital NHS Foundation Trust 49 (18.6)
Royal Free London NHS Foundation Trust 77 (29.3)
St George’s University Hospitals NHS Foundation Trust 6 (2.3)
Frimley Health NHS Foundation Trust 2 (0.8)
University Hospitals of Leicester NHS Trust 28 (10.7)
London North West Healthcare NHS Trust 8 (3)
Oxford University Hospitals NHS Trust 6 (2.3)
Sandwell and West Birmingham Hospitals NHS Trust 1 (0.4)
King’s College Healthcare NHS Foundation Trust 3 (1.1)
Barts Health NHS Trust 8 (3)
Total 263 (100)
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HIV-positive patients with suspected TB
(n = 263)
Eligible for analyses
(n = 201)
Highly
probable TB
(n = 14)
Culture-confirmed 
TB
(n = 18)
Active TB
excluded
(n = 165)
Clinically
indeterminate
(n = 4)
T-SPOT.TB, n = 13
QFT-GIT, n = 14
T-SPOT.TB, n = 18
QFT-GIT, n = 18
T-SPOT.TB, n = 160
QFT-GIT, n = 164
T-SPOT.TB, n = 4
QFT-GIT, n = 4
Reasons for exclusion
• Previous TB diagnosis, n = 42
• Exclusion by investigators, n = 9a
• Loss to follow-up, n = 8 
• Withdrawal of consent, n = 3
FIGURE 6 Study flow diagram of HIV-positive patients with suspected active TB. The final four boxes show the
number of patients with available IGRA results. a, On advice from the Study Steering Committee, and following
consultation between the study management group and data management groups, nine patients were excluded
from analyses. Two patients recruited from Frimley Health NHS Foundation Trust were excluded because all
patients recruited from that site had diagnoses of confirmed or highly probable TB (categories 1 and 2) due an
error of implementation of recruitment criteria, i.e. the natural spectrum of patients with suspected TB was not
being recruited. Two patients were, on review, considered by the expert diagnostic panel to be ineligible (before
unblinding IGRA results) on the basis that they were being investigated for TB (due to an incidental abnormal
chest X-ray, known contact with active TB, or screening for anti-TNF treatment), but did not present with
symptoms or signs suggestive of TB. An additional five patients were excluded due to invalid consent forms.
TABLE 28 Reference standard categories for HIV-positive patients
Diagnostic category Patients, n (%)
1: Culture-confirmed TB 18 (9.0)
2: Highly probable TB 14 (7.0)
3: Clinically indeterminate 4 (2.0)
4: Active TB excluded
4A 2 (1.0)
4B 2 (1.0)
4C 93 (46.3)
4D 68 (33.8)
Total 201 (100)
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TABLE 29 Demographic characteristics of HIV-positive cohort
Characteristic
Dosanjh category
Total
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
Age (years), median (range) 43 (26–62) 40 (24–66) 55 (30–62) 44 (18–79) 43 (18–79)
Male, n (%) 13 (72.2) 10 (71.4) 2 (50.0) 111 (67.3) 136 (67.7)
Ethnic origin, n (%)
Asian 1 (5.6) 2 (14.3) 0 (0.0) 3 (1.8) 6 (3.0)
Black 12 (66.7) 7 (50.0) 2 (50.0) 70 (42.4) 91 (45.3)
Hispanic 0 (0.0) 1 (7.1) 0 (0.0) 7 (4.2) 8 (4.0)
Indian subcontinent 3 (16.7) 0 (0.0) 1 (25.0) 8 (4.8) 12 (6.0)
Middle Eastern 1 (5.6) 0 (0.0) 0 (0.0) 2 (1.2) 3 (1.5)
Mixed 0 (0.0) 1 (7.1) 0 (0.0) 4 (2.4) 5 (2.5)
White 1 (5.6) 3 (21.4) 1 (25.0) 71 (43.0) 76 (37.8)
Country of birth, n (%)
UK 2 (11.1) 1 (7.1) 1 (25.0) 57 (34.5) 61 (30.3)
Zimbabwe 1 (5.6) 2 (14.3) 0 (0.0) 16 (9.7) 19 (9.5)
Nigeria 2 (11.1) 0 (0.0) 1 (25.0) 6 (3.6) 9 (4.5)
India 2 (11.1) 0 (0.0) 1 (25.0) 4 (2.4) 7 (3.5)
Uganda 0 (0.0) 0 (0.0) 0 (0.0) 6 (3.6) 6 (3.0)
Ethiopia 2 (11.1) 2 (14.3) 0 (0.0) 1 (0.6) 5 (2.5)
Ireland 0 (0.0) 0 (0.0) 0 (0.0) 5 (3.0) 5 (2.5)
Kenya 0 (0.0) 1 (7.1) 0 (0.0) 4 (2.4) 5 (2.5)
Portugal 0 (0.0) 0 (0.0) 0 (0.0) 5 (3.0) 5 (2.5)
South Africa 0 (0.0) 1 (7.1) 0 (0.0) 4 (2.4) 5 (2.5)
Brazil 0 (0.0) 1 (7.1) 0 (0.0) 3 (1.8) 4 (2.0)
Jamaica 1 (5.6) 1 (7.1) 0 (0.0) 2 (1.2) 4 (2.0)
Poland 0 (0.0) 0 (0.0) 0 (0.0) 4 (2.4) 4 (2.0)
Angola 1 (5.6) 0 (0.0) 0 (0.0) 2 (1.2) 3 (1.5)
The Democratic Republic
of the Congo
0 (0.0) 0 (0.0) 0 (0.0) 3 (1.8) 3 (1.5)
Malawi 1 (5.6) 1 (7.1) 0 (0.0) 1 (0.6) 3 (1.5)
Sierra Leone 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.8) 3 (1.5)
Sri Lanka 1 (5.6) 0 (0.0) 0 (0.0) 2 (1.2) 3 (1.5)
Thailand 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.8) 3 (1.5)
Othera 5 (27.8) 4 (28.6) 1 (25.0) 32 (19.4) 42 (20.9)
Years in the UK, median
(range)
9.6
(0.05–33.5)
10.1
(1.0–37.1)
8.8
(6.2–10.6)
11.9
(0.2–60.3)
11.6
(0.05–60.3)
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The clinical characteristics of the patients are presented in Table 30. Of the 201 patients, 71 (35.3%) had no
other comorbidities. There were 10 (5.0%) patients with pre-existing diabetes mellitus, four (2.0%) with
chronic/end-stage renal failure and none was on immunosuppressive therapy. Vitamin D measurement was
unknown for most (85.1%) patients (see Appendix 5, Table 55, for thresholds used to categorise vitamin D
status). Table 30 shows CD4 (cluster of differentiation 4) count grouped into four categories. CD4 count
was missing for eight patients. Most of the 193 patients had a CD4 count of ≥ 200 cells/µl (46.8%). The
median CD4 count was 285 cells/µl (range 0–1228 cells/µl). The distribution of CD4 count in the cohort is
shown in Figure 7.
TABLE 29 Demographic characteristics of HIV-positive cohort (continued )
Characteristic
Dosanjh category
Total
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
Profession, n (%)b
Paid employment 9 (50.0) 6 (42.9) 1 (25.0) 81 (49.1) 97 (48.3)
Unpaid employment 6 (33.3) 3 (21.4) 3 (75.0) 61 (37.0) 73 (36.3)
Student 1 (5.6) 0 0 8 (4.8) 9 (4.5)
Health-care/laboratory
worker
1 (5.6) 3 (21.4) 0 9 (5.5) 13 (6.5)
Social/prison worker 1 (5.6) 1 (7.1) 0 3 (1.8) 5 (2.5)
Sex worker 0 1 (7.1) 0 2 (1.2) 3 (1.5)
Unknown 0 0 0 1 (0.6) 1 (0.5)
a Summarises results from 34 countries with fewer than three patients.
b Some patients had more than one profession.
TABLE 30 Clinical characteristics of HIV-positive cohort
Characteristic
Dosanjh category
Total
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
Height (m), median (range) 1.7 (1.4–1.8) 1.8 (1.6–1.9) 1.7 (1.6–1.8) 1.7 (1.3–1.9) 1.7 (1.3–1.9)
Weight (kg), median (range) 69 (52–91) 65 (42–116) 62 (57–110) 67 (43–112) 67 (42–116)
BMI (kg/m2), median (range) 24 (18–48) 22 (16–40) 21 (21–34) 23 (12–39) 23 (12–48)
BCG vaccinated, n (%) 15 (83.3) 12 (85.7) 4 (100.0) 136 (82.4) 167 (83.1)
BCG scar visible, n (%)
Yes 13 (72.2) 12 (85.7) 2 (50.0) 114 (69.1) 141 (70.1)
No 0 (0.0) 0 (0.0) 0 (0.0) 17 (10.3) 17 (8.5)
Unsure 2 (11.1) 0 (0.0) 2 (50.0) 17 (10.3) 21 (10.4)
Missing 3 (16.7) 2 (14.3) 0 (0.0) 17 (10.3) 22 (10.9)
Known TB contact, n (%) 3 (16.7) 2 (14.3) 1 (25.0) 19 (11.5) 25 (12.4)
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TABLE 30 Clinical characteristics of HIV-positive cohort (continued )
Characteristic
Dosanjh category
Total
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
Other pre-existing conditions/comorbidities, n (%)a
None 9 (50.0) 8 (57.1) 2 (50.0) 52 (31.5) 71 (35.3)
Diabetes 2 (11.1) 0 (0.0) 1 (25.0) 7 (4.2) 10 (5.0)
Hepatitis B 4 (22.2) 1 (7.1) 0 (0.0) 8 (4.8) 13 (6.5)
Hepatitis C 0 (0.0) 0 (0.0) 0 (0.0) 10 (6.1) 10 (5.0)
Chronic/end-stage renal
failure
0 (0.0) 0 (0.0) 1 (25.0) 3 (1.8) 4 (2.0)
Cancer 0 (0.0) 0 (0.0) 0 (0.0) 7 (4.2) 7 (3.5)
Organ transplantation 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.5)
Asthma 0 (0.0) 2 (14.3) 0 (0.0) 12 (7.3) 14 (7.0)
Other 8 (44.4) 4 (28.6) 2 (50.0) 101 (61.2) 115 (57.2)
Medication, n (%)a
None/missing 4 (22.2) 7 (50.0) 0 (0.0) 46 (27.9) 57 (28.4)
Chemotherapy 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.5)
Corticosteroids
≥ 15mg/day
1 (5.6) 1 (7.1) 0 (0.0) 14 (8.5) 16 (8.0)
Corticosteroids
< 15mg/day
0 (0.0) 1 (7.1) 0 (0.0) 5 (3.0) 6 (3.0)
Ciclosporin, tacrolimus
or everolimus
0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.5)
Methotrexate 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.5)
Other 18 (100.0) 14 (100.0) 4 (100.0) 164 (99.4) 200 (99.5)
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.5)
Vitamin D deficiency, n (%)
Deficient 3 (16.7) 1 (7.1) 1 (25.0) 9 (5.5) 14 (7.0)
Insufficient 1 (5.6) 2 (14.3) 0 (0.0) 2 (1.2) 5 (2.5)
Normal 0 (0.0) 1 (7.1) 2 (50.0) 7 (4.2) 10 (5.0)
Not known 14 (77.8) 10 (71.4) 1 (25.0) 147 (89.1) 172 (85.6)
CD4 count, n (%)
< 50 cells/µl 1 (5.6) 4 (28.6) 0 (0.0) 48 (29.1) 53 (26.4)
≥ 50 cells/µl and
< 100 cells/µl
2 (5.6) 0 (0.0) 0 (0.0) 15 (9.1) 16 (8.0)
≥ 100 cells/µl and
< 200 cells/µl
5 (27.8) 3 (21.4) 2 (50.0) 20 (12.1) 30 (14.9)
≥ 200 cells/µl 8 (44.4) 6 (42.9) 2 (50.0) 78 (47.3) 94 (46.8)
Missing 3 (16.7) 1 (7.14) 0 (0.0) 4 (2.4) 8 (4.0)
CD4 count, cells/µl (range) 293 (14–670) 267 (0–669) 370 (183–800) 283 (0–1228) 285 (0–1228)
BMI, body mass index.
a Some patients had multiple comorbidities and so the numbers do not add up to 201. The percentages are column
percentages for each row. The same applies to medication.
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Table 31 gives the social history of patients. Smoking history was missing for one patient; almost half
(48.8%) of the patients had never smoked, whereas the remaining were current (31.3%) or ex-smokers
(19.4%). Fourteen (7.0%) patients had a history of alcohol misuse and the history of recreational drug use
was unknown for many (64.7%) patients. Few patients (6.0%) had a history of homelessness and 7.5%
had a history of imprisonment.
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FIGURE 7 Distribution of CD4 counts in HIV-positive substudy cohort.
TABLE 31 Social history of the HIV-positive cohort
Characteristic
Dosanjh category
Total
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
Smoking history, n (%)
Never smoked 13 (72.2) 7 (50.0) 3 (75.0) 75 (45.5) 98 (48.8)
Ex-smoker 3 (16.7) 2 (14.3) 0 (0.0) 34 (20.6) 39 (19.4)
Current smoker 2 (11.1) 5 (35.7) 1 (25.0) 55 (33.3) 63 (31.3)
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.5)
Pack years if current smoker, n (%)
≤ 10 years 0 (0.0) 1 (20.0) 0 (0.0) 9 (16.4) 10 (15.9)
11–20 years 0 (0.0) 0 (0.0) 0 (0.0) 2 (3.6) 2 (3.2)
21–50 years 0 (0.0) 0 (0.0) 0 (0.0) 3 (5.5) 3 (4.8)
Unknown 2 (100.0) 4 (80.0) 1 (100.0) 41 (74.5) 48 (76.2)
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The frequency of symptoms is shown in Table 32 based on data from 197 patients. The four other patients
were recruited on the basis of abnormal clinical signs rather than symptoms. The main symptoms were
cough, fever, night sweats, weight loss and lethargy. Patients generally presented with multiple symptoms;
the median number of symptoms was three (range 1–10). Cough, as a symptom, was often present
(68.5%) in patients.
TABLE 31 Social history of the HIV-positive cohort (continued )
Characteristic
Dosanjh category
Total
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
History of alcohol use, n (%)
Non-drinker 10 (55.6) 6 (42.9) 3 (75.0) 67 (40.6) 86 (42.8)
Ex-drinker 1 (5.6) 1 (7.1) 0 (0.0) 17 (10.3) 19 (9.5)
Current drinker 7 (38.9) 7 (50.0) 1 (25.0) 79 (47.9) 94 (46.8)
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.2) 2 (1.0)
Units/week if current drinker,
median (range)
5 (0–75) 8 (0–19) 10 (10–10) 5 (0–126) 5 (0–126)
History of alcohol misuse, n (%) 1 (5.6) 0 (0.0) 0 (0.0) 13 (7.9) 14 (7.0)
History of recreational drug use, n (%)
Non-user 6 (33.3) 2 (14.3) 2 (50.0) 31 (18.8) 41 (20.4)
Ex-user 1 (5.6) 0 (0.0) 0 (0.0) 7 (4.2) 8 (4.0)
Current user 0 (0.0) 3 (21.4) 0 (0.0) 19 (11.5) 22 (11.0)
Unknown 11 (61.1) 9 (64.3) 2 (50.0) 108 (65.5) 130 (64.7)
History of homelessness, n (%) 1 (5.6) 1 (7.1) 0 (0.0) 10 (6.1) 12 (6.0)
Years homeless if currently or
previously homeless, median
(range)
0 (0.0) 12 – 5 (0–12) 5 (0–12)
History of imprisonment, n (%) 0 (0.0) 1 (7.1) 0 (0.0) 14 (8.5) 15 (7.5)
TABLE 32 Symptoms at presentation for the HIV-positive cohort
Symptoma
Dosanjh category
Total
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
Cough, n (%) 13 (72.2) 4 (30.8) 3 (75.0) 115 (71.0) 135 (68.5)
Fever, n (%) 13 (72.2) 8 (61.5) 3 (75.0) 85 (52.5) 109 (55.3)
Night sweats, n (%) 11 (61.1) 9 (69.2) 1 (25.0) 86 (53.1) 107 (54.3)
Weight loss, n (%) 12 (66.7) 11 (84.6) 2 (50.0) 89 (54.9) 114 (57.9)
Haemoptysis, n (%) 2 (11.1) 1 (7.7) 0 18 (11.1) 21 (10.7)
Lethargy, n (%) 7 (38.9) 8 (61.5) 1 (25.0) 81 (50.0) 97 (49.2)
Other, n (%) 11 (61.1) 5 (38.5) 2 (50.0) 79 (48.8) 97 (49.2)
Number of symptoms, median
(range)
4 (1–8) 4 (3–6) 3.5 (1–5) 3 (1–9) 3 (1–10)
a Based on 197 patients.
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Final diagnosis in human immunodeficiency virus-positive patients
The diagnostic tests performed during the diagnostic workup of patients are shown in Table 33.
Chest radiography and culture were the most common tests performed (with each performed in 90.6%
of patients). The number of T-SPOT.TB, QFT-GIT and TST tests performed as part of routine care, at each
centre, is shown in Appendix 14 (see Table 78). These routine IGRA results were not used in the final
diagnosis of patients in the IDEA study. TSTs were performed in only 12 patients at 3 of the 11 centres;
TST results were available for all 12 patients.
The final diagnoses of active TB patients are summarised in Table 34. Of the 32 patients with active TB,
19 (59.4%) had smear-negative TB. A total of 13 patients (40.6%) had pulmonary TB, 15 (46.9%) patients
had extrapulmonary TB, and the remaining four (12.5%) patients had both forms of TB. The most common
sites of infection were the lungs (53.1%) and lymph nodes (31.1%). Of the 31 culture tests performed,
20 (64.5%) had no drug resistance. Table 35 shows the final diagnosis of non-active TB patients. A patient
may have multiple conditions, but pneumonia was the most frequent diagnosis (40.0%).
Test results for human immunodeficiency virus-positive patients
Of the 201 patients, 194 (96.5%) had results for both T-SPOT.TB and QFT-GIT; reasons for missing
T-SPOT.TB and QFT-GIT results are shown in Table 36. The cross-classified results of the two tests are
given in Appendix 14, Table 79. Table 37 shows the results for T-SPOT.TB, QFT-GIT and the TST according
to the four diagnostic categories. Table 38 shows the cross-classification of the two tests for those with
(categories 1 and 2) and without active TB (category 4).
TABLE 33 Diagnostic tests performed in the diagnostic workup of active TB in HIV-positive patients
Test
Dosanjh category, n (%)
Total,
n (%)
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
BAL investigation 5 (27.8) 4 (28.6) 3 (75.0) 68 (41.2) 80 (39.8)
CXR 14 (77.8) 14 (100.0) 3 (75.0) 151 (91.5) 182 (90.5)
CSF investigation 3 (16.7) 6 (42.9) 1 (25.0) 17 (10.3) 27 (13.4)
CT 14 (77.8) 12 (85.7) 3 (75.0) 122 (73.9) 151 (75.1)
Culture 18 (100.00) 13 (92.9) 3 (75.0) 148 (89.7) 182 (90.5)
Histology or biopsy 3 (16.7) 5 (35.7) 0 (0.0) 49 (29.7) 57 (28.4)
MRI 4 (22.2) 9 (64.3) 1 (25.0) 28 (17.0) 42 (20.9)
PCR 10 (55.6) 5 (35.7) 1 (25.0) 42 (25.5) 58 (28.9)
Smear test 14 (77.8) 14 (100.0) 2 (50.0) 139 (84.2) 169 (84.1)
CSF, cerebrospinal fluid; CXR, chest radiography.
SUBSTUDY OF HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE PARTICIPANTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
52
TABLE 35 Final diagnosis of non-TB in HIV-positive patients
Diagnosis Number of patients (%)
Cancer 17 (10.3)
Chest infection 2 (1.2)
LRTI 13 (7.9)
LTBI – treatment indicated 1 (0.6)
Pneumonia 66 (40.0)
Sarcoidosis 3 (1.8)
Other 75 (45.5)
LRTI, lower respiratory tract infection; LTBI, latent TB infection.
TABLE 34 Final diagnosis of TB in HIV-positive patients
Characteristic
Category of TB, n (%)
Total, n (%)1 2
All TB 18 (56.3) 14 (43.7) 32 (100)
Smear-positive TB 8 (44.4) 1 (7.1) 9 (28.1)
Smear-negative TB 6 (33.3) 13 (92.9) 19 (59.4)
Pulmonary TB 10 (55.6) 3 (21.4) 13 (40.6)
Extrapulmonary TB 5 (27.8) 10 (71.4) 15 (46.9)
Pulmonary/extrapulmonary TB 3 (16.7) 1 (7.1) 4 (12.5)
Site of infectiona
Brain 0 (0.0) 2 (14.3) 2 (6.3)
Central nervous system 0 (0.0) 1 (7.1) 1 (3.1)
Lung 13 (72.2) 4 (28.6) 17 (53.1)
Lymph node 4 (22.2) 6 (42.9) 10 (31.3)
Miliary TB (disseminated) 3 (16.7) 0 (0.0) 3 (9.4)
Pericardium 0 (0.0) 1 (7.1) 1 (3.1)
Pleura 1 (5.6) 0 (0.0) 1 (3.1)
Spine 1 (5.6) 1 (7.1) 2 (6.3)
Multidrug resistanceb
None 18 (100) 2 (15.4) 20 (64.5)
Not tested 0 (0.0) 11 (84.6) 11 (35.5)
a There were multiple TB infection sites for some patient and so the percentages do not add up to 100%.
b Available where culture tests were performed during diagnostic workup (n= 31).
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Diagnostic accuracy of T-SPOT.TB and QuantiFERON GOLD In-Tube in
human immunodeficiency virus-positive cohort
The proportion of indeterminate test results was 23.1% (45/195) for T-SPOT.TB and 19.5% (39/200) for
QFT-GIT. The difference between the two proportions was 3.6% (95% CI –4.5% to 11.6%; p = 0.4).
Sensitivity was 68.0% (95% CI 48.4% to 82.8%) for T-SPOT.TB and 56.7% (95% CI 39.2% to 72.6%)
for QFT-GIT (Table 39). The specificities were 83.5% (95% CI 75.8% to 89.0%) and 91.4% (95% CI
85.3% to 95.1%). The PPVs for T-SPOT.TB and QFT-GIT were 46.0% (95% CI 31.0% to 61.6%) and
60.7% (95% CI 42.4% to 76.4%), respectively, and the NPVs were 92.7% (95% CI 86.2% to 96.2%)
and 90.0% (95% CI 83.6% to 94.1%), respectively.
TABLE 37 Results for T-SPOT.TB and QFT-GIT, by final diagnosis, in the cohort of HIV-positive patients
Index test
Dosanjh category
Total1 2 3 4A 4B 4C 4D 4A–D
T-SPOT.TB
Positive 10 6 1 0 1 8 3 12 29
Negative 5 3 2 1 1 57 42 101 111
Borderline 0 1 1 0 0 6 2 8 10
Indeterminate 3 3 0 1 0 19 19 39 45
Missing 0 1 0 0 0 3 2 5 6
Total 18 14 4 2 2 93 68 165 201
Median SFCs
ESAT-6 (range)
17
(0–462)
8
(0–395)
1
(0–3)
0 0 0
(0–66)
0
(0–74)
0
(0–74)
0
(0–462)
Median SFCs
CFP-10 (range)
6
(0–136)
0
(0–315)
3
(0–20)
0 8
(0–16)
0
(0–67)
0
(0–56)
0
(0–67)
0
(0–315)
QFT-GIT
Positive 11 6 1 0 1 8 2 11 29
Negative 7 6 2 1 1 61 54 117 132
Indeterminate 0 2 1 1 0 24 11 36 39
Missing 0 0 0 0 0 0 1 1 1
Total 18 14 4 2 2 93 68 165 201
Median IFN-γ
levels (range)
0.76
(0–3.78)
0.03
(0–10)
0.01
(0–0.54)
0.04
(0–0.07)
1.33
(0–2.65)
0
(0–7.3)
0
(0–1.56)
0
(0–7.3)
0.01
(0–10)
TABLE 36 Reasons for missing IGRA results for HIV-positive patients
Reason
Test, n
QFT-GIT T-SPOT.TB
No sample could be taken 1 –
Sample destroyed for laboratory reasons – 2
Sample unsuitable for testing – 4
Total 1 6
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TABLE 38 Cross-tabulation of T-SPOT.TB and QFT-GIT against final diagnosis in the cohort of HIV-positive patients
T-SPOT.TB
TB positive (categories 1 and 2) TB negative (category 4)
Positive Negative Borderline Indeterminate Missing Total Positive Negative Borderline Indeterminate Missing Total
QFT-GIT
Positive 14 1 0 2 0 17 4 3 1 3 0 11
Negative 1 6 1 4 1 13 5 75 7 26 4 117
Indeterminate 1 1 0 0 0 2 3 22 0 10 1 36
Missing 0 0 0 0 0 0 0 1 0 0 0 1
Total 16 8 1 6 1 32 12 101 8 39 5 165
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Using only culture-confirmed active TB cases, the sensitivity of T-SPOT.TB decreased slightly to 66.7%
(95% CI 41.7% to 84.8%), whereas that of QFT-GIT increased to 61.1% (95% CI 38.6% to 79.7%).
When the analyses were restricted to category 4D patients without active TB, specificities were higher than
using all patients without active TB (see Table 39). In sensitivity analyses with indeterminate test results
included as test positives, the sensitivity of T-SPOT.TB was 74.2% (95% CI 56.8% to 86.3%) and 59.4%
(95% CI 42.3% to 74.5%) for QFT-GIT. The specificity of T-SPOT.TB was 63.1% (95% CI 55.4% to
70.2%) and 71.3% (95% CI 64.0% to 77.7%) for QFT-GIT. See Appendix 14, Table 80, for full results.
The diagnostic performance of the two IGRAs is shown stratified by CD4 count in Table 40. The estimates
within each stratum give results comparable to the entire cohort in terms of the higher sensitivity of T-SPOT.TB
and higher specificity of QFT-GIT. However, the estimates are based on very small numbers of active TB and
non-active TB cases and are presented solely for illustrative purposes.
TABLE 39 Diagnostic accuracy of T-SPOT.TB and QFT-GIT for diagnosis of active TB in the HIV-positive cohort
Test performance
Test
T-SPOT.TB QFT-GIT
n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
All TB 17/25 68.0 (48.4 to 82.8) 17/30 56.7 (39.2 to 72.6)
Culture-positive TB 10/15 66.7 (41.7 to 84.8) 11/18 61.1 (38.6 to 79.7)
Culture-negative TB 7/10 70.0 (39.7 to 89.2) 6/11 54.5 (28.0 to 78.7)
Smear-positive TB 4/8 50.0 (21.5 to 78.5) 6/9 66.7 (35.4 to 87.9)
Smear-negative TB 9/13 69.2 (42.4 to 87.3) 8/17 47.1 (26.2 to 69.0)
Pulmonary TB 7/10 70.0 (39.7 to 89.2) 9/13 69.2 (42.4 to 87.3)
Extrapulmonary TB 8/11 72.7 (43.4 to 90.3) 6/14 42.9 (21.4 to 67.4)
Specificity for a diagnosis of active TB
Active TB excluded 101/121 83.5 (75.8 to 89.0) 117/128 91.4 (85.3 to 95.1)
Active TB excluded, TST
negative, no risk factors for LTBI
42/47 89.4 (77.4 to 95.4) 54/56 96.4 (87.9 to 99.0)
Predictive value
PPV 17/37 46.0 (31.0 to 61.6) 17/28 60.7 (42.4 to 76.4)
NPV 101/109 92.7 (86.2 to 96.2) 117/130 90.0 (83.6 to 94.1)
Likelihood ratios
Positive likelihood ratio – 4.11 (2.54 to 6.66) – 6.59 (3.46 to 12.6)
Negative likelihood ratio – 0.38 (0.22 to 0.68) – 0.47 (0.31 to 0.72)
Note
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA results were excluded from
these analyses. Sensitivity analyses with indeterminates as test positives are presented in Appendix 14, Table 80.
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Comparison of diagnostic accuracy of T-SPOT.TB and QuantiFERON GOLD
In-Tube in human immunodeficiency virus-positive cohort
Excluding indeterminate IGRA results, there were 146 T-SPOT.TB results and 158 QFT-GIT results. The
sensitivity of T-SPOT.TB was higher than that of QFT-GIT, with a relative sensitivity of 1.12 (95% CI 0.87 to
1.44). There was no statistical evidence of a difference (p = 0.4). In contrast, the specificity of T-SPOT.TB was
significantly lower than that of QFT-GIT, with a relative specificity of 0.91 (95% CI 0.84 to 0.99) (Table 41).
When indeterminate IGRA results were included as test positives in a sensitivity analysis, the analysis included
191 T-SPOT.TB results and 196 QFT-GIT results. Unlike the primary analysis, there was no statistical evidence
of a difference in specificity (see Appendix 14, Table 81).
TABLE 40 Diagnostic accuracy of T-SPOT.TB and QFT-GIT stratified by CD4 count in the HIV-positive
substudy cohort
CD4 count
Test
T-SPOT.TB QFT-GIT
n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
< 50 cells/µl 1/3 33.3 (6.15 to 79.2) 1/4 25.0 (4.56 to 70.0)
≥ 50 cells/µl and < 100 cells/µl 0/1 0.00 (0.00 to 79.4) 0/1 0.00 (0.00 to 79.4)
≥ 100 cells/µl and < 200 cells/µl 5/6 83.3 (43.7 to 97.0) 4/7 57.1 (25.1 to 84.2)
≥ 200 cells/µl 10/12 83.3 (55.2 to 95.3) 11/14 78.6 (52.4 to 92.4)
Specificity for a diagnosis of active TB
< 50 cells/µl 26/29 89.7 (73.6 to 96.4) 26/29 89.7 (73.6 to 96.4)
≥ 50 cells/µl and < 100 cells/µl 11/13 84.6 (57.8 to 95.7) 11/12 91.7 (64.6 to 98.5)
≥ 100 cells/µl and < 200 cells/µl 10/13 76.9 (49.7 to 91.8) 14/15 93.3 (70.2 to 98.8)
≥ 200 cells/µl 53/64 83.1 (72.2 to 90.3) 63/69 91.3 (82.3 to 96.0)
Note
Sensitivity and specificity are presented as percentages.
TABLE 41 Comparison of diagnostic accuracy of T-SPOT.TB and QFT-GIT in HIV-positive patients
Test
Number of
test resultsa Sensitivity (95% CI)
Number of
test resultsb Specificity (95% CI)
T-SPOT.TB 25 62.8 (44.1 to 78.3) 121 83.4 (75.7 to 88.9)
QFT-GIT 30 56.1 (38.3 to 72.4) 128 91.7 (85.4 to 95.4)
Ratio (95% CI);c p-value – 1.12 (0.87 to 1.44); 0.4 – 0.91 (0.84 to 0.99); 0.02
a Number of test results among those patients with active TB.
b Number of test results among those without active TB.
c The ratio of the sensitivity (or specificity) of T-SPOT.TB to that of QFT-GIT. The natural outputs from GEE models are odds
ratios. Ratios of sensitivities (relative sensitivity) and ratios of specificities (relative specificity) were computed post
estimation of the models. Confidence intervals were obtained using the delta method.
Note
Sensitivities and specificities are presented as percentages.
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Discussion
Of the 263 patients recruited, 201 patients were included in the analyses. This is well below the target
sample size of 390. Although T-SPOT.TB showed higher sensitivity than QFT-GIT, a relative increase of
12%, there was no statistical evidence of a difference in sensitivity. The sensitivity of QFT-GIT in the IDEA
study was lower than that in other recent studies29–31 (see Appendix 11, Table 74).
The indeterminate rate was lower for QFT-GIT (19.5%) than for T-SPOT.TB (23.1%). The indeterminate results
were mainly in those without active TB, with 92.3% (36/39) for QFT-GIT and 86.7% (39/45) for T-SPOT.TB.
The impact of indeterminate results was explored in sensitivity analyses by including indeterminate results as
test positives. There was a small increase in the sensitivity of QFT-GIT but a large increase in the sensitivity of
T-SPOT.TB. This is because of the higher indeterminate rate for T-SPOT.TB (18.2%) among category 1 and 2
active TB cases than for QFT-GIT (5.9%).
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Chapter 6 Economic evaluation methods
In this chapter we present methods for assessment of the cost-effectiveness of IGRAs as rule-out tests foractive TB. That is, we consider using an IGRA as an initial test, with a negative result indicating that a
patient does not have TB, thus accelerating diagnosis of the actual cause of disease in such patients. The
use of QFT-GIT and T-SPOT.TB was compared against current practice, as determined by analysis of patient
records. We considered which diagnostic tests were performed, their costs and the time taken between
decision points involving each test. The time taken to diagnose or rule out TB is a key consideration. Our
report adheres to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.32
Decision tree model
We developed a decision tree model to calculate the incremental costs and incremental health utilities
(quality-adjusted life-year; QALYs) of changing from current practice to using an IGRA as an initial rule-out
test. Current practice was determined by the analysis of patient records. The model structure representing
current practice is shown in Figure 7. Adding a rule-out test to the diagnostic pathway introduces
additional delay in the diagnosis of active TB in those patients who have the disease, as it introduces an
additional step in the pathway. Patients who were not initially diagnosed with active TB have a follow-up
consultation after approximately 2 months; those who had a false-negative rule-out test result, that is, they
had TB incorrectly ruled out, can have TB identified at this point. The final diagnostic outcomes were the
four categories described in Dosanjh et al.,3 herein referred to as ‘Dosanjh categories’ (see Appendix 2,
Table 52). The health economic analysis was undertaken from a NHS perspective. No discounting was
required, as the diagnostic process occurs over a relatively short time period.
The model contained two levels of uncertainty.
1. Individual-level uncertainty: patient records revealed variation in the number and type of tests used for
TB diagnosis and time to diagnosis.
2. Parameter uncertainty: uncertainty in the costs of tests and procedures, and the sensitivity and
specificity of IGRAs.
A (balanced) bootstrap sample of TB and non-TB patients was created for each simulation of the decision
tree, which retained the subsample sizes. Individual patient costs and time to diagnosis were jointly
sampled to preserve the dependency between them. A Bayesian forward sampling approach generated
values from all of these distributions to simulate a particular model outcome. This was then repeated in
a Monte Carlo framework to obtain a sample of several thousand model runs that encapsulated the
first-order (patient variability) and second-order (parameter) uncertainty in the model outputs. Table 42
summarises the model parameters. The model was implemented in the statistical programming language
R (version R-3.3.0; R Foundation for Statistical Computing, Vienna, Austria).
Distributional formulation of individual-level/sample uncertainty
The number of individuals who enter the diagnostic pathway was defined as n. Of these, we defined n+ as
active TB cases and the remainder as non-active TB cases. We defined the probability of a given patient
being an active TB case as n+/n and so the probability of being a non-active TB case is 1 – (n+/n). This can
therefore be considered a draw from a Bernoulli distribution and so for the total sample the binomial
distribution gives the number of TB cases in a sample population as:
XTB ∼ Bin(n+ /n,n)
X∼TB = n− XTB,
(1)
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that is,
p(XTBjn+/n) =
 n
XTB

(n+/n)
XTB (1− n+/n)
(n − XTB). (2)
By the same principle, patients are then randomly split between those who are ruled out and those who
are not ruled out from the active TB and non-active TB subgroups:
XTB+ ∼ Bin(p+, XTB)
XTB− = XTB − X
TB
+
X∼TB+ ∼ Bin(1− p−,X∼TB)
X∼TB− = X∼TB − X
∼TB
+ .
(3)
This process results in a final random subdivision of the sample population into one of the end states.
Health economics outcomes
Each of the terminal nodes (outcomes) of the decision tree has an associated cost and health utility
(measured in QALYs). Incremental QALY differences are due to differences in the time taken to start
appropriate treatment, leading to differences in morbidity. For simplicity of notation, we shall denote
1 – DQoL by q. For the patient cohort these were defined as:
Ccurrent = c
Cnovel =
n+/n

(c +Cruleout )+
n−/n

((1− p−)c +Cruleout)
Ecurrent = qt
Enovel =
n+/n

q(t + T ruleout + (1− p+)TFN)+
n−/n

q((1− p−)t +Truleout ).
(4)
Estimation of costs used in the model
The costs and distributions used in the sensitivity analyses are summarised in Tables 43–45, using 2014/15
prices. When necessary, costs were inflated from previous years using the Hospital and Community Health
Service pay and price index.37
TABLE 42 Decision tree model parameters and values from sensitivity analyses
Parameter Symbol Main model values Sensitivity range
Rule-out test unit cost (£) Cruleout T-SPOT.TB or QFT-GIT 1–200
Follow-up time for those not diagnosed with TB
(days)
TFN Direct estimate from the
IDEA study clinical data set
54–127a
Cohort active TB prevalence n+/n Direct estimate from the
IDEA study clinical data set
0.1–0.5
Rule-out test time (days) Truleout Uniform(2,14)
Quality-of-life detriment for active TB symptoms DQoL Triangle(0.11,0.21,0.31)
33,34
Current time to diagnosis by TB status ti Direct estimate from the
IDEA study clinical data set
From the IDEA
study data set
Current combined cost of diagnosis by TB status ci Direct estimate from the
IDEA study clinical data set
From the IDEA
study data set
a 5% and 95% quantiles of the time to follow-up visit observed in the IDEA study clinical data.
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TABLE 43 Health-care professional consultation visit monetary costs incurred
Consultation type Cost (£) Distribution Sources
First visit: respiratory
medicine,
multiprofessional
241 Gamma(53.3,4.52) National Tariff Payment System 2014/15. Annex 5A35
167 (SE 33) Hughes et al., 201236
Follow-up visit:
respiratory medicine,
multiprofessional
143 Gamma(18.78,7.62) National Tariff Payment System 2014/15. Annex 5A35
167 (SE 33) Hughes et al., 201236
SE, standard error.
TABLE 44 Test and sampling procedure costs for cost-effectiveness calculations
Test
Unit cost (£)
[min., max.] Distribution Sources
Culture 22.29 (SE 2.23) Gamma(100,0.22) Drobniewski et al., 201538
Sputum smear
microscopy
7 Gamma(106,0.07) NICE’s Tuberculosis: Prevention, Diagnosis, Management
and Service Organisation. NICE Guideline 33, 201639
1.56 (SE 0.68) Hughes et al., 201236
TST 17.48 Auguste et al., 201640,41
16 [8, 32] Uniform(8,36) NICE’s Tuberculosis: Clinical Diagnosis and
Management of Tuberculosis, and Measures for its
Prevention and Control. NICE Guideline. Update of
CG117 – Appendix 6. Cost Effectiveness Analysis of
Interferon Gamma Release Assay (IGRA) Testing for
Latent Tuberculosis, 201042
T-SPOT.TB 59.57 Sutcliffe, 201641
55 [45, 99] Uniform(50,106) NICE’s Tuberculosis: Clinical Diagnosis and
Management of Tuberculosis, and Measures for its
Prevention and Control. NICE Guideline. Update of
CG117 – Appendix 6. Cost Effectiveness Analysis of
Interferon Gamma Release Assay (IGRA) Testing for
Latent Tuberculosis, 201042
QFT-GIT 58 [29, 87] Uniform(29,87) Pareek et al., 201343
CXR 35 NICE’s Tuberculosis: Prevention, Diagnosis, Management
and Service Organisation. NICE Guideline 33, 201639
28 [19, 34] Uniform(23,43) NICE’s Tuberculosis: Clinical Diagnosis and
Management of Tuberculosis, and Measures for its
Prevention and Control. NICE Guideline. Update of
CG117 – Appendix 6. Cost Effectiveness Analysis of
Interferon Gamma Release Assay (IGRA) Testing for
Latent Tuberculosis, 201042
Bronchoalveolar
lavage
23.24 – St Mary’s R&D office
[11.62, 46.48] Uniform (11.62, 46.48) Proportions from NICE’s Clinical Diagnosis and
Management of Tuberculosis and Measures for its
Prevention and Control. NICE Guideline 33, 2006,44
Pareek et al., 201343 and NICE’s Tuberculosis: Clinical
Diagnosis and Management of Tuberculosis, and
Measures for its Prevention and Control. NICE
Guideline. Update of CG117 – Appendix 6. Cost
Effectiveness Analysis of Interferon Gamma Release
Assay (IGRA) Testing for Latent Tuberculosis, 201042
continued
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When uncertainty bounds were not available in the recent sources used, uncertainty ranges were informed
by previous studies. Uniform distributions were used when the upper and lower limits were available and
gamma distributions were used when the standard error of the average cost was available.
When the lower, upper and mean values were available, the range between the lower and upper bound
was defined by the proportional decrease and increase from the mean, respectively. These proportions
were then used with an alternative, more appropriate, mean to calculate associated upper and lower
TABLE 44 Test and sampling procedure costs for cost-effectiveness calculations (continued )
Test
Unit cost (£)
[min., max.] Distribution Sources
EBUS 2634 – St Mary’s R&D office
Bronchoscopy
procedure
612 – St Mary’s R&D office
[306, 1224] Uniform(306,1224) Proportions from NICE’s Clinical Diagnosis and
Management of Tuberculosis and Measures for its
Prevention and Control. NICE Guideline 33, 2006,44
Pareek et al., 201343 and NICE’s Tuberculosis: Clinical
Diagnosis and Management of Tuberculosis, and
Measures for its Prevention and Control. NICE
Guideline. Update of CG117 – Appendix 6. Cost
Effectiveness Analysis of Interferon Gamma Release
Assay (IGRA) Testing for Latent Tuberculosis, 201042
Histology from
biopsy
25 – St Mary’s R&D office
[12.5, 50] Uniform(12.5,50) Proportions from NICE’s Clinical Diagnosis and
Management of Tuberculosis and Measures for its
Prevention and Control. NICE Guideline 33, 2006,44
Pareek et al., 201343 and NICE’s Tuberculosis: Clinical
Diagnosis and Management of Tuberculosis, and
Measures for its Prevention and Control. NICE
Guideline. Update of CG117 – Appendix 6. Cost
Effectiveness Analysis of Interferon Gamma Release
Assay (IGRA) Testing for Latent Tuberculosis, 201042
Needle aspirate 90.21 – St Mary’s R&D office
[45.1, 180.42] Uniform(45.1,180.42) Proportions from NICE’s Clinical Diagnosis and
Management of Tuberculosis and Measures for its
Prevention and Control. NICE Guideline 33, 2006,44
Pareek et al., 201343 and NICE’s Tuberculosis: Clinical
Diagnosis and Management of Tuberculosis, and
Measures for its Prevention and Control. NICE
Guideline. Update of CG117 – Appendix 6. Cost
Effectiveness Analysis of Interferon Gamma Release
Assay (IGRA) Testing for Latent Tuberculosis, 201042
PCR 202.45 – St Mary’s R&D office
[101.2, 404.9] Uniform(101.2,404.9) Proportions from NICE’s Clinical Diagnosis and
Management of Tuberculosis and Measures for its
Prevention and Control. NICE Guideline 33, 2006,44
Pareek et al., 201343 and NICE’s Tuberculosis: Clinical
Diagnosis and Management of Tuberculosis, and
Measures for its Prevention and Control. NICE
Guideline. Update of CG117 – Appendix 6. Cost
Effectiveness Analysis of Interferon Gamma Release
Assay (IGRA) Testing for Latent Tuberculosis, 201042
CXR, chest radiography; EBUS, endobronchial ultrasound; max., maximum; min., minimum; SE, standard error.
Note
Uncertainty distributions for each test are estimated either for uniform or gamma distributions depending on the form of
the data available.
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limits. For example, a lower bound of half and an upper bound of twice the point estimate values were
used.42,43,46 Skewed distributions were represented using a gamma distribution.
As the end point of the analysis is diagnosis of TB or ruling out TB, treatment costs after final diagnosis are
out of scope. However, when a patient was started on TB treatment and then a lack of response to that
treatment informed a decision that the patient did not in fact have TB, the cost of this treatment was
included, as it is part of the cost of ruling out TB for those patients.
Tests used in the diagnostic pathways are either specific to the diagnosis of active TB or, in the case of
imaging tests [CT, MRI and positron emission tomography (PET)], can aid the diagnosis of multiple diseases.
For patients who do not have TB, these imaging tests will be used to inform the ultimate diagnosis.
The treatment costs for those patients who have TB ruled out after starting treatment are given in Table 45.
Following the NICE guidelines for active TB management,39 it was assumed that such patients are on
treatment until their 2-month follow-up appointment, when they are reassessed for response to treatment.
The regimen in this period is a daily treatment with rifampicin, isoniazid, pyrazinamide and ethambutol. The
British National Formulary45 provides fixed dosages for adults, except for ethambutol hydrochloride, which is
determined by patient weight. The mean weight at time of first presentation of 67.98 kg was used in the
model. Table 46 summarises the sensitivity and specificity values previously given in Chapter 4, Comparison
of diagnostic accuracy of T-SPOT.TB and QuantiFERON GOLD In-Tube and Tables 15 and 61 along with
values for the beta PERT (project evaluation and review technique) distributions used for the probabilistic
sensitivity analyses.
TABLE 45 Active TB treatment costs for the first 60 days
Drug
Dosage
(mg/day)a
Dosage by
patient weight
(mg/kg/day)a
Batch
costb (£)
Quantity per
batch (capsule
or tablet)b
Dosage per
capsule or
tabletb
60-day
total
cost (£)
Rifampicin 600 – 48.00 100 300 57.60
Isoniazid 300 – 19.24 56 50 123.69
Pyrazinamide 2000 – 38.34 30 500 306.72
Ethambutol hydrochloride – 15 42.74 56 400 116.74
a Data taken from the British National Formulary.45
b Data taken from NICE’s Tuberculosis: Prevention, Diagnosis, Management and Service Organisation. NICE Guideline 33 (2016).39
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TABLE 46 Diagnostic test performance and distributions for different patient strata
Patient strata Test
Indeterminate
IGRA results Sensitivity 95% CI
Beta distribution,
Beta (a, b) Specificity 95% CI
Beta distribution,
Beta (a, b)
All QFT-GIT Excluded 0.673 0.620 to 0.721 (147,72) 0.804 0.761 to 0.841 (315,77)
All T-SPOT.TB Excluded 0.823 0.778 to 0.861 (299,64) 0.826 0.786 to 0.861 (293,60)
All QFT-GIT Included 0.697 0.647 to 0.742 (147,64) 0.715 0.671 to 0.756 (145,58)
All T-SPOT.TB Included 0.832 0.789 to 0.868 (290,59) 0.754 0.711 to 0.793 (348,112)
HIV positive QFT-GIT Excluded 0.565 0.368 to 0.744 (15,11) 0.920 0.843 to 0.961 (67,6)
HIV positive T-SPOT.TB Excluded 0.632 0.410 to 0.809 (14,8) 0.899 0.813 to 0.948 (74,7)
HIV positive QFT-GIT Included 0.600 0.407 to 0.766 (17,11) 0.748 0.658 to 0.820 (70,24)
HIV positive T-SPOT.TB Included 0.708 0.508 to 0.851 (18,7) 0.664 0.570 to 0.746 (73,36)
HIV negative QFT-GIT Excluded 0.681 0.627 to 0.731 (147,69) 0.770 0.718 to 0.814 (226,68)
HIV negative T-SPOT.TB Excluded 0.835 0.790 to 0.872 (287,57) 0.808 0.760 to 0.848 (250,59)
HIV negative QFT-GIT Included 0.704 0.653 to 0.751 (146,61) 0.704 0.652 to 0.752 (208,88)
HIV negative T-SPOT.TB Included 0.841 0.797 to 0.877 (280,53) 0.785 0.736 to 0.827 (264,72)
ECO
N
O
M
IC
EVA
LU
A
TIO
N
M
ETH
O
D
S
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
64
Chapter 7 Economic evaluation results
Introduction
This chapter presents the results of the economic evaluation. First, a data analysis with a health economics
focus is given. This demonstrates the patterns and variability in times and costs between patients and
also indicates why a simple direct estimation of the relevant summary statistics is not appropriate. Second,
the modelling results are given and, finally, the main base-case scenario results are presented.
Results
The idealised diagnostic pathway representing current practice is shown in Figure 8. Patient records were
analysed to determine what proportion of patients followed the pathways in this diagram. For each Dosanjh
category, the particular tests expected to be performed and their corresponding results were determined
and then compared with patient records. Tables 47 and 48 present the frequencies of different tests
performed, stratified by final diagnostic outcome. Importantly, the process of TB diagnosis rarely followed
the idealised diagnostic pathways. Although culture, IGRAs (QFT-GIT and T-SPOT.TB), TSTs, sputum smear
microscopy and chest radiography were frequently used, there was substantial variation between patients.
These results are presented graphically in Figure 9, in which the number of patients who traverse each
branch are indicated by the width of the branch. From the individual-level patient data, we used the
empirical distributions of time to diagnosis and total test costs in the probabilistic sensitivity analysis in the
following health economic evaluation.
Table 49 gives distributional statistics of the cost of testing for each final diagnosis category. There are
long right-hand tails, making single centrality summary statistics misleading.
The decision tree model structure is shown in Figure 10 and includes true-negative, false-negative, true-positive
and false-positive rule-out test results. Patients receiving a positive rule-out test result (i.e. TB is not ruled out)
then follow the standard diagnostic pathway, whereas patients receiving a negative rule-out test result are
regarded as not having TB. If the rule-out test result is a false negative, then at the 2-month follow-up
consultation the patient’s persistent symptoms leads to them entering the standard TB diagnostic pathway.
For patients who are TB negative and who receive a true negative in the rule-out test, the rule-out test
results in a faster diagnosis of the true cause of their illness. However, for other patients, the rule-out test
increases the delay in their ultimate diagnosis, both for those who have TB and those who do not.
The ‘standard pathway’ branch represents the range of variation observed in the patient cohort.
Probabilities are shown below branches following a circular chance node and costs are below branches
following a square decision node. The rule-out test is either T-SPOT.TB or QFT-GIT.
Results of the cost-effectiveness analysis are summarised in Table 50. Figure 11 shows cost-effectiveness
planes for the use of T-SPOT.TB or QFT-GIT as rule-out tests, including three clouds of results for all patients,
HIV-negative patients and HIV-positive patients. Figures 12 and 13 show the cost-effectiveness planes with
uncertainty represented by ellipses showing the 95% and 50% ranges of uncertainty, respectively.
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Suspected active TB
IGRA/TST positive
and/or
chest radiography
positive and 
smear negative
Symptoms of TB
and sputum available
IGRA/TST
Chest radiography
Smear microscopy
Culture
Smear negative
Culture negative
Active TB
Dosanjh category 2
Smear positive
Culture positive
Active TB
Dosanjh category 1
IGRA/TST/chest
radiography/smear negative
Culture negative
Active TB excluded
Dosanjh category 4
Smear negative
Culture negative
Active TB
Dosanjh category 2
Smear positive
Culture positive
Active TB
Dosanjh category 1
Smear negative
Culture negative
Active TB excluded
Dosanjh category 4
Symptoms of TB
and no sputum available
IGRA/TST
Chest radiography
IGRA/TST positive
and/or chest 
radiography positive
CT
BAL
Smear microscopy
Culture
All negative
and no high-risk factors
(e.g. recent significant
contact/antiTNF 
treatment)
TB excluded
Dosanjh category 4
FIGURE 8 Idealised TB diagnostic pathway.
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TABLE 47 Test result combinations of culture, sputum smear microscopy and chest radiography by final diagnosis
Culture Sputum smear Chest radiography
Dosanjh category, n
Total, n1 2 3 4
Not performed Not performed Not performed 0 0 3 13 16
Not performed Not performed Indeterminate 0 0 2 13 15
Not performed Not performed Negative 0 0 7 61 68
Not performed Not performed Positive 0 3 0 1 4
Not performed Negative Not performed 0 0 0 3 3
Not performed Negative Indeterminate 0 0 1 2 3
Not performed Negative Negative 0 0 1 6 7
Not performed Negative Positive 0 0 0 1 1
Indeterminate Not performed Negative 0 0 1 0 1
Indeterminate Negative Negative 0 0 0 1 1
Indeterminate Positive Positive 0 0 0 1 1
Negative Not performed Not performed 0 0 2 8 10
Negative Not performed Indeterminate 0 1 1 10 12
Negative Not performed Negative 0 1 3 18 22
Negative Not performed Positive 0 2 0 1 3
Negative Negative Not performed 0 2 2 34 38
Negative Negative Indeterminate 0 4 4 65 73
Negative Negative Negative 0 7 16 235 258
Negative Negative Positive 0 11 4 48 63
Negative Positive Not performed 0 0 0 2 2
Negative Positive Indeterminate 0 0 0 1 1
Negative Positive Negative 0 0 0 4 4
Negative Positive Positive 0 1 0 1 2
Positive Not performed Not performed 1 0 0 0 1
Positive Not performed Indeterminate 3 0 0 0 3
Positive Not performed Positive 4 0 0 0 4
Positive Negative Not performed 8 0 0 0 8
Positive Negative Indeterminate 17 0 0 0 17
Positive Negative Negative 14 0 0 0 14
Positive Negative Positive 57 0 0 0 57
Positive Positive Not performed 3 0 0 0 3
Positive Positive Indeterminate 5 0 0 0 5
Positive Positive Negative 2 0 0 0 2
Positive Positive Positive 47 0 0 0 47
Total 161 32 47 529 769
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TABLE 48 Tests performed at least once in the in-practice routine diagnostic pathways for suspected active TB
Test/sampling method
Dosanjh category, n
1 2 3 4
Culture 161 (1.00) 29 (0.91) 33 (0.70) 429 (0.81)
QFT-GIT 15 (0.09) 8 (0.25) 9 (0.19) 45 (0.09)
T-SPOT.TB 29 (0.18) 6 (0.19) 19 (0.40) 150 (0.28)
TST 55 (0.34) 10 (0.31) 21 (0.45) 164 (0.31)
Sputum smear microscopy 153 (0.95) 25 (0.78) 28 (0.60) 404 (0.76)
Bronchoalveolar lavage 50 (0.31) 14 (0.44) 9 (0.19) 135 (0.26)
Histology from biopsy 23 (0.14) 11 (0.34) 14 (0.30) 113 (0.21)
Needle aspirate 28 (0.17) 6 (0.19) 10 (0.21) 60 (0.11)
PCR 70 (0.43) 5 (0.16) 7 (0.15) 84 (0.16)
CXR 148 (0.92) 29 (0.91) 40 (0.85) 465 (0.88)
CT 85 (0.53) 22 (0.69) 27 (0.57) 323 (0.61)
MRI 16 (0.10) 3 (0.09) 7 (0.15) 57 (0.11)
PET 1 (0.01) 0 (0) 5 (0.11) 13 (0.02)
CXR, chest radiography.
Note
For each test, the proportion for each Dosanjh category is given in brackets.
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(a)
FIGURE 9 Representation of numbers of patients undergoing various TB tests, stratified by final diagnosis.
(a) Culture-confirmed TB, Dosanjh category 1; (b) TB non-culture-confirmed, Dosanjh category 2; (c) Indeterminate,
Dosanjh category 3; and (d) TB excluded, Dosnajh category 4. CXR, chest radiography. Patient numbers are shown
on the branches. The frequencies of patients in each branch are proportional to the width of the branch. Upwards
branches are for negative test results or if the decision was taken not to take a test (for chest radiography and
culture) and the downwards branches are for positive results or a decision to test. (continued )
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(c)
FIGURE 9 Representation of numbers of patients undergoing various TB tests, stratified by final diagnosis.
(a) Culture-confirmed TB, Dosanjh category 1; (b) TB non-culture-confirmed, Dosanjh category 2; (c) Indeterminate,
Dosanjh category 3; and (d) TB excluded, Dosnajh category 4. CXR, chest radiography. Patient numbers are shown
on the branches. The frequencies of patients in each branch are proportional to the width of the branch. Upwards
branches are for negative test results or if the decision was taken not to take a test (for chest radiography and
culture) and the downwards branches are for positive results or a decision to test. (continued )
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CXR taken CXR Smear TST taken TST Culture
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(d)
FIGURE 9 Representation of numbers of patients undergoing various TB tests, stratified by final diagnosis.
(a) Culture-confirmed TB, Dosanjh category 1; (b) TB non-culture-confirmed, Dosanjh category 2; (c) Indeterminate,
Dosanjh category 3; and (d) TB excluded, Dosnajh category 4. CXR, chest radiography. Patient numbers are shown
on the branches. The frequencies of patients in each branch are proportional to the width of the branch. Upwards
branches are for negative test results or if the decision was taken not to take a test (for chest radiography and
culture) and the downwards branches are for positive results or a decision to test.
TABLE 49 Summary statistics for cost of diagnosis for the patient cohort by final diagnosis category
Dosanjh category
Diagnosis cost (£)
Lower quartile Median Mean Upper quartile
1 292.31 (29.93) 442.92 (17.64) 469.77 (20.59) 640.03 (30.78)
2 383.73 (66.96) 476.12 (29.6) 474.73 (37.87) 572.03 (53.04)
3 254.08 (72.77) 502.04 (49.58) 535.48 (57.55) 644.12 (83.71)
4 202.00 (17.21) 433.39 (7.69) 445.61 (12.25) 588.47 (17.75)
Note
A total of 1000 bootstrap samples were used to give means and standard errors (in brackets) for each statistic.
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Active PTB excluded 
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Test 
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No rule-out test
FIGURE 10 Decision tree comparing current practice (‘no rule-out test’) with a diagnostic pathway incorporating an initial rule-out test (‘rule-out test’). PTB, pulmonary tuberculosis.
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TABLE 50 Main results from cost-effectiveness analyses for the entire patient cohort
Patient strata Test
Indeterminate
test results
Incremental
QALYs
Incremental
cost (£000) ICER (× 103)
Probability cost-effective
at £20,000 per QALY
Probability cost-effective
at £30,000 per QALY
All QFT-GIT Excluded –6.22 –86.85 13.97 0.08 0.05
All T-SPOT.TB Excluded –3.58 –78.81 22.01 0.26 0.22
All QFT-GIT Included –6.50 –70.14 10.79 0.06 0.04
All T-SPOT.TB Included –4.14 –65.12 15.73 0.21 0.17
HIV positive QFT-GIT Excluded –7.14 –106.09 14.85 0.09 0.07
HIV positive T-SPOT.TB Excluded –5.91 –86.87 14.70 0.12 0.08
HIV positive QFT-GIT Included –7.86 –72.64 9.24 0.04 0.02
HIV positive T-SPOT.TB Included –6.34 –42.11 6.64 0.04 0.03
HIV negative QFT-GIT Excluded –6.66 –80.27 12.06 0.06 0.04
HIV negative T-SPOT.TB Excluded –3.52 –75.31 21.40 0.26 0.21
HIV negative QFT-GIT Included –6.47 –69.35 10.72 0.05 0.03
HIV negative T-SPOT.TB Included –3.57 –71.45 20.04 0.24 0.19
ICER, incremental cost-effectiveness ratio.
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FIGURE 11 Cost-effectiveness planes comparing the use of T-SPOT.TB or QFT-GIT as rule-out tests with current practice.
Results for (a) T-SPOT.TB with indeterminate diagnostic outcomes excluded; (b) T-SPOT.TB with indeterminate diagnostic
outcomes included; (c) QFT-GIT with indeterminate diagnostic outcomes excluded; and (d) QFT-GIT with indeterminate
diagnostic outcomes included. Statistics were calculated for the entire patient cohort. The upper panels show results
for T-SPOT.TB, whereas the lower panels show results for QFT-GIT. Left- and right-hand panels present results with
indeterminate diagnostic outcomes excluded and included, respectively. Note that an indeterminate IGRA result should
not be confused with a diagnostic categorisation of a patient as being ‘clinically indeterminate’ with regard to having
active TB (i.e. Dosanjh category 3). The analyses considered all patients (black circle), HIV-positive patients (green square)
and HIV-negative patients (blue triangle), with each point showing the results of a single simulation result. The red
points indicate the median values for each scenario. Diagonal lines indicate the cost-effectiveness thresholds of
£20,000 per QALY (blue vertical line) and £30,000 per QALY (green vertical line). A total of 1000 simulations were
run for each scenario. (continued )
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FIGURE 11 Cost-effectiveness planes comparing the use of T-SPOT.TB or QFT-GIT as rule-out tests with current practice.
Results for (a) T-SPOT.TB with indeterminate diagnostic outcomes excluded; (b) T-SPOT.TB with indeterminate diagnostic
outcomes included; (c) QFT-GIT with indeterminate diagnostic outcomes excluded; and (d) QFT-GIT with indeterminate
diagnostic outcomes included. Statistics were calculated for the entire patient cohort. The upper panels show results
for T-SPOT.TB, whereas the lower panels show results for QFT-GIT. Left- and right-hand panels present results with
indeterminate diagnostic outcomes excluded and included, respectively. Note that an indeterminate IGRA result should
not be confused with a diagnostic categorisation of a patient as being ‘clinically indeterminate’ with regard to having
active TB (i.e. Dosanjh category 3). The analyses considered all patients (black circle), HIV-positive patients (green square)
and HIV-negative patients (blue triangle), with each point showing the results of a single simulation result. The red
points indicate the median values for each scenario. Diagonal lines indicate the cost-effectiveness thresholds of
£20,000 per QALY (blue vertical line) and £30,000 per QALY (green vertical line). A total of 1000 simulations were
run for each scenario.
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FIGURE 12 Cost-effectiveness planes comparing the use of T-SPOT.TB or QFT-GIT as rule-out tests with current
practice (95% density of simulation results). Results for (a) T-SPOT.TB with indeterminate diagnostic outcomes
excluded; (b) T-SPOT.TB with indeterminate diagnostic outcomes included; (c) QFT-GIT with indeterminate
diagnostic outcomes excluded; and (d) QFT-GIT with indeterminate diagnostic outcomes included. Statistics were
calculated for the entire patient cohort. The upper panels show results for T-SPOT.TB, whereas the lower panels
show results for QFT-GIT. Left- and right-hand panels present results with indeterminate diagnostic outcomes
excluded and included, respectively. Ellipses show 95% density of simulation results. The analyses considered all
patients (black lines), HIV-positive patients (green dashed lines) and HIV-negative patients (blue dotted lines). The
green dots indicate the median values for each scenario. Diagonal lines indicate the cost-effectiveness thresholds of
£20,000 per QALY (blue vertical line) and £30,000 per QALY (green vertical line). A total of 1000 simulations were
run for each scenario. (continued )
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FIGURE 12 Cost-effectiveness planes comparing the use of T-SPOT.TB or QFT-GIT as rule-out tests with current
practice (95% density of simulation results). Results for (a) T-SPOT.TB with indeterminate diagnostic outcomes
excluded; (b) T-SPOT.TB with indeterminate diagnostic outcomes included; (c) QFT-GIT with indeterminate
diagnostic outcomes excluded; and (d) QFT-GIT with indeterminate diagnostic outcomes included. Statistics were
calculated for the entire patient cohort. The upper panels show results for T-SPOT.TB, whereas the lower panels
show results for QFT-GIT. Left- and right-hand panels present results with indeterminate diagnostic outcomes
excluded and included, respectively. Ellipses show 95% density of simulation results. The analyses considered all
patients (black lines), HIV-positive patients (green dashed lines) and HIV-negative patients (blue dotted lines). The
green dots indicate the median values for each scenario. Diagonal lines indicate the cost-effectiveness thresholds of
£20,000 per QALY (blue vertical line) and £30,000 per QALY (green vertical line). A total of 1000 simulations were
run for each scenario.
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FIGURE 13 Cost-effectiveness planes comparing the use of T-SPOT.TB or QFT-GIT as rule-out tests with current
practice (50% density of simulation results). Results for (a) T-SPOT.TB with indeterminate diagnostic outcomes
excluded; (b) T-SPOT.TB with indeterminate diagnostic outcomes included; (c) QFT-GIT with indeterminate
diagnostic outcomes excluded; and (d) QFT-GIT with indeterminate diagnostic outcomes included. Upper panels
show results for T-SPOT.TB, whereas lower panels show results for QFT-GIT. Left- and right-hand panels present
results with indeterminate diagnostic outcomes excluded and included, respectively. Ellipses show 50% density of
simulation results. The analyses considered all patients (black lines), HIV-positive patients (green dashed lines) and
HIV-negative patients (blue dotted lines). The green dots indicate the median values for each scenario. Diagonal
lines indicate the cost-effectiveness thresholds of £20,000 per QALY (blue vertical line) and £30,000 per QALY
(green vertical line). A total of 1000 simulations were run for each scenario. (continued )
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FIGURE 13 Cost-effectiveness planes comparing the use of T-SPOT.TB or QFT-GIT as rule-out tests with current
practice (50% density of simulation results). Results for (a) T-SPOT.TB with indeterminate diagnostic outcomes
excluded; (b) T-SPOT.TB with indeterminate diagnostic outcomes included; (c) QFT-GIT with indeterminate
diagnostic outcomes excluded; and (d) QFT-GIT with indeterminate diagnostic outcomes included. Upper panels
show results for T-SPOT.TB, whereas lower panels show results for QFT-GIT. Left- and right-hand panels present
results with indeterminate diagnostic outcomes excluded and included, respectively. Ellipses show 50% density of
simulation results. The analyses considered all patients (black lines), HIV-positive patients (green dashed lines) and
HIV-negative patients (blue dotted lines). The green dots indicate the median values for each scenario. Diagonal
lines indicate the cost-effectiveness thresholds of £20,000 per QALY (blue vertical line) and £30,000 per QALY
(green vertical line). A total of 1000 simulations were run for each scenario.
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Using IGRAs as a rule-out test is likely to be cost saving (except perhaps for T-SPOT.TB when used with
HIV-positive patients), but also harmful to health. The magnitude of the health detriment is such that it
would not be cost-effective if a QALY is valued at either £20,000 or £30,000 (indicated by diagonal lines).
As the use of IGRAs as a rule-out test is detrimental to health (because of the increased average time to
diagnosis) but cost saving, the cost-effectiveness acceptability curves (Figure 14) show a high probability of
rule-out testing being cost-effective when the value of a QALY is low, with the probability declining steeply
as the value of a QALY increases. This is because if a QALY has a low value then for a given cost saving a
relatively large loss of QALYs would be considered acceptable, whereas if a QALY has a high value then
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FIGURE 14 Cost-effectiveness acceptability curves for T-SPOT.TB or QFT-GIT as rule-out tests compared with current
practice. Results for (a) T-SPOT.TBwith indeterminate IGRA result patients excluded; (b) T-SPOT.TBwith indeterminate
IGRA result patients included; (c) QFT-GIT with indeterminate IGRA result patients excluded; and (d) QFT-GIT with
indeterminate IGRA result patients included. Upper panels show results for T-SPOT.TB, whereas lower panels show
results for QFT-GIT. Left- and right-hand panels present results with indeterminate IGRA result patients excluded and
included, respectively. The analyses considered all patients (black lines), HIV-positive patients (green dashed lines) and
HIV-negative patients (blue dotted lines). Vertical lines indicate thresholds of £20,000 per QALY (green vertical line)
and £30,000 per QALY (blue vertical line). (continued )
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such a QALY loss would not be acceptable. If a QALY is valued at £20,000, then all scenarios have a
probability of < 30% of being cost-effective and many of them have a probability of < 10%. For £30,000
all scenarios have a probability of < 25% of being cost-effective, but many of them are in single figures.
Figure 15 shows the corresponding upper and lower 95% binomial CIs for the cost-effectiveness
acceptability curves in Figure 14, calculated using the normal approximation to the binomial distribution.
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FIGURE 14 Cost-effectiveness acceptability curves for T-SPOT.TB or QFT-GIT as rule-out tests compared with current
practice. Results for (a) T-SPOT.TBwith indeterminate IGRA result patients excluded; (b) T-SPOT.TBwith indeterminate
IGRA result patients included; (c) QFT-GIT with indeterminate IGRA result patients excluded; and (d) QFT-GIT with
indeterminate IGRA result patients included. Upper panels show results for T-SPOT.TB, whereas lower panels show
results for QFT-GIT. Left- and right-hand panels present results with indeterminate IGRA result patients excluded and
included, respectively. The analyses considered all patients (black lines), HIV-positive patients (green dashed lines) and
HIV-negative patients (blue dotted lines). Vertical lines indicate thresholds of £20,000 per QALY (green vertical line)
and £30,000 per QALY (blue vertical line).
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FIGURE 15 Cost-effectiveness acceptability curves (with 95% CI values) for T-SPOT.TB or QFT-GIT as rule-out tests
compared with current practice. Results for (a) T-SPOT.TB with indeterminate IGRA result patients excluded;
(b) T-SPOT.TB with indeterminate IGRA result patients included; (c) QFT-GIT with indeterminate IGRA result patients
excluded; and (d) QFT-GIT with indeterminate IGRA result patients included. Upper and lower 95% CI values shown
assuming normal approximation to the binomial distribution. Upper panels show results for T-SPOT.TB, whereas
lower panels show results for QFT-GIT. Left- and right-hand panels present results with indeterminate IGRA result
patients excluded and included, respectively. The analyses considered all patients (black solid lines), HIV-positive
patients (green lines) and HIV-negative patients (blue lines). Vertical lines indicate thresholds of £20,000 per QALY
(green vertical line) and £30,000 per QALY (blue vertical line). (continued )
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Discussion
An important finding of this study is that TB diagnosis rarely follows the idealised diagnostic pathways,
meaning that costs and time delays until diagnosis may be very different from what economic analyses
typically assume. In particular, costs of diagnosis may be typically underestimated, particularly when
scanning is involved. Furthermore, there is considerable individual-level variation in the costs and time
taken for TB diagnosis, which needs to be represented in the analysis. Therefore, we included the empirical
distributions of time to diagnosis and total test costs in the probabilistic sensitivity analysis in the health
economic evaluation.
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FIGURE 15 Cost-effectiveness acceptability curves (with 95% CI values) for T-SPOT.TB or QFT-GIT as rule-out tests
compared with current practice. Results for (a) T-SPOT.TB with indeterminate IGRA result patients excluded;
(b) T-SPOT.TB with indeterminate IGRA result patients included; (c) QFT-GIT with indeterminate IGRA result patients
excluded; and (d) QFT-GIT with indeterminate IGRA result patients included. Upper and lower 95% CI values shown
assuming normal approximation to the binomial distribution. Upper panels show results for T-SPOT.TB, whereas
lower panels show results for QFT-GIT. Left- and right-hand panels present results with indeterminate IGRA result
patients excluded and included, respectively. The analyses considered all patients (black solid lines), HIV-positive
patients (green lines) and HIV-negative patients (blue lines). Vertical lines indicate thresholds of £20,000 per QALY
(green vertical line) and £30,000 per QALY (blue vertical line).
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The use of current IGRA tests for ruling out active TB would be unlikely to be considered cost-effective if a
QALY were to be valued at £20,000 or £30,000; although it is cost saving, the health detriment is large.
Health detriment occurs because of a delay in diagnosing active TB, prolonging illness, for two reasons.
First, adding a rule-out test to the diagnostic pathway adds a step and increases the costs and time taken
to ultimate diagnosis for all patients except those who do not have TB and receive a true-negative rule-out
test result so that they do not undergo the remainder of TB-specific tests. Second, some patients with TB
receive a false-negative result from the rule-out test, which delays their diagnosis of TB until after their
follow-up appointment. However, for patients who do not have TB, and who have TB correctly ruled out
by the initial test, the time to diagnosis of the cause of their illness is reduced, producing a health gain,
and there is a cost saving owing to their not having further tests for TB. Whether there is a net health
detriment or gain for the patient cohort as a whole depends on the prevalence of active TB in the patients,
the performance characteristics of the rule-out test and the length of delay introduced by adding the initial
rule-out test.
Limitations and generalisability
The multicentre design means that the study population is representative of the general population with
clinically relevant risk of TB in the UK and is therefore representative of the greatest TB burden in the
country. In areas where TB rates are low, the patient populations might be substantially different, and this
has not been tested in the study. The model is flexible and is suitable for analysing rule-out tests with a
range of performance characteristics, and could also be applied to patient populations in lower-burden
settings if suitable data were available. A limitation is that, although we have quantified the health
detriment of delayed treatment due to prolonged morbidity, we were unable to account for any additional
detriment due to a potentially poorer prognosis, because of a lack of suitable data. In addition to a lack of
data, the assumed time taken to apply the hypothetical rule-out test is an assumption based on expert
opinion, and we have assumed that the time to follow-up of those patients who receive a negative
hypothetical rule-out test result can be inferred from our existing data set. The timings of in-practice events
were estimated from the study population. The variability in times between patients were explicitly
included in the model.
Conclusions and recommendations
The use of current IGRA tests for ruling out active TB would be unlikely to be considered cost-effective if a
QALY were to be valued at £20,000 or £30,000. A health detriment in patients with active TB whose
diagnosis and treatment are delayed needs to be balanced against health gains in patients who do not
have active TB whose diagnosis of the true cause of illness and commencement of appropriate treatment
are accelerated, with consideration given to cost savings of faster ruling out of active TB. Although the
performance of current IGRA tests means they are not cost-effective, improved test technology or
alternative algorithms using current technology could potentially have a performance that is cost-effective.
Future research recommendations are that improved testing technology, including combinations of tests,
be investigated with an equivalent analysis. The knowledge base in this field of research is improved data
and understanding at the national and local level.
DOI: 10.3310/hta23230 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 23
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Takwoingi et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed
to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
83

Chapter 8 Discussion
D iagnostic accuracy findings for T-SPOT.TB and QFT-GIT were described in detail in Chapters 4 and 5,and the results of the economic evaluation were discussed in Chapter 7. Therefore, this chapter
focuses on the principal findings, strengths and limitations of the study, and implications for health care
and research.
Principal findings
This large multicentre study of a consecutive series of patients being investigated for possible TB is
representative of routine clinical practice in the UK. The study clearly showed that T-SPOT.TB is more
sensitive than QFT-GIT (relative sensitivity 1.22, 95% CI 1.14 to 1.31; p < 0.001), but that specificities are
similar (relative specificity 1.02, 95% CI 0.97 to 1.08; p = 0.3). For T-SPOT.TB and QFT-GIT, the sensitivities
were 82.3% (95% CI 77.7% to 85.9%) and 67.3% (95% CI 62.1% to 72.2%), respectively, whereas the
specificities were 82.6% (95% CI 78.6% to 86.1%) and 80.4% (95% CI 76.1% to 84.1%), respectively.
In the substudy of HIV-positive patients, the highest-risk subgroup for TB, T-SPOT.TB also showed higher
sensitivity than QFT-GIT (a relative increase of 12%), but there was no statistical evidence of a difference in
sensitivity. The sensitivity of T-SPOT.TB in all patients (82.3%) or among HIV co-infected patients (68.0%) is
not of sufficient clinical utility as a rule-out test for the diagnosis of active TB in routine clinical practice and
cannot be used in isolation as a rule-out test. This is further supported by the economic evaluation. The
use of current IGRA tests for ruling out active TB would be unlikely to be considered cost-effective if a
QALY were to be valued at £20,000 or £30,000. There are cost savings, but the health detriment is large
because of the delay in diagnosing active TB.
The specificities of the IGRAs were also not adequate for IGRAs to be recommended as rule-in tests.
However, in category 4D patients (active TB excluded, TST negative and no risk factors for LTBI), both
T-SPOT.TB and QFT-GIT showed high specificity: 92.3% (95% CI 85.4% to 96.4%) and 93.4% (95% CI
86.4% to 96.9%), respectively. This suggests that IGRAs may have potential value for ruling in TB in
settings with a low probability of active TB. However, it should be noted that the number of category 4D
patients was small.
For key subgroups in our main study cohort – patients with pre-existing diabetes mellitus, end-stage renal
failure or iatrogenic immunosuppression – data were limited. Of the 845 patients included in our analyses,
88 (10.4%) had diabetes mellitus, 12 (1.4%) had chronic/end-stage renal failure and 105 (12.4%) patients
were on immunosuppressive therapy. Analysis of patients with and without diabetes mellitus showed
that the sensitivities and specificities of both tests were higher in those without diabetes mellitus than in
those with diabetes mellitus. However, there was no statistical evidence of an effect on the relative test
performance of T-SPOT.TB and QFT-GIT. Although this finding should be interpreted with caution because
of the small number of active TB cases in the analyses, association between diabetes mellitus and IGRA
performance has been reported. Faurholt-Jepsen et al.47 reported an association between diabetes mellitus
and lower levels of Mtb antigen-specific IFN-γ and the impact on QFT-GIT results. Our findings are similar,
even though diabetes mellitus was self-reported in the IDEA study. We found no study that has evaluated the
effect of diabetes mellitus on the diagnostic performance of T-SPOT.TB; the IDEA study appears to be the first
study to suggest differences in the performance of T-SPOT.TB between diabetic and non-diabetic patients.
A new generation of QFT-GIT, QuantiFERON-TB Gold Plus (QFT®-Plus; Qiagen GmbH, Hilden, Germany),
was recently launched. QFT-Plus includes a set of peptides designed to stimulate Mtb-specific cluster of
differentiation 8-positive T cells.48 There is very little published evidence about the performance of the test.
According to Barcellini et al.,48 who reported the first independent assessment of QFT-Plus, the test had
sensitivity of 87.9% (95% CI 80.8% to 92.7%) in 116 TB patients and specificity of 97.2% (95% CI
92.0% to 99.0%) in 106 low-risk controls. In the IDEA study, second-generation IGRAs utilising novel
DOI: 10.3310/hta23230 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 23
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Takwoingi et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed
to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
85
antigens showed potential as rule-out tests. In particular, the use of a combination of existing antigens –
ESAT-6 and CFP-10 – and the newer antigens – Rv3615c and Rv3879c – achieved a sensitivity of 89.9%
(95% CI 86.2% to 92.7%) based on all active TB cases and 94.4% (95% CI 90.7% to 96.7%) among
culture-confirmed cases. Similar results were obtained for the two-antigen combination of CFP-10 and
Rv3615c and the three-antigen combination of ESAT-6, CFP-10 and Rv3615c. The added value of Rv3615c
to T-SPOT.TB was a 9% (95% CI 5% to 12%) relative increase in sensitivity at the expense of specificity
with a relative decrease of 7% (95% CI 4% to 10%). The incremental gain in sensitivity to 90% is likely to
be clinically useful in ruling out active TB.
Strengths and limitations
To our knowledge, the IDEA study is the largest, prospective comparative accuracy study of the role of
IGRAs for the diagnosis of active TB. Furthermore, we recruited a consecutive series of patients who were
representative of UK clinical practice in a high-income setting. We ensured completeness and quality of
the data such that missing data were minimal. Therefore, this well- designed and well-conducted study
enabled robust and precise estimation of the relative performance of T-SPOT.TB and QFT-GIT in the main
study cohort.
Our study has wide applicability as we did not exclude key subgroups, such as HIV-positive patients, but
aimed to also compare the clinical performance of T-SPOT.TB and QFT-GIT in this population. In spite of
not achieving the target sample size for the HIV-positive subgroup, compared with the five comparative
studies identified in a systematic review published in 2012 and our literature review,15 the IDEA study
remains the largest prospective head-to-head comparison of the two IGRAs in a HIV co-infected population.
The final diagnosis of TB is challenging in non-culture-confirmed cases and relies on a combination of
epidemiological, radiological and diagnostic parameters. We used a composite reference standard applied
by a panel of experienced clinicians. The panel followed a strict protocol. In the group of patients with
non-microbiologically defined highly probable TB, there was a rigorous process to ensure that the clinical
panel reviewed all cases using case histories, imaging, other test results and follow-up data to ensure that
categorisation was as accurate as possible. The panel was blinded to the study and routine IGRA results to
avoid potential for bias.
The IDEA study has limitations. First, owing to the low number of bronchoalveolar samples analysed,
we were unable to fully characterise the value of IGRAs using BAL fluid. Therefore, we did not fulfil the
secondary objective of determining the diagnostic accuracy of the two IGRAs applied to BAL samples in
patients with suspected pulmonary TB who were sputum smear negative, as stated in the protocol.
Second, as already alluded to, we did not achieve our recruitment target for the HIV co-infected population.
The IDEA study was extended to facilitate recruitment and more centres were included. We did achieve our
original target of 200 patients, which was based on a prevalence of active TB of 50%. However, the final
diagnosis of active TB in the 201 HIV-positive patients included in the analyses of the substudy was even
lower (32/201, 15.9%) than the 20% used in our revised sample size calculation.
Finally, for the economic evaluation, we found that TB diagnosis rarely followed idealised diagnostic
pathways, implying that costs and time delays until diagnosis may be very different from what economic
analyses typically assume. In particular, costs of diagnosis may be typically underestimated, particularly
when other modalities of imaging apart from plain chest radiology such as CT, ultrasound or magnetic
resonance scanning are involved.
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Implications for health care
Despite the significantly higher diagnostic sensitivity of T-SPOT.TB over QFT-GIT, neither of the two IGRAs
can be used routinely as a reliable rule-out test for suspected active TB in this patient population in
secondary care. Both IGRAs were also not cost-effective in this setting. However, for patients in which
there is a suspicion of TB, but the pre-test probability is low, the NPV of a negative T-SPOT.TB result would
be correspondingly higher.
The specificity of both IGRAs for a diagnosis of active TB was similar and too low to use as a rule-in test.
However, in patients with suspected active TB, a positive IGRA result could help in certain circumstances to
keep TB in the differential diagnosis and guide further diagnostic testing towards confirming or excluding
a diagnosis of TB. A positive result in the setting of a HIV-infected patient with suspected TB provides
clinically useful information, as specificity in this setting was higher than in HIV-negative patients, especially
for QFT-GIT.
The incorporation of novel antigens into T-SPOT.TB, in particular Rv3615c, yielded a high sensitivity
coupled with a modest reduction in specificity. The sensitivity and NPV of 90% in this high-prevalence
population in secondary care are compatible with the use of this assay to exclude a diagnosis of TB in
patients with lower pre-test probabilities. The 95% sensitivity in culture-confirmed TB is similar to that of
the D-dimer assay, which is routinely used as a rapid rule-out test for suspected venous thromboembolism
in patients with a low to moderate pre-test probability.
Notably, replacing ESAT-6 with Rv3615c also conferred higher sensitivity than T-SPOT.TB. Indeed, the
diagnostic sensitivity and NPV of 89% were similar to that achieved by the incorporation of Rv3615c
alongside both ESAT-6 and CFP-10. This observation is relevant for TB control internationally because
one of the leading TB vaccine candidates currently in clinical trials, H56/IC31, incorporates ESAT-6. The
vaccine is protective in the non-human primate model and if it proves to be protective in humans, it is
likely to be licensed. If rolled out, vaccinated individuals will likely develop T-cell responses to ESAT-6,
which would give false-positive IGRA results, akin to the current scenario with BCG vaccination inducing
false-positive TST results. Replacing ESAT-6 with Rv3615c may be a potential solution because a CFP-10-
and Rv3615c-based IGRA would have significantly higher sensitivity than existing IGRAs and specificity
would not be compromised in H56/IC31-vaccinated individuals.
Recommendations for research
The second-generation IGRAs evaluated in this study do not need to be re-evaluated in a UK routine
practice setting because this study enabled an equally rigorous evaluation of these novel assays as it did
for conventional IGRAs. Precise estimates of diagnostic accuracy were obtained. However, it would be of
interest to evaluate these new assays and their combinations in distinct clinical settings with much lower
or much higher prevalence of active TB. It will also be important to assess how these novel IGRAs perform
in immunosuppressed subgroups, including HIV-infected patients, diabetic patients with chronic renal
impairment and those on immunosuppressive therapy. A comparative accuracy study of the novel assays
and QFT-Plus may also be needed to determine how their sensitivity compares in routine practice.
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Appendix 1 Reporting checklist for diagnostic
accuracy studies
TABLE 51 The Standards for Reporting Diagnostic Accuracy Studies (STARD) checklist
Section and
topic Number Item Reported on page number
Title or abstract
1 Identification as a study of diagnostic accuracy using at least
one measure of accuracy (such as sensitivity, specificity,
predictive values or AUC)
vii, viii
Abstract
2 Structured summary of study design, methods, results and
conclusions
vii, viii
Introduction
3 Scientific and clinical background, including the intended
use and clinical role of the index test
1, 2
4 Study objectives and hypotheses 2
Methods
Study design 5 Whether data collection was planned before the index test
and reference standard were performed (prospective study)
or after (retrospective study)
3
Participants 6 Eligibility criteria 3
7 On what basis potentially eligible participants were identified
(such as symptoms, results from previous tests, inclusion in
registry)
3
8 Where and when potentially eligible participants were
identified (setting, location and dates)
3, 15
9 Whether participants formed a consecutive, random or
convenience series
3, Figure 1
Test methods 10a Index test, in sufficient detail to allow replication 5–8
10b Reference standard, in sufficient detail to allow replication 8, 9
11 Rationale for choosing the reference standard (if alternatives
exist)
Not applicable
12a Definition of and rationale for test positivity cut-off points
or result categories of the index test, distinguishing
pre-specified from exploratory
6–8
12b Definition of and rationale for test positivity cut-off points or
result categories of the reference standard, distinguishing
pre-specified from exploratory
Appendix 2
13a Whether clinical information and reference standard results
were available to the performers/readers of the index test
5
13b Whether clinical information and index test results were
available to the assessors of the reference standard
8, 9
continued
DOI: 10.3310/hta23230 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 23
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Takwoingi et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed
to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
99
TABLE 51 The Standards for Reporting Diagnostic Accuracy Studies (STARD) checklist (continued )
Section and
topic Number Item Reported on page number
Analysis 14 Methods for estimating or comparing measures of
diagnostic accuracy
10, 11
15 How indeterminate index test or reference standard results
were handled
11
16 How missing data on the index test and reference standard
were handled
11
17 Any analyses of variability in diagnostic accuracy,
distinguishing pre-specified from exploratory
11
18 Intended sample size and how it was determined 9, 10
Results
Participants 19 Flow of participants, using a diagram 15, 16, Figure 4
20 Baseline demographic and clinical characteristics of
participants
15–21, Tables 3–7,
Appendix 4
21a Distribution of severity of disease in those with the target
condition
22, 23, Table 9
21b Distribution of alternative diagnoses in those without the
target condition
22, 24, Table 10
22 Time interval and any clinical interventions between index
test and reference standard
8
Test results 23 Cross-tabulation of the index test results (or their
distribution) by the results of the reference standard
Tables 11, 13, 20, 22, 37,
38 and 62
24 Estimates of diagnostic accuracy and their precision (such as
95% CIs)
25–41, 54–57, Appendix 13
25 Any adverse events from performing the index test or the
reference standard
Not applicable
Discussion
26 Study limitations, including sources of potential bias,
statistical uncertainty and generalisability
86, 87
27 Implications for practice, including the intended use and
clinical role of the index test
87
Other information
28 Registration number and name of registry Not registered
29 Where the full study protocol can be accessed www.nets.nihr.ac.uk/__data/
assets/pdf_file/0011/51977/
PRO-08-106-02.pdf
30 Sources of funding and other support; role of funders viii
AUC, area under the curve.
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
100
Appendix 2 Composite reference standard for
diagnosis of active tuberculosis
TABLE 52 Diagnostic categories for active TB
Diagnostic category Criteria
1: Culture-confirmed TB Microbiological culture of M. tuberculosis AND suggestive clinical and radiological
findings
2: Highly probable TB Clinical and radiological features highly suggestive of TB and unlikely to be caused
by other disease, AND a decision to treat made by a clinician, AND appropriate
response to therapy AND histology supportive, if available
3: Clinically indeterminate Final diagnosis of TB neither highly probable nor reliably excluded
4: Active TB excluded
Subclassification
4A: inactive TB Stable CXR changes, AND TST positivea (if done), AND bacteriologically negative
(if done) AND no clinical evidence of active disease
4B: one or more risk factors for
TB exposure,a TST positiveb
TST positive,b AND bacteriologically negative (if done) AND no clinical evidence of
active disease
4C: one or more risk factors for
TB exposure,a TST negative
History of TB exposure AND TST negative (if done)
4D: no risk factors for TB
exposure,a TST negative
No history of TB exposure AND TST negative (if done)
CXR, chest radiography.
a Risk factors for TB exposure: recent exposure to active TB patient, born in country of high prevalence or belonging to an
ethnic group with a high prevalence of TB (incidence > 100/100,00026).
b A TST using the Mantoux test, with a threshold of ≥ 15mm considered positive.
Diagnostic categories adapted from Dosanjh et al.3
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Appendix 3 Protocol amendments
TABLE 53 Summary of protocol amendments
Amendment number
(date) Details of changes
AM01
Substantial amendment
(April 2011)
1. Changed title of the project to a more memorable acronym after discussion with the project
team. The new title was ‘IGRA in Diagnostic Evaluation of Active TB’ the ‘IDEA’ project.
The protocol, patient information sheet and consent forms were changed accordingly
2. Addition of two new recruiting sites:
– Heart of England NHS Foundation Trust with Dr Martin Dedicoat as PI
– Sandwell and West Birmingham Hospitals NHS Trust with Dr Naz Nathani as PI
A site-specific information form was submitted for each site and R&D approval was
obtained before commencing recruitment at the sites
3. Because of staff retirement/staff changes, the PIs at three sites changed after our original
submission for ethics approval
AM02
Substantial amendment
(October 2011)
1. Correction of some grammatical and spelling errors in the protocol and patient
information sheet
2. Updates to the contact information in the protocol and patient information sheet to
include the study co-ordinator’s details
3. The following changes were made to the protocol to provide further clarification to sites:
– Insertion of a summary of the eligibility criteria to ensure that this stands out. Eligibility
criteria were previously contained in the text of the protocol
– Addition of table 2 and further text to clarify research sampling time points and time
windows for collection of samples. Baseline research samples must be taken after
informed consent, but no later than 48 hours after the start of treatment for TB or
within 7 days of consent, whichever occurs sooner. Follow-up research samples will be
taken at 2 months (± 7 days) and at 6 months (± 7 days) after recruitment
– Clarification that surplus BAL samples will only be collected at Imperial College NHS
Healthcare Trust, St Mary’s Hospital
– Clarification of the adverse event and serious adverse event reporting procedures to the
study co-ordinator
4. The following changes were made to the patient information sheet:
– Insertion of local research nurse contact details to allow patients to gain further
information on the study. This is in addition to the PI’s details currently present
– The following sentence, ‘This provision does not apply to claims which arise as a result
of HIV/AIDS or any related conditions. This does not affect your legal rights to seek
compensation’, was added to correct the sponsor’s indemnity and insurance
information to reflect that HIV-positive patients will be recruited into the study
5. Update to the consent form to reflect the change in the patient information sheet version
and date
continued
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TABLE 53 Summary of protocol amendments (continued )
Amendment number
(date) Details of changes
AM03
Substantial amendment
(October 2012)
1. Clarification in the protocol that participants with previous history of TB (including
previous TB treatment) are eligible for recruitment
2. Inclusion of instructions to investigators that the minimum diagnostic tests carried out for
diagnosing TB should follow NICE and local guidelines in order to ensure that all sites
assess patients for active TB in the same manner. This was added to section 5.1 under
patient recruitment
3. As a patient’s diagnosis is not known at the point of recruitment, clarified guidance was
added to section 5.4 of the protocol to assist sites in patient follow-up
4. Extension of the follow-up visit time frame to ± 21 days from a specified time point for
the 2-month follow-up and ± 8 days from a specified time point for the 6-month
follow-up
5. Addition of a data collection section to summarise the data collection forms used in
the study
6. Clarification of patient withdrawal as withdrawal of consent only. Patients with a non-TB
diagnosis are not considered as withdrawn from follow-up. Information was provided on
how to report the inability to follow-up patients with a non-TB diagnosis
7. Addition of information about collection of samples of Mycobacteria from culture-positive
diagnostic tests. These samples will be bacteria grown in diagnostic tests. As these
samples are not classified as ‘relevant material’ under the Human Tissue Act49 and are not
samples directly from the patient, additional consent to collect this type of sample is not
required for participants enrolled in the IDEA study
8. Details of the study’s clinical panel that will be responsible for reviewing and confirming all
patient diagnosis outcomes (see protocol section 9.3)
9. The details of the DMC were altered to provide details of the DMG, which will oversee
data collection and disease prevalence. As there is no reason to stop the study on safety
grounds and as there will not be any interim analyses, the DMG was formed as a more
appropriate method of oversight of the data collected instead of a DMC
AM04
Non-substantial
(February 2013)
1. Minor typographical errors were corrected
2. Addition of Ealing Hospital NHS Trust as a site in the study in order to obtain clinical
information for patients recruited during diagnostic procedures performed under referral
at one of our existing sites. The intention is to open this site in order to obtain clinical
details of the patient’s final diagnosis and treatment in these cases. Recruitment of new
participants will also occur at this site
3. Participant recruitment will be extended in order to achieve the 200 HIV-positive,
suspected active TB cases initially set out in the protocol. This will result in the overall
sample size increasing beyond 1012 (HIV and non-HIV infected participants). Extended
recruitment will occur at a reduced number of sites until recruitment targets are achieved.
The following sites will close to recruitment on 31 April 2013 and continue the follow-up
phase until the end of the study:
(a) University Hospitals of Leicester NHS Trust
(b) Oxford University Hospitals NHS Trust
(c) St George’s Healthcare NHS Trust
(d) Frimley Health NHS Foundation Trust
(e) Sandwell and West Birmingham Hospitals NHS Trust
4. Sites remaining open and continuing to recruit as normal include:
(a) London North West Healthcare NHS Trust
(b) Imperial College Healthcare NHS Trust
(c) Royal Free London NHS Foundation Trust
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TABLE 53 Summary of protocol amendments (continued )
Amendment number
(date) Details of changes
AM05
Substantial amendment
(October 2013)
1. From preliminary data, the proportion of HIV-positive patients with a final diagnosis of
active TB is lower than anticipated. Thus, the revised required population size for this
subgroup of HIV-positive patients with suspected active TB is 390, as detailed in a new
paragraph in section 9.2
2. The study was extended by 12 months to achieve this increase in sample size. The study
duration stated in the protocol was therefore increased from 3 to 4 years
3. A number of existing IDEA study sites will stay open for the extension. In addition, four
new sites were added:
– University College London Hospitals NHS Foundation Trust (PI: Dr Robert Miller)
– King’s College Hospital NHS Foundation Trust (PI: Dr Frank Post)
– Barts Health NHS Trust (covering St. Bartholomew’s hospital) (PI: Dr Guy Baily)
– Lewisham and Greenwich NHS Trust (covering Queen Elizabeth Hospital) (PI: Dr
Palchaudhuri Paramita)
4. Dr Melanie Scott, the study co-ordinator, went on maternity leave and so contact details
were added for Dr Hilary Whitworth (maternity cover)
5. Dr Howard Branley was added as the PI for Ealing Hospital NHS Trust and the reasons for
addition of the site were clarified
AM06
Substantial amendment
(April 2014)
1. The lead Research Nurse was changed from Dr Lee Potiphar to Mrs Amarjit Badhan
2. The PI at Barts NHS Trust was changed from Dr Guy Bailey to Dr Rebecca O’Connell
3. The following amendment was made to section 5.3:
In some circumstances, other appropriately qualified staff may carry out recruitment
procedures usually performed by a Research Nurse (identifying patients, taking informed
consent, taking blood, completing CRFs)
4. Minor typographical errors were amended
AM07
Substantial amendment
(February 2015)
1. The following amendments were made to participant follow-up in section 5.4:
– For some patients, additional follow-up data may be collected for up to 2 years if
requested by expert clinical panel)
– Imperial College London, TB Research Centre will hold copies of all consent forms for
patients recruited to the IDEA study and hold their personal-identifiable data. This will
be stored in a locked cabinet in a secured room with limited access
– Recurrence of TB cases within 2 years will be verified from the London Tuberculosis
Register and Enhanced Tuberculosis Surveillance
2. The following amendment was made to data collection in section 5.5:
The study team will retrospectively collate data on patient hospital admissions, including
dates of admission and discharge. This data will be collected by research nurses using
patient notes and hospital inpatient records
3. The study was extended by 10 months to allow for the health economic analysis to be
performed. The revised study end date was 31 December 2015
4. The PI at Ealing Hospital NHS Trust was changed from Dr Howard Branley to
Dr William Lynn
5. The study co-ordinator was changed to Dr Hilary Whitworth
6. Minor typographical errors were amended
AIDS, acquired immunodeficiency syndrome; DMC, Data Monitoring Committee.
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Appendix 4 Country of birth of patients
TABLE 54 Country of birth of all patients included in the analyses
Country of birth
Dosanjh category, n
Total, N
Culture-
confirmed TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
Afghanistan 3 0 0 3 6
Algeria 0 0 0 2 2
Angola 1 0 0 1 2
Antigua and Barbuda 0 0 0 1 1
Argentina 0 0 0 2 2
Bangladesh 4 1 1 13 19
Belarus 0 0 0 1 1
Belgium 1 0 0 0 1
The Plurinational State of
Bolivia
1 0 0 1 2
Brazil 0 0 0 6 6
Burundi 2 0 0 0 2
Cameroon 0 0 0 1 1
Chile 0 0 0 1 1
China 1 0 0 0 1
Colombia 1 0 0 0 1
Democratic Republic of
the Congo
1 0 0 2 3
Cyprus 0 0 0 3 3
Denmark 0 0 0 1 1
Djibouti 0 0 0 1 1
Ecuador 0 0 0 1 1
Egypt 0 0 0 1 1
Eritrea 5 2 3 3 13
Estonia 0 0 0 1 1
Ethiopia 2 2 0 4 8
France 0 0 0 2 2
The Gambia 0 0 0 1 1
Germany 0 0 0 2 2
Ghana 0 1 0 6 7
Grenada 1 0 0 0 1
Guinea-Bissau 0 0 0 1 1
continued
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TABLE 54 Country of birth of all patients included in the analyses (continued )
Country of birth
Dosanjh category, n
Total, N
Culture-
confirmed TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
Hong Kong 1 0 0 1 2
India 117 42 5 62 226
Indonesia 1 0 0 0 1
Iran 0 0 0 5 5
Iraq 1 0 0 4 5
Ireland 4 1 0 6 11
Italy 0 0 1 2 3
Jamaica 5 1 2 6 14
Kazakhstan 1 0 0 0 1
Kenya 5 2 0 19 26
Kuwait 2 0 1 0 3
Libya 1 0 0 0 1
Lithuania 0 0 0 1 1
Malawi 1 2 1 1 5
Mauritius 0 0 0 1 1
Morocco 1 0 0 4 5
Mozambique 0 0 0 1 1
Nepal 7 5 0 5 17
Niger 0 0 0 1 1
Nigeria 7 1 0 4 12
Pakistan 14 8 4 27 53
Philippines 9 5 1 6 21
Poland 1 1 1 10 13
Portugal 1 0 0 2 3
Romania 3 0 2 1 6
Saudi Arabia 0 0 0 1 1
Sierra Leone 0 0 0 3 3
Somalia 10 9 3 16 38
South Africa 1 2 1 5 9
Spain 0 0 1 0 1
Sri Lanka 7 0 1 13 21
Sudan 1 0 0 4 5
Swaziland 0 1 0 1 2
Sweden 0 0 0 1 1
Switzerland 0 0 0 1 1
Syria 0 0 0 1 1
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TABLE 54 Country of birth of all patients included in the analyses (continued )
Country of birth
Dosanjh category, n
Total, N
Culture-
confirmed TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
United Republic of
Tanzania
1 0 1 1 3
Thailand 0 1 0 2 3
Uganda 2 0 1 8 11
UK 32 11 12 138 193
USA 0 2 0 1 3
Uruguay 0 0 0 1 1
Yemen 0 0 0 1 1
Zambia 1 0 0 1 2
Zimbabwe 1 2 1 10 14
Total 261 102 43 439 845
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Appendix 5 Thresholds used by centres for
defining vitamin D status
TABLE 55 Definition of vitamin D status by recruiting centre
Hospital trust
Vitamin D status
Deficient Insufficient Normal
Imperial College Healthcare NHS Trust < 40 nmoI/l 40–70 nmoI/l 70–150 nmoI/l
Heart of England NHS Foundation Trust < 30 nmoI/l Not specified > 49.9 nmoI/l
Chelsea and Westminster Hospital NHS Foundation Trust < 40 nmoI/l 40–70 nmoI/l 70–150 nmoI/l
Royal Free London NHS Foundation Trust < 25 nmoI/l 25–75 nmoI/l > 75 nmol/l
St George’s University Hospitals NHS Foundation Trust < 50 nmoI/l Not specified 50–200 nmoI/l
Frimley Health NHS Foundation Trust < 50 nmoI/l Not specified 50–150 nmoI/l
University Hospitals of Leicester NHS Trust < 25 nmoI/l 25–50 nmoI/l > 50 nmoI/l
London North West Healthcare NHS Trust < 12.5 nmoI/l 12.5–50 nmoI/l 50–140 nmoI/l
Oxford University Hospitals NHS Foundation Trust < 50 nmoI/l Not specified > 50 nmoI/l
Sandwell and West Birmingham Hospitals NHS Trust < 30 nmoI/l 30–50 nmoI/l > 50 nmoI/l
King’s College Hospital NHS Foundation Trust < 20 µg/l Not specified 20–50 µg/l
Barts Health NHS Trust < 30 nmoI/l 30–50 nmoI/l 80–150 nmoI/l
Ealing Hospital < 25 nmoI/l 25–50 nmoI/l 51–163 nmoI/l
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Appendix 6 Interferon gamma release assays and
tuberculin skin test performed in routine workup of
active tuberculosis: main study cohort
TABLE 56 Hospital trusts performing T-SPOT.TB, QFT-GIT and/or the TST in the diagnostic workup of active TB in
all patients
Hospital trust
Tests performed, n
Number of patientsaT-SPOT.TB QFT-GIT TST
Imperial College Healthcare NHS Trust 125 14 87 238
Heart of England NHS Foundation Trust 29 28 21 83
Chelsea and Westminster Hospital NHS Foundation Trust 26 0 0 40
Royal Free London NHS Foundation Trust 1 2 0 41
St George’s University Hospitals NHS Foundation Trust 29 1 29 43
University Hospitals of Leicester NHS Trust 4 22 0 100
London North West Healthcare NHS Trust 2 2 191 257
Oxford University Hospitals NHS Foundation Trust 0 0 0 2
Sandwell and West Birmingham Hospitals NHS Trust 6 2 8 41
Total 222 71 336b 845
a Number of patients included from each centre in the analyses of the IDEA study.
b TST results available for 322 of the 336 patients. Results were missing for four, eight and two patients from Imperial
College Healthcare NHS Trust, London North West Healthcare NHS Trust and Sandwell and West Birmingham Hospitals
NHS Trust, respectively.
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Appendix 7 Additional T-SPOT.TB and QFT-GIT
results in all patients in the main study cohort
TABLE 57 Cross-tabulation of T-SPOT.TB and QFT-GIT results in all patients in main study cohort
T-SPOT.TB, n (%)
Positive Negative Borderline Indeterminate Missing Total
QFT-GIT, n (%)
Positive 234 (73.4) 45 (11.3) 9 (27.3) 13 (22.8) 7 (19.4) 308 (36.4)
Negative 65 (20.4) 307 (76.8) 20 (60.6) 35 (61.4) 6 (16.7) 433 (51.2)
Indeterminate 19 (6.0) 45 (11.3) 4 (12.1) 9 (15.8) 2 (5.6) 79 (9.3)
Missing 1 (0.3) 3 (0.8) 0 (0.0) 0 (0.0) 21 (58.3) 25 (3.0)
Total 319 (100) 400 (100) 33 (100) 57 (100) 36 (100) 845 (100)
TABLE 58 Diagnostic accuracy of T-SPOT.TB and QFT-GIT: sensitivity analyses with borderline T-SPOT.TB
results excluded
Test performance
T-SPOT.TB QFT-GIT
n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
All TB 253/311 81.4 (76.6 to 85.3) 220/327 67.3 (62.0 to 72.1)
Culture-positive TB 185/218 84.9 (79.5 to 89.0) 163/231 70.6 (64.4 to 76.1)
Culture-negative TB 58/83 69.9 (59.3 to 78.7) 48/84 57.1 (46.5 to 67.2)
Smear-positive TB 45/55 81.8 (69.7 to 89.8) 42/56 75.0 (62.3 to 84.5)
Smear-negative TB 169/206 82.0 (76.2 to 86.7) 148/222 66.7 (60.2 to 72.5)
Pulmonary TB 79/105 75.2 (66.2 to 82.5) 79/115 68.7 (59.7 to 76.5)
Extrapulmonary TB 141/169 83.4 (77.1 to 88.3) 113/171 66.1 (58.7 to 72.8)
Specificity for a diagnosis of active TB
Active TB excluded 319/370 86.2 (82.3 to 89.4) 304/378 80.4 (76.1 to 84.1)
Active TB excluded, TST
negative, no risk factors
for LTBI
87/93 93.5 (86.6 to 97.0) 85/91 93.4 (86.4 to 96.9)
Predictive values
PPV 253/304 83.2 (78.6 to 87.0) 220/294 74.8 (69.6 to 79.5)
NPV 319/377 84.6 (80.6 to 87.9) 304/411 74.0 (69.5 to 78.0)
Likelihood ratios
Positive likelihood ratio – 5.90 (4.55 to 7.66) – 3.44 (2.76 to 4.27)
Negative likelihood ratio – 0.22 (0.17 to 0.27) – 0.41 (0.35 to 0.48)
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA results were excluded in
these analyses.
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For T-SPOT.TB, there were 68 test positives out of 93 highly probable TB cases, with a sensitivity (95% CI)
of 73.1% (63.3% to 81.1%). For QFT-GIT, there were 57 test positives out of 96 highly probable TB cases,
with a sensitivity (95% CI) of 59.4% (49.4% to 68.7%). Indeterminate IGRA results were excluded from
all analyses.
TABLE 59 Diagnostic accuracy of T-SPOT.TB and QFT-GIT: sensitivity analyses with indeterminate IGRA results included
Test performance
Test
T-SPOT.TB QFT-GIT
n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
All TB 287/345 83.2 (78.9 to 86.8) 246/353 69.7 (64.7 to 74.2)
Culture-positive TB 213/246 86.6 (81.8 to 90.3) 184/252 73.0 (67.2 to 78.1)
Culture-negative TB 64/88 72.7 (62.6 to 80.9) 53/89 59.6 (49.2 to 69.1)
Smear-positive TB 53/63 84.1 (73.2 to 91.1) 53/67 79.1 (67.9 to 87.1)
Smear-negative TB 192/229 83.8 (78.5 to 88.0) 159/232 68.2 (62.0 to 73.9)
Pulmonary TB 94/120 78.3 (70.2 to 84.8) 89/125 71.2 (62.7 to 78.4)
Extrapulmonary TB 155/183 84.7 (78.8 to 89.2) 127/185 68.6 (61.6 to 74.9)
Specificity for a diagnosis of active TB
Active TB excluded 319/423 75.4 (71.1 to 79.3) 304/425 71.5 (67.1 to 75.6)
Active TB excluded, TST
negative, no risk factors for LTBI
87/111 78.4 (69.8 to 85.0) 85/110 77.3 (68.6 to 84.1)
Predictive values
PPV 287/391 73.4 (68.8 to 77.5) 246/367 67.0 (62.1 to 71.6)
NPV 319/377 84.6 (80.6 to 87.9) 304/411 74.0 (69.5 to 78.0)
Likelihood ratios
Positive likelihood ratio – 3.38 (2.85 to 4.03) – 2.45 (2.07 to 2.89)
Negative likelihood ratio – 0.22 (0.18 to 0.28) – 0.42 (0.36 to 0.50)
Note
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA results were included in
these analyses.
TABLE 60 Comparison of diagnostic accuracy of T-SPOT.TB and QFT-GIT: sensitivity analysis with borderline
T-SPOT.TB results excluded
Test
Number of
test resultsa Sensitivity (95% CI)
Number of
test resultsb Specificity (95% CI)
T-SPOT.TB 311 80.7 (76.1 to 84.7) 370 86.5 (82.7 to 89.6)
QFT-GIT 327 67.3 (62.0 to 72.1) 378 81.1 (76.9 to 84.7)
Ratioc (95% CI); p-value – 1.20 (1.12 to 1.29); < 0.001 – 1.07 (1.02 to 1.12); 0.004
a Number of test results among those with active TB.
b Number of test results among those without active TB.
c Ratio of the sensitivity (or specificity) of T-SPOT.TB to that of QFT-GIT. The natural outputs from GEE models are odds
ratios. Ratios of sensitivities (relative sensitivity) and ratios of specificities (relative specificity) were computed post
estimation of the models. CIs were obtained using the delta method.
Note
Sensitivities and specificities are presented as percentages.
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TABLE 61 Comparison of T-SPOT.TB and QFT-GIT: sensitivity analysis with indeterminate IGRA results included
Test
Number of
test resultsa Sensitivity (95% CI)
Number of
test resultsb Specificity (95% CI)
T-SPOT.TB 345 83.3 (78.9 to 86.8) 386 75.4 (71.1 to 79.3)
QFT-GIT 353 69.7 (64.7 to 74.3) 378 71.6 (67.1 to 75.7)
Ratioc (95% CI); p-value – 1.19 (1.12 to 1.28); < 0.001 – 1.05 (0.98 to 1.13); 0.1
a Number of test results among those with active TB.
b Number of test results among those without active TB.
c The ratio of the sensitivity (or specificity) of T-SPOT.TB to that of QFT-GIT. The natural outputs from GEE models are odds
ratios. Ratios of sensitivities (relative sensitivity) and ratios of specificities (relative specificity) were computed post
estimation of the models. CIs were obtained using the delta method.
Note
Sensitivities and specificities are presented as percentages.
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Appendix 8 Additional T-SPOT.TB and QFT-GIT
results in human immunodeficiency virus-positive
and -negative patients in the main study cohort
TABLE 62 T-SPOT.TB and QFT-GIT results by active TB status in HIV-positive patients in the main study cohort
Index test
result
Dosanjh category
Total1 2 3 4A 4B 4C 4D 4A–D
T-SPOT.TB
Positive 7 5 0 0 0 4 1 5 17
Negative 4 3 2 0 1 42 28 71 80
Borderline 0 0 0 0 0 3 0 0 3
Indeterminate 2 3 0 1 0 11 16 28 33
Missing 0 1 0 0 0 1 0 1 2
Total 13 12 2 1 1 61 45 108 135
Median SFCs
ESAT-6
(range)
10
(0–94)
8
(0–395)
0 0 0 0
(0–42)
0
(0–69)
0
(0–69)
0
(0–395)
Median SFCs
CFP-10
(range)
2
(0–136)
0
(0–315)
0 0 0 0
(0–37)
0
(0–44)
0
(0–44)
0
(0–315)
QFT-GIT
Positive 8 5 0 0 0 5 2 7 20
Negative 5 5 1 1 1 42 36 80 91
Indeterminate 0 2 1 0 0 14 6 20 23
Missing 0 0 0 0 0 0 1 1 1
Total 13 12 2 1 1 61 45 108 135
Median IFN-γ
levels (range)
0.95
(0–3.78)
0.01
(0–10)
0.01
(0–0.02)
0.07 0 0.01
(0–3.82)
0.01
(0–1.56)
0.01
(0–3.82)
0.02
(0–10)
TABLE 63 Cross-tabulation of T-SPOT.TB and QFT-GIT results in HIV-positive patients in main study cohort
T-SPOT.TB, n (%)
Positive Negative Borderline Indeterminate Missing Total
QFT-GIT, n (%)
Positive 13 (76.4) 3 (3.8) 0 4 (12.1) 0 20 (14.8)
Negative 2 (11.8) 60 (75.0) 3 (100.0) 24 (72.7) 2 (100.0) 91 (67.4)
Indeterminate 2 (11.8) 16 (20.0) 0 5 (15.2) 0 23 (17.0)
Missing 0 1 (1.3) 0 0 0 1 (0.7)
Total 17 (100.0) 80 (100.0) 3 (100.0) 33 (100.0) 2 (100.0) 135 (100.0)
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TABLE 64 Diagnostic accuracy of T-SPOT.TB and QFT-GIT in HIV-positive patients in the main study cohort:
sensitivity analyses with indeterminate IGRA results included
Test performance
Test
T-SPOT.TB QFT-GIT
n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
All TB 17/24 70.8 (50.8 to 85.1) 15/25 60.0 (40.7 to 76.6)
Culture-positive TB 9/13 69.2 (42.4 to 87.3) 8/13 61.5 (35.5 to 82.3)
Culture-negative TB 8/11 72.7 (43.4 to 90.3) 7/11 63.6 (35.4 to 84.8)
Smear-positive TB 2/5 40.0 (11.8 to 76.9) 3/5 60.0 (23.1 to 88.2)
Smear-negative TB 11/15 73.3 (48.0 to 89.1) 9/16 56.2 (33.2 to 76.9)
Pulmonary TB 6/8 75.0 (40.9 to 92.9) 5/8 62.5 (30.6 to 86.3)
Extrapulmonary TB 9/12 75.0 (46.8 to 91.1) 7/13 53.8 (29.1 to 76.8)
Specificity for a diagnosis of active TB
Active TB excluded 71/107 66.4 (57.0 to 74.6) 80/107 74.8 (65.8 to 82.0)
Active TB excluded, TST negative,
no risk factors for LTBI
28/45 62.2 (47.6 to 74.9) 36/44 81.8 (68.0 to 90.5)
Predictive values
PPV 17/53 32.1 (21.1 to 45.5) 15/42 35.7 (23.0 to 50.8)
NPV 71/78 91.0 (82.6 to 95.6) 80/90 88.9 (80.7 to 93.9)
Likelihood ratios
Positive likelihood ratio – 2.11 (1.46 to 3.05) – 2.38 (1.51 to 3.76)
Negative likelihood ratio – 0.44 (0.23 to 0.83) – 0.54 (0.33 to 0.88)
Note
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA results were included in these
analyses as test positives.
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TABLE 65 Diagnostic accuracy of T-SPOT.TB and QFT-GIT in HIV-negative patients in the main study cohort:
sensitivity analyses with indeterminate IGRA results included
Test performance
Test
T-SPOT.TB QFT-GIT
n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
All TB 270/321 84.1 (79.7 to 87.7) 231/328 70.4 (65.3 to 75.1)
Culture-positive TB 204/233 87.6 (82.7 to 91.2) 176/239 73.6 (67.7 to 78.8)
Culture-negative TB 56/77 72.7 (61.9 to 81.4) 46/78 59.0 (47.9 to 69.2)
Smear-positive TB 51/58 87.9 (77.1 to 94.0) 50/62 80.6 (69.1 to 88.6)
Smear-negative TB 181/214 84.6 (79.1 to 88.8) 150/217 69.1 (62.7 to 74.9)
Pulmonary TB 88/112 78.6 (70.1 to 85.2) 84/117 71.8 (63.0 to 79.2)
Extrapulmonary TB 146/171 85.4 (79.3 to 89.9) 120/172 69.8 (62.5 to 76.1)
Specificity for a diagnosis of active TB
Active TB excluded 248/316 78.5 (73.6 to 82.7) 224/318 70.4 (65.2 to 75.2)
Active TB excluded, TST negative,
no risk factors for LTBI
59/66 89.4 (79.7 to 94.8) 49/66 74.2 (62.6 to 83.3)
Predictive values
PPV 270/338 79.9 (75.3 to 83.8) 231/325 71.1 (65.9 to 75.7)
NPV 248/299 82.9 (78.3 to 86.8) 224/321 69.8 (64.6 to 74.6)
Likelihood ratios
Positive likelihood ratio – 3.91 (3.15 to 4.85) – 2.38 (1.98 to 2.86)
Negative likelihood ratio – 0.20 (0.16 to 0.26) – 0.42 (0.35 to 0.50)
Note
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA results were included in these
analyses as test positives.
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Appendix 9 Additional T-SPOT.TB and QFT-GIT
results in patients with diabetes mellitus in the main
study cohort
TABLE 67 Cross-tabulation of T-SPOT.TB and QFT-GIT results in patients with diabetes mellitus
T-SPOT.TB, n (%)
Positive Negative Borderline Indeterminate Missing Total
QFT-GIT, n (%)
Positive 18 (66.7) 5 (10.0) 1 (33.3) 2 (50.0) 1 (25.0) 27 (30.7)
Negative 8 (29.6) 41 (82.0) 2 (66.7) 2 (50.0) 1 (25.0) 54 (61.4)
Indeterminate 1 (3.7) 4 (8.0) 0 0 0 5 (5.7)
Missing 0 0 0 0 2 (50.0) 2 (2.3)
Total 27 (100.0) 50 (100.0) 3 (100.0) 4 (100.0) 4 (100.0) 88 (100.0)
TABLE 66 T-SPOT.TB and QFT-GIT results by active TB status in patients with diabetes mellitus in the main study cohort
Index test
result
Dosanjh category
Total1 2 3 4A 4B 4C 4D 4A–D
T-SPOT.TB
Positive 13 3 2 0 2 6 1 9 27
Negative 7 1 4 1 4 27 6 38 50
Borderline 1 0 0 0 0 2 0 2 3
Indeterminate 1 1 2 0 0 0 0 0 4
Missing 0 0 0 0 0 4 0 4 4
Total 22 5 8 1 6 39 7 53 88
Median SFCs
ESAT-6
(range)
8 (0–123) 12
(1–26)
0
(0–4)
0 0
(0–9)
0
(0–83)
0
(0–22)
0
(0–83)
0
(0–123)
Median SFCs
CFP-10
(range)
5
(0–275)
51
(2–103)
1
(0–20)
0 0
(0–20)
0
(0–120)
0
(0–4)
0
(0–120)
1
(0–275)
QFT-GIT
Positive 12 3 2 0 1 8 1 10 27
Negative 10 2 5 1 5 27 4 37 54
Indeterminate 0 0 1 0 0 2 2 4 5
Missing 0 0 0 0 0 2 0 2 2
Total 22 5 8 1 6 39 7 53 88
Median IFN-γ
levels (range)
0.39
(0–10)
1.1
(0.11–5.84)
0.07
(0–3.58)
0 0.01
(0–0.84)
0.01
(0–10)
0
(0–5.92)
0
(0–10)
0.07
(0–10)
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TABLE 68 Diagnostic accuracy of T-SPOT.TB and QFT-GIT in patients with diabetes mellitus in main study cohort:
sensitivity analyses with indeterminate IGRA results included
Test performance
Test
T-SPOT.TB QFT-GIT
n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
All TB 19/27 70.4 (51.5 to 84.2) 15/27 55.6 (37.3 to 72.4)
Culture-positive TB 15/22 68.2 (47.3 to 83.6) 12/22 54.5 (34.7 to 73.1)
Culture-negative TB 4/5 80.0 (37.6 to 96.4) 3/5 60.0 (23.1 to 88.2)
Smear-positive TB 7/9 77.8 (45.3 to 93.7) 6/9 66.7 (35.4 to 87.9)
Smear-negative TB 11/16 68.8 (44.4 to 85.8) 7/16 43.8 (23.1 to 66.8)
Pulmonary TB 5/9 55.6 (26.7 to 81.1) 5/9 55.6 (26.7 to 81.1)
Extrapulmonary TB 11/14 78.6 (52.4 to 92.4) 8/14 57.1 (32.6 to 78.6)
Specificity for a diagnosis of active TB
Active TB excluded 38/49 77.6 (64.1 to 87.0) 37/51 72.6 (59.1 to 82.9)
Active TB excluded, TST negative,
no risk factors for LTBI
6/7 85.7 (48.7 to 97.4) 4/7 57.1 (25.0 to 84.2)
Predictive values
PPV 19/30 63.3 (45.5 to 78.1) 15/29 51.7 (34.4 to 68.6)
NPV 38/46 82.6 (69.3 to 90.9) 37/49 75.5 (61.9 to 85.4)
Likelihood ratios
Positive likelihood ratio – 3.14 (1.76 to 5.57) – 2.02 (1.16 to 3.54)
Negative likelihood ratio – 70.4 (51.5 to 84.2) – 55.6 (37.3 to 72.4)
Note
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA results were included in these
analyses as test positives.
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Appendix 10 Additional results for evaluations of
second-generation interferon gamma release assay in
the main study cohort
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TABLE 69 Diagnostic accuracy of second-generation IGRAs: sensitivity analyses based on all patients in the main study cohort
Test performance
Antigens
Rv3615c Rv3879c Rv3873 Rv2654 ESAT-6 CFP-10
n/N
Estimate
(95% CI) n/N
Estimate
(95% CI) n/N
Estimate
(95% CI) n/N
Estimate
(95% CI) n/N
Estimate
(95% CI) n/N
Estimate
(95% CI)
Sensitivity for a diagnosis of active TB
All TB 274/345 79.4
(74.8 to 83.4)
148/345 42.9
(37.8 to 48.2)
135/345 39.1
(34.1 to 44.4)
146/345 42.3
(37.2 to 47.6)
246/345 71.3
(66.3 to 75.8)
253/345 73.3
(68.4 to 77.7)
Culture-positive TB 208/246 84.6
(79.5 to 88.5)
108/246 43.9
(37.8 to 50.2)
100/246 40.7
(34.7 to 46.9)
108/246 43.9
(37.8 to 50.2)
183/246 74.4
(68.6 to 79.4)
189/246 76.8
(71.2 to 81.7)
Culture-negative TB 57/88 64.8
(54.4 to 73.9)
34/88 38.6
(29.1 to 49.1)
31/88 35.2
(26.1 to 45.6)
3388 37.5
(28.1 to 47.9)
53/88 60.2
(49.8 to 69.8)
56/88 63.6
(53.2 to 72.9)
Smear-positive TB 53/63 84.1
(73.2 to 91.1)
28/63 44.4
(32.8 to 56.7)
26/63 41.3
(30.0 to 53.6)
21/63 33.3
(22.9 to 45.6)
44/63 69.8
(57.6 to 79.8)
47/63 74.6
(62.7 to 83.7)
Smear-negative TB 179/229 78.2
(72.4 to 83.0)
103/229 45.0
(38.7 to 51.5)
88/229 38.4
(32.4 to 44.9)
103/229 45.0
(38.7 to 51.5)
167/229 72.9
(66.8 to 78.3)
169/229 73.8
(67.7 to 79.1)
Pulmonary TB 94/120 78.3
(70.1 to 84.8)
44/120 36.7
(28.6 to 45.6)
37/120 30.8
(23.3 to 39.6)
50/120 41.7
(33.2 to 50.6)
80/120 66.7
(57.8 to 74.5)
82/120 68.3
(59.6 to 76.0)
Extra pulmonary TB 144/183 78.7
(72.2 to 84.0)
84/183 45.9
(38.8 to 53.1)
77/183 42.1
(35.2 to 49.3)
76/183 41.5
(34.6 to 48.8)
134/183 73.2
(66.4 to 79.1)
138/183 75.4
(68.7 to 81.1)
Specificity for a diagnosis of active TB
Active TB excluded 320/423 75.7
(71.3 to 79.5)
359/423 84.9
(81.1 to 88.0)
366/423 86.5
(82.9 to 89.5)
352/423 83.2
(79.4 to 86.5)
339/423 80.1
(76.1 to 83.7)
333/423 78.7
(74.6 to 82.4)
Active TB
excluded, TST
negative, no risk
factors for LTBI
86/111 77.5
(68.9 to 84.3)
90/111 81.1
(72.8 to 87.3)
92/111 82.9
(74.8 to 88.8)
88/111 79.3
(70.8 to 85.8)
87/111 78.4
(69.8 to 85.0)
90/111 81.1
(72.8 to 87.3)
A
PPEN
D
IX
10
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
126
Test performance
Antigens
Rv3615c Rv3879c Rv3873 Rv2654 ESAT-6 CFP-10
n/N
Estimate
(95% CI) n/N
Estimate
(95% CI) n/N
Estimate
(95% CI) n/N
Estimate
(95% CI) n/N
Estimate
(95% CI) n/N
Estimate
(95% CI)
Predictive values
PPV 274/377 72.7
(68 to 76.9)
148/212 69.8
(63.3 to 75.6)
135/192 70.3
(63.5 to 76.3)
146/217 67.3
(60.8 to 73.2)
246/330 74.5
(69.6 to 78.9)
255/343 74.3
(69.5 to 78.7)
NPV 320/391 81.8
(77.7 to 85.4)
359/556 64.6
(60.5 to 68.4)
366/576 63.5
(59.5 to 67.4)
352/551 63.9
(59.8 to 67.8)
339/438 77.4
(73.3 to 81.1)
333/425 78.4
(74.2 to 82.0)
Likelihood ratios
Positive likelihood
ratio
3.26
(2.73 to 3.89)
2.83
(2.19 to 3.66)
2.93
(2.23 to 3.86)
2.52
(1.97 to 3.22)
3.59
(2.93 to 4.40)
3.45
(2.84 to 4.19)
Negative likelihood
ratio
0.27
(0.22 to 0.34)
0.67
(0.61 to 0.74)
0.70
(0.64 to 0.77)
0.69
(0.63 to 0.77)
0.36
(0.30 to 0.43)
0.35
(0.28 to 0.41)
Note
Sensitivity, specificity and predictive values are presented as percentages.
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TABLE 70 Diagnostic accuracy of IGRA combinations with borderline excluded: sensitivity analyses based on all patients in main study cohort
Test performance
Antigen combinations
ESAT-6+ CFP-10+ Rv3615c+ Rv3879c ESAT-6+ CFP-10+ Rv3615c CFP-10+ Rv3615c+ Rv3879c CFP-10+ Rv3615c
n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
All TB 273/306 89.2 (85.2 to 92.2) 273/306 89.2 (85.2 to 92.2) 263/299 88.0 (3.8 to 91.2) 263/301 87.4 (83.1 to 90.7)
Culture-positive TB 203/216 94.0 (90.0 to 96.4) 203/216 94.0 (90.0 to 96.4) 197/211 93.4 (89.2 to 96.0) 197/212 92.9 (88.7 to 95.7)
Culture-negative TB 60/80 75.0 (64.5 to 83.2) 60/80 75.0 (64.5 to 83.2) 57/78 73.1 (62.3 to 81.7) 57/80 71.2 (60.5 to 80.0)
Smear-positive TB 48/51 94.1 (84.1 to 98.0) 48/51 94.1 (84.1 to 98.0) 47/50 94.0 (83.8 to 97.9) 47/50 94.0 (83.8 to 97.9)
Smear-negative TB 183/207 88.4 (83.3 to 92.1) 183/207 88.4 (83.3 to 92.1) 176/202 87.11 (81.8 to 91.1) 176/204 86.3 (80.9 to 90.3)
Pulmonary TB 88/100 88.0 (80.2 to 93.0) 88/100 88.0 (80.2 to 93.0) 85/97 87.6 (79.6 to 92.8) 85/98 86.7 (78.6 to 92.1)
Extra pulmonary TB 148/167 88.6 (82.9 to 92.6) 148/167 88.6 (82.9 to 92.6) 142/164 86.6 (80.5 to 91.0) 142/165 86.1 (80.0 to 90.5)
Specificity for a diagnosis of active TB
Active TB excluded 290/368 78.8 (74.3 to 82.7) 296/370 80.0 (75.6 to 83.8) 296/372 79.6 (75.2 to 83.4) 302/372 81.2 (76.9 to 84.8)
Active TB excluded, TST negative,
no risk factors for LTBI
82/91 90.1 (82.3 to 94.7) 84/92 91.3 (83.8 to 95.5) 84/93 90.3 (82.6 to 94.8) 86/93 92.5 (85.3 to 96.3)
Predictive values
PPV 273/351 77.8 (73.1 to 81.8) 273/347 78.7 (74.1 to 82.7) 263/339 77.6 (72.8 to 81.7) 263/333 79.0 (74.3 to 83.0)
NPV 290/323 89.8 (86.0 to 92.6) 296/329 90.0 (86.2 to 92.8) 296/332 89.2 (85.4 to 92.1) 302/340 88.8 (85.0 to 91.7)
Likelihood ratios
Positive likelihood ratio 4.21 (3.44 to 5.15) 4.46 (3.62 to 5.49) 4.31 (3.51 to 5.28) 4.64 (3.74 to 5.76)
Negative likelihood ratio 0.14 (0.10 to 0.19) 0.13 (0.10 to 0.19) 0.15 (0.11 to 0.21) 0.16 (0.12 to 0.21)
Sensitivity, specificity and predictive values are presented as percentages.
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For both the four-antigen (ESAT-6, CFP-10, Rv3615c and Rv3879c) and three-antigen (ESAT, CFP-10,
Rv3615), there were 70 test positives out of 94 highly probable TB cases with sensitivity (95% CI) of
74.5% (64.8% to 82.2%). For the other three-antigen (CFP-10, Rv3615c, Rv3879c) and two-antigen
combination of CFP-10 and Rv3615, there were 66 test positives out of 93 highly probable TB cases with
sensitivity (95% CI) of 71.0% (61.1% to 79.2%). Indeterminate IGRA results were excluded from
all analyses.
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TABLE 71 Diagnostic accuracy of IGRA combinations: sensitivity analyses based on all patients in main study cohort
Test performance
Antigen combinations
ESAT-6+ CFP-10+ Rv3615c+ Rv3879c ESAT-6+ CFP-10+ Rv3615c CFP-10+ Rv3615c+ Rv3879c CFP-10+ Rv3615c
n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
All TB 312/345 90.4 (86.9 to 93.1) 312/345 90.4 (86.9 to 93.1) 309/345 89.6 (85.9 to 92.4) 307/345 89.0 (85.2 to 91.9)
Culture-positive TB 233/246 94.7 (91.2 to 96.9) 233/246 94.7 (91.2 to 96.9) 232/246 94.3 (90.7 to 96.6) 231/246 93.9 (90.2 to 96.3)
Culture-negative TB 68/88 77.3 (67.5 to 84.8) 68/88 77.3 (67.5 to 84.8) 67/88 76.1 (66.3 to 83.8) 66/88 75.0 (65.0 to 82.9)
Smear-positive TB 60/63 95.2 (86.9 to 98.4) 60/63 95.2 (86.9 to 98.4) 60/63 95.2 (86.9 to 98.4) 60/63 95.2 (86.9 to 98.4)
Smear-negative TB 205/229 89.5 (84.9 to 92.9) 205/229 89.5 (84.9 to 92.9) 203/229 88.6 (83.9 to 92.1) 201/229 87.8 (82.9 to 91.4)
Pulmonary TB 108/120 90.0 (83.3 to 94.2) 108/120 90.0 (83.3 to 94.2) 108/120 90.0 (83.3 to 94.2) 107/120 89.2 (82.3 to 93.6)
Extra pulmonary TB 164/183 89.6 (84.4 to 93.3) 164/183 89.6 (84.4 to 93.3) 161/183 88.0 (82.5 to 91.9) 160/183 87.4 (81.8 to 91.5)
Specificity for a diagnosis of active TB
Active TB excluded 290/423 68.6 (64.0 to 72.8) 296/423 70.0 (65.4 to 74.2) 296/423 70.0 (65.4 to 74.2) 302/423 71.4 (66.9 to 75.5)
Active TB excluded, TST
negative, no risk factors for LTBI
82/111 73.9 (65.0 to 81.2) 84/111 75.7 (66.9 to 82.7) 84/111 75.7 (66.9 to 82.7) 83/111 74.8 (66.0 to 81.9)
Predictive values
PPV 312/445 70.1 (65.7 to 74.2) 312/439 71.1 (66.7 to 75.1) 309/436 70.9 (66.4 to 74.9) 307/428 71.7 (67.3 to 75.8)
NPV 290/323 89.8 (86.0 to 92.6) 296/329 90.0 (86.3 to 92.8) 296/332 89.2 (85.4 to 92.1) 302/340 88.8 (85.0 to 91.8)
Likelihood ratios
Positive likelihood ratio 2.88 (2.49 to 3.33) 3.01 (2.59 to 3.50) 2.98 (2.57 to 3.47) 3.11 (2.66 to 3.63)
Negative likelihood ratio 0.14 (0.10 to 0.19) 0.14 (0.10 to 0.19) 0.15 (0.11 to 0.20) 0.15 (0.11 to 0.21)
Note
Sensitivity, specificity and predictive values are presented as percentages.
A
PPEN
D
IX
10
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
130
TABLE 72 Comparison of sensitivity of novel IGRA combinations and T-SPOT.TB: sensitivity analysis based on all
patients in main study cohort
Test
Number of
test results
Sensitivity
(95% CI)
Relative sensitivitya
(95% CI) p-value
T-SPOT.TB (ESAT-6 + CFP-10) 345 83.3 (79.0 to 86.9) – –
CFP-10 + Rv3615c 345 89.0 (85.2 to 91.9) 1.07 (1.03 to 1.11) < 0.001
CFP-10 + Rv3615c+ Rv3879c 345 89.6 (85.9 to 92.4) 1.08 (1.04 to 1.11) < 0.001
ESAT-6+ CFP-10 + Rv3615c 345 90.4 (86.8 to 93.1) 1.09 (1.05 to 1.12) < 0.001
ESAT-6+ CFP-10 + Rv3615c + Rv3879c 345 90.5 (86.9 to 93.2) 1.09 (1.05 to 1.12) < 0.001
a Sensitivity of the combination test divided by the sensitivity of T-SPOT.TB.
Note
Indeterminate test results were included as test positives.
Sensitivity is presented as a percentage.
TABLE 73 Comparison of specificity of novel IGRA combinations and T-SPOT.TB: sensitivity analysis based on all
patients in main study cohort
Test
Number of
test results
Specificity
(95% CI)
Relative specificitya
(95% CI) p-value
T-SPOT.TB (ESAT-6 + CFP-10) 423 75.4 (71.1 to 79.3) – –
CFP-10 + Rv3615c 423 71.4 (66.9 to 75.5) 0.95 (0.92 to 0.98) 0.002
CFP-10 + Rv3615c+ Rv3879c 423 70.0 (65.4 to 74.2) 0.93 (0.89 to 0.96) < 0.001
ESAT-6+ CFP-10 + Rv3615c 423 70.0 (65.4 to 74.2) 0.93 (0.90 to 0.96) < 0.001
ESAT-6+ CFP-10 + Rv3615c + Rv3879c 423 68.6 (64.0 to 72.8) 0.91 (0.88 to 0.94) < 0.001
a Specificity of the combination test divided by specificity of the T-SPOT.TB.
Note
Indeterminate test results were included as test positives.
Specificity is presented as a percentage.
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TABLE 74 Summary of studies of IGRAs for the diagnosis of active TB published between 1 January 2013 and 16 March 2016
Reference
(author and
year of
publication) Study design Population
Setting
(recruitment period)
Test
T-SPOT.TB QFT-GIT TST
Adewole
et al., 201350
Prospective study of
QFT-GIT compared with
the TST for diagnosis of
pulmonary active TB
61 smear-positive TB cases
[mean age 35.1 years (SD
4.3 years)] and 41 healthy
disease-free controls
[mean age 27.8 years
(SD 2.1 years)] were
enrolled and analysed
Nigeria (full text was
unavailable, so unable
to extract more
information)
NE Sensitivity: 76.0%
(95% CI 61.8% to 85.2%)
Specificity: 63.7%
(95% CI 46.0% to 76.0%)
Indeterminate rate: 3.5%
Sensitivity: 96.6%
(95% CI 88.5% to 98.3%)
Specificity: 30.0%
(95% CI 20.0% to 56.0%)
Jeon et al.,
201351
Retrospective analysis of
laboratory and clinical
records to evaluate
factors associated with
indeterminate and
negative QFT-GIT results
in active TB patients
1301 patients including
168 confirmed active TB
cases [mean age of active
TB cases 54.8 years
(SD 20.1 years)]
Kyung Hee University
Hospital, Seoul, Korea
(September 2009 and
April 2012)
NE Sensitivity: 76.8%
(95% CI 69.8% to 82.5%)
Specificity: 58.3%
(95% CI 55.3% to 61.4%)
Indeterminate rate: 8%
NE
Jia et al.,
201352
Prospective study of
T-SPOT.TB for diagnosis
of osteoarticular TB
145 patients were enrolled
and all were HIV negative.
18 possible cases and
17 indeterminates were
excluded. 86 culture-
confirmed or probable
patients (age range
18–76 years) with
osteoarticular TB and
24 without active TB
(age range 16–80 years)
were analysed
Beijing Chest Hospital,
China (July 2011–June
2012)
Sensitivity: 94.2%
(95% CI 87.1% to 97.5%)
Specificity: 70.8%
(95% CI 50.8% to 85.1%)
No indeterminates
NE NE
Khalil et al.,
201353
Comparison of QFT-GIT
and the TST for the
diagnosis of pulmonary
active TB
50 pulmonary active TB
cases [mean age 41.8 years
(SD 19.0 years)]
Fauji Foundation
Hospital, Rawalpindi,
Pakistan (July 2011–
January 2012)
NE Sensitivity: 80% Sensitivity: 28%
Kim et al.,
201354
Retrospective study of
QFT-GIT for diagnosis of
GUTB
57 patients [mean age
52 years (range 17–88 years)]
with clinical or radiological
features suspicious of GUTB
Urology clinic in Korea
(March 2009–August
2011)
NE Sensitivity: 63.3%
(95% CI 45.5% to 78.1%)
Specificity: 59.3%
(95% CI 40.7% to 75.5%)
NE
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Reference
(author and
year of
publication) Study design Population
Setting
(recruitment period)
Test
T-SPOT.TB QFT-GIT TST
Lagrange
et al., 201330
Prospective study of
QFT-GIT compared with
the TST for diagnosis of
TB, stratified by HIV
infection status
2213 patients were
enrolled. QFT-GIT was
performed for 96 patients
[median age 38.0 years
(IQR 30.5–42.0 years)] with
pulmonary active TB and
180 non-active TB cases. Of
the 276 patients, a TST was
performed in 53 active TB
cases and 82 non-active TB
cases
Nine centres in India
(January 2006–July
2008)
NE HIV positive
Sensitivity: 66.7%
(95% CI 48.2% to 82.0%)
Specificity: 64.8%
(95% CI 50.6% to 77.3%)
HIV negative
Sensitivity: 95.0%
(95% CI 75.1% to 99.9%)
Specificity: 25.0%
(95% CI 10.7% to 44.9%)
Total
Sensitivity: 77.4%
(95% CI 63.8% to 87.7%)
Specificity: 51.2%
(95% CI 39.9% to 62.4%)
Results above are from
135 patients in which data
were available for both
QFT-GIT and the TST
Indeterminate rate among
the 276 patients: 7%
HIV positive
Sensitivity: 51.5%
(95% CI 33.5% to 69.2%)
Specificity: 83.3%
(95% CI 70.7% to 92.1%)
HIV negative
Sensitivity: 85.0%
(62.1% to 96.8%)
Specificity: 57.1%
(95% CI 37.2% to 75.5%)
Total
Sensitivity: 64.2%
(95% CI 49.8% to 76.9%)
Specificity: 74.4%
(95% CI 63.3% to 82.4%)
Threshold: ≥ 10mm
Lavender
et al., 201355
Retrospective review
of clinical records of
patients with QFT-GIT
results for the diagnosis
of active TB
415 QFT-GIT requested, of
which 120 were excluded.
295 patients [median age
40 years (range 16–90 years)]
with and without HIV
infection were analysed
Newcastle upon Tyne
Hospitals, UK (clinical
records of patients who
had QFT-GIT requested
between 29 June 2005
and 28 October 2010)
NE Sensitivity: 71.4%
(95% CI 59.3% to 81.1%)
Specificity: 81.0%
(95% CI 75.5% to 85.6%)
NE
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TABLE 74 Summary of studies of IGRAs for the diagnosis of active TB published between 1 January 2013 and 16 March 2016 (continued )
Reference
(author and
year of
publication) Study design Population
Setting
(recruitment period)
Test
T-SPOT.TB QFT-GIT TST
Lei et al.,
201356
Case–control study of
T-SPOT.TB for differential
diagnosis of intestinal TB
and Crohn’s disease
88 patients with intestinal
TB [mean age 36.2 years
(SD 14.1 years)] and
103 with Crohn’s disease
[mean age 37.0 years
(SD 15.7 years)]
Inflammatory Bowel
Disease Centre,
Zhongnan Hospital,
China (2003–11)
Sensitivity: 86%
(95% CI 75% to 96%)
Specificity: 93%
(95% CI 86% to 99%)
NE Sensitivity: 60%
(95% CI 49% to 71%)
Specificity: 80%
(95% CI 71% to 89%)
Threshold: ≥ 10mm
Liu et al.,
201357
Prospective study of
T-SPOT.TB for diagnosis
of pleural TB
168 patients were enrolled,
but 70 were excluded
because they had no final
diagnosis. 98 subjects with
pleural effusion and no HIV
co-infection were analysed.
55 patients [median age
39 years (range 25–59 years)]
had pleural TB and
43 patients [median age
39 years (range 25–59 years)]
without pleural TB
Beijing Chest Hospital,
China (May 2012–June
2013)
Sensitivity: 92.7%
(95% CI 82.7% to 97.1%)
Specificity: 62.8%
(95% CI 47.9% to 76.0%)
Indeterminate rate: 2%
(These are results from the
analysis of peripheral
blood samples)
NE NE
Lodha et al.,
201358
Prospective study
comparing QFT-GIT with
the TST for diagnosis of
intrathoracic childhood
TB
362 children [median
age 115.5 months
(IQR 73–144 months)]
were enrolled in a RCT
of micronutrient
supplementation in children
with intrathoracic TB
Two tertiary care
hospitals in India
(recruitment period not
reported)
NE Sensitivity: 82.0%
(95% CI 77.8 to 85.6%)
Sensitivity: 93.0%
(95% CI 90.0% to 95.5%)
Threshold: ≥ 10mm
Mahomed
et al., 201359
Prospective study
screening for active TB
in adolescents
6363 adolescents (age range
12–16 years) were screened.
21 had active TB. The TST
and QFT-GIT results were
available for 5071 and 5524
adolescents, respectively
11 high schools in
Worcester, South Africa
(2005–7)
NE Sensitivity: 93.8%
(95% CI 78.8% to 100.0%)
Specificity: 46.8%
(95% CI 36.3% to 57.2%)
Sensitivity: 84.6%
(95% CI 61.9% to 100.0%)
Specificity: 58.1%
(95% CI 49.5% to 66.7%)
Threshold: ≥ 10mm
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Reference
(author and
year of
publication) Study design Population
Setting
(recruitment period)
Test
T-SPOT.TB QFT-GIT TST
Danel et al.,
201429
Nested cohort study of
QFT-GIT for ruling out
active TB in HIV-positive
adults
975 adults in Cote d’Ivoire
(median age 35 years),
25 with active TB on day 0
Nine clinical centres in
Abidjan, Cote d’Ivoire
(March 2008–August
2009)
NE Sensitivity: 88.0%
(95% CI 75.3% to 100.0%)
Specificity: 66.6%
(95% CI 63.6% to 69.6%)
Indeterminate rate: 3%
NE
Fei et al.,
201460
Case–control study of
T-SPOT.TB compared
with the TST for diagnosis
of laryngeal TB
83 patients with laryngeal
TB and 52 patients with
vocal cord polyps as
controls (age range
31–66 years), all without
HIV infection
China (August 2007–
December 2012)
Sensitivity: 90.4%
(95% CI 82.1% 95.0%)
Specificity: 92.3%
(81.8% to 97.0%)
NE Sensitivity: 50.6%
(95% CI 40.1% to 61.1%)
Specificity: 61.5%
(95% CI 48.0% to 73.5%)
Threshold: ≥ 5mm
Garazzino
et al., 201461
Retrospective multicentre
study of children (aged
0–24 months) tested at
least once with QFT-GIT
and/or the TST for active
TB
823 children [median age
13.4 months (range
8.4–18.9 months)], 105
with confirmed TB. Results
for both the TST and
QFT-GIT were available for
616 children
18 paediatric centres in
Italy
NE Sensitivity: 91.1%
Specificity: 98.1%
(Results above are for the
subset of patients with both
the QFT-GIT and TST results)
Indeterminate rate in entire
cohort with QFT-GIT: 4.3%
Sensitivity: 85.1%
Specificity: 97.9%
Threshold: ≥ 5mm
Kim et al.,
201462
Prospective study of
T-SPOT.TB for diagnosis
of active TB
134 patients [mean age
55.9 years (SD 20.2 years)]
suspected of active TB and
62 healthy adults [mean
age 30.6 years (SD 8.5
years)] were consecutively
recruited. All had been BCG
vaccinated at a very young
age. All received T-SPOT.TB
and 53 had TST results
Hallym University
Han-gang Sacred Heart
Hospital, Korea
(June 2008–June 2010)
Sensitivity: 87.8%
(95% CI 74.5% to 94.7%)
Specificity: 44.1%
(95% CI 34.4% to 54.2%)
Specificity in healthy
adults: 75.8%
(63.8% to 84.8%)
NE Sensitivity: 70.0%
(95% CI 48.1% to 85.5%)
Specificity: 48.5%
(95% CI 32.5% to 64.8%)
Specificity in healthy
adults: 40.3%
(95% CI 29.0% to 52.7%)
Threshold: ≥ 10mm
continued
D
O
I:10.3310/hta23230
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2019
VO
L.23
N
O
.23
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2019.This
w
ork
w
as
produced
by
Takw
oingiet
al.under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,the
fullreport)m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:N
IH
R
Journals
Library,N
ationalInstitute
for
H
ealth
Research,Evaluation,Trials
and
Studies
C
oordinating
C
entre,A
lpha
H
ouse,U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,U
K
.
137
TABLE 74 Summary of studies of IGRAs for the diagnosis of active TB published between 1 January 2013 and 16 March 2016 (continued )
Reference
(author and
year of
publication) Study design Population
Setting
(recruitment period)
Test
T-SPOT.TB QFT-GIT TST
Kim et al.,
201463
Prospective study of
QFT-GIT for diagnosis of
miliary TB
44 patients [mean age
64 years (SD 19 years)]
with miliary TB
Kyungpook National
University Hospital,
Daegu, South Korea
(September 2009–July
2013)
NE Sensitivity: 68.2%
(95% CI 53.4% to 80.0%)
Indeterminate rate: 16%
NE
Park et al.,
201464
Retrospective study of
the QFT-GIT and TST for
diagnosis of smear-
negative active PTB
224 sputum smear-negative
PTB suspects, 94 confirmed
as having active PTB [mean
age 46.5 years (SD 20.4
years)] and 130 confirmed
as non-PTB [mean age
56.6 years (SD 18.3 years)].
106 patients received a TST
Gangnam Severance
Hospital, Seoul, Korea
(October 2007–April
2013)
NE Sensitivity: 81.9%
(95% CI 74.1% to 89.7%)
Specificity: 62.3%
(95% CI 54.0% to 70.6%)
Sensitivity: 58.1%
(95% CI 45.8% to 70.4%)
Specificity: 63.6%
(95% CI 49.4% to 77.9%)
Threshold: ≥ 10mm
Sauzullo et al.,
201431
Prospective study of
QFT-GIT in HIV patients
with active TB
44 patients infected with
HIV [median age 42 years
(range 31–62 years)] with
active TB
Department of Public
Health and Infectious
Diseases, Sapienza
University, Rome, Italy
(September 2008–12)
NE Sensitivity: 65.9%
(95% CI 51.1% to 78.1%)
with indeterminates
included as negatives
Indeterminate rate: 22.7%
Sensitivity: 54.5%
(95% CI 40.1% to 68.3%)
Schopfer
et al., 201465
QFT-GIT evaluated in
children with
microbiologically
confirmed TB
52,400 children were
admitted to hospital, of
which 405 children had TB,
including 91 children with
microbiologically confirmed
TB. 81 of these children
were tested with QFT-GIT
Jayavarman VII Hospital,
a large paediatric
referral hospital in
Cambodia (July 2005–
March 2006)
NE Sensitivity: 53.1%
(95% CI 42.3% to 63.6%)
NE
Wang et al.,
201466
Retrospective study of
T-SPOT.TB for diagnosis
of paediatric TB
102 patients with TB, aged
≤ 15 years
China (March 2012–
September 2013)
Sensitivity: 58.8%
(95% CI 49.1% to 67.9%)
NE NE
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Reference
(author and
year of
publication) Study design Population
Setting
(recruitment period)
Test
T-SPOT.TB QFT-GIT TST
Wlodarczyk
et al., 201467
Study of the QFT-GIT
and TST for diagnosis of
PTB
126 adult patients admitted
with a clinical diagnosis of
pneumonia. Of these,
43 were culture positive
[mean age 48.6 years
(SD 18.2 years)], 37 culture
negative [mean age 51.7
years (SD 15.5 years)], and
46 with non-mycobacterial,
community-acquired lung
diseases [mean age 52.7
years (SD 17.3 years)]
Regional Specialised
Hospital of Tuberculosis
and Lung Diseases in
Tuszyn, Poland (January
2010–June 2011)
NE Sensitivity (culture positive):
65.1%
Sensitivity (culture negative):
55.6%
Specificity: 87%
Sensitivity (culture positive):
55.8%
Sensitivity (culture negative):
64.9%
Specificity: 71.7%
Threshold: ≥ 10mm
Aggarwal
et al., 201528
Systematic review and
meta-analysis of IGRAs
for diagnosis of pleural
TB
20 evaluations of T-SPOT.TB
including 1085 subjects; 14
evaluations of QFT assays
including 727 subjects (only
one high-quality study;
considerable heterogeneity)
China, Taiwan, Egypt,
Turkey, South Korea,
Italy, South Africa,
Norway, Italy, Germany
and the Netherlands
(included studies
published between
2007 and 2014)
NE separately. Results
pooled across QFT and
T.SPOT.TB assays
NE separately NE
Anwar et al.,
201568
Retrospective study of
QFT-GIT for diagnosis of
active PTB in hospital
setting
142 cases of confirmed TB
and 226 pneumonia cases
in Saudi Arabia (only
patients with QFT-GIT result
included)
King Abdulaziz Medical
City in Riyadh, Saudi
Arabia (January
2009–December 2013)
NE Sensitivity: 74.6%
(95% CI 66.1% to 81.7%)
Specificity: 76.5%
(95% CI 69.9% to 82.2%)
Indeterminate rate: 11.4%
NE
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TABLE 74 Summary of studies of IGRAs for the diagnosis of active TB published between 1 January 2013 and 16 March 2016 (continued )
Reference
(author and
year of
publication) Study design Population
Setting
(recruitment period)
Test
T-SPOT.TB QFT-GIT TST
Bao et al.,
201569
Prospective study of
performance of QFT-GIT
for diagnosis of TB in
children and adults
60 children and 212 adults
with suspected active TB.
31 had confirmed TB.
HIV-positive patients were
excluded
Children
Shanghai Public Health
Clinical Center and
Children’s Hospital of
Fudan University, China
(December 2010–
August 2011)
Adults
Huashan Hospital of
Fudan University
(December 2010–
December 2011)
NE Children
Sensitivity: 83.9%
(95% CI 66.3% to 94.6%)
Specificity: 88.5%
(95% CI 70.2% to 96.8%)
Adults
Sensitivity: 73.7%
(95% CI 57.8% to 85.2%)
Specificity: 70.4%
(95% CI 62.9% to 77.0%)
Indeterminate rate: 9.1%
NE
Sali et al.,
201570
Retrospective study of
QFT-GIT for diagnosis of
TB infection or disease
in children
621 children with suspected
active TB, screened for
LTBI or clinically healthy,
nationally or internationally
adopted children evaluated
by a national protocol
for immigrants and
nationally/internationally
adopted children, with or
without known history of
contact with adult active
TB cases; 140 active TB
suspects; 19 confirmed
TB cases
Paediatric Infectious
Disease Unit and
Catholic University of
the Sacred Heart–A.
Gemelli Hospital in
Rome, Italy (January
2007–July 2010)
NE Sensitivity: 87.5%
Specificity: 93.6%
Indeterminate rate: 4.2%
NE
(a TST was performed in
less than half of the
patients. Hence, TST
results were not included
in the analysis)
Shin et al.,
201571
Retrospective review
of clinical records to
evaluate use of IGRAs
for diagnosing EPTB in
suspected cases
418 patients with suspected
EPTB in Korea; 324 with
confirmed active EPTB. Only
56 had QFT-GIT results
Gangnam Severance
Hospital in Seoul, South
Korea. (July 2005–June
2012)
NE Sensitivity: 70.2%
(95% CI 56.0% to 81.3%)
Specificity: 66.7%
(95% CI 35.4% to 87.9%)
Sensitivity: 62.1%
(95% CI 42.3% to 79.3%)
Specificity: 87.5%
(95% CI 52.9% to 97.8%)
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Reference
(author and
year of
publication) Study design Population
Setting
(recruitment period)
Test
T-SPOT.TB QFT-GIT TST
Sun et al.,
201572
Prospective study to
evaluate utility of
T-SPOT.TB for diagnosis
of paediatric TB in
hospital setting
117 children with active TB
in China; 413 children with
respiratory tract infection
Beijing Children’s
Hospital (March
2011–June 2014)
Sensitivity: 82.9%
Specificity: 96.1%
Indeterminate rate: 8.5%
NE Sensitivity: 67.5%
Specificity: 75.3
Threshold: ≥ 10mm
Results were also available
for ≥ 5mm and ≥ 15mm
and combinations of TST
with T-SPOT.TB
Wong et al.,
201573
Retrospective chart
analysis for paediatric
patients who underwent
the QFT-GIT and TST
for confirmation of
active TB
70 paediatric patients in
a population with high
uptake of neonatal BCG
vaccination; eight children
had confirmed TB. 47
children had the QFT-GIT
Intermediate-burden
region in Taiwan
(January 2008–June
2014)
NE Sensitivity: 100%
(95% CI 63.1% to 100%)
Specificity: 97.1%
(95% CI 85.1% to 99.9%)
Indeterminate rate: 6.4%
Sensitivity: 62.5%
(95% CI 24.5% to 91.5%)
Specificity: 95.2%
(95% CI 76.2% to 99.9%)
Threshold: ≥ 10mm
Xia et al.,
201574
Prospective study of the
QFT-GIT and TST for
diagnosing PTB
300 PTB, 41 disease
controls and 59 health
community controls were
enrolled
Heilongjiang Province
and south-east Zhejiang
Province, China (May
2010–April 2011)
NE Sensitivity: 80.9%
(95% CI 75.9% to 85.2%)
Specificity: 36.6%
(95% CI 22.1% to 53.1%)
Indeterminate rate: 0.5%
Sensitivity: 79.5%
(95% CI 74.3% to 84.4%)
Specificity: 36.6%
(95% CI 22.1 to 53.1%)
Threshold: ≥ 10mm
Results were also available
for ≥ 5-mm and ≥ 15-mm
thresholds, as well as
combinations with
QFT-GIT
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TABLE 74 Summary of studies of IGRAs for the diagnosis of active TB published between 1 January 2013 and 16 March 2016 (continued )
Reference
(author and
year of
publication) Study design Population
Setting
(recruitment period)
Test
T-SPOT.TB QFT-GIT TST
Uzunhan
et al., 201575
Prospective comparison
of the QFT-GIT and TST
for diagnosis of
childhood TB
53 children with TB (16
culture positive); 92 healthy
children with no risk factors
for TB
Children referred to
hospital paediatric
clinics in Turkey
(recruitment period not
reported)
NE Sensitivity in all TB: 62.3%
Specificity: 97.8%
Sensitivity in all TB: 97.8%
Specificity: 100%
Azghay et al.,
201676
Retrospective analysis
of hospital records to
analyse contribution of
QFT-GIT to TB diagnosis
A total of 395 QFT-GIT
assays were performed for
suspected TB patients
Jean Verdier Hospital in
Bondy, Paris, France
(June 2008–June 2011)
NE Sensitivity: 85%
(95% CI 73% to 92%)
Specificity: 73.3%
(95% CI 68% to 78%)
Indeterminate rate: 11.6%
Sensitivity: 78%
(95% CI 57% to 91%)
Combined test: 92.6%
(95% CI 74% to 99%)
Jia et al.,
201677
Prospective study to
evaluate T-SPOT.TB in
lymph node TB
405 patients with suspected
lymph node TB; 83 with
confirmed TB; 282 with TB
excluded (21 clinically
indeterminate and 19
clinical TB excluded from
analyses)
Beijing Chest Hospital,
China (July 2011–April
2015)
Sensitivity: 90.4%
Specificity: 70.5%
Indeterminate rate: 3.8%
NE NE
EPTB, extrapulmonary tuberculosis; GUTB, genitourinary tuberculosis; IQR, interquartile range; NE, not evaluated; PTB, pulmonary tuberculosis; QFT, QuantiFERON; RCT, randomised
controlled trial; SD, standard deviation.
Note
If 95% CIs were not reported and raw data were available, we calculated 95% CIs using the Wilson method.17,18
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Appendix 12 Key characteristics of patients with
indeterminate QFT-GIT and T-SPOT.TB results
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TABLE 75 Summary of key characteristics studies of patients with indeterminate QFT-GIT and T-SPOT.TB results
Characteristic
Test, n (%)
QFT-GIT T-SPOT.TB
Dosanjh category
Total
Dosanjh category
Total
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
Culture-confirmed
TB
Highly
probable TB
Clinically
indeterminate
Active TB
excluded
All 21 5 6 47 79 12 5 3 37 57
HIV infection status
Positive 0 (0) 2 (40) 1 (16.7) 20 (42.6) 23 (29.1) 2 (16.7) 3 (60) 0 (0) 28 (75.7) 33 (57.9)
Negative 21 (100) 3 (60) 5 (83.3) 27 (57.4) 56 (70.9) 10 (83.3) 2 (40) 3 (100) 9 (24.3) 24 (42.1)
Diabetes
Yes 0 (0) 0 (0) 1 (16.7) 4 (8.5) 5 (6.3) 1 (8.3) 1 (20) 2 (66.7) 0 (0) 4 (7)
No 21 (100) 5 (100) 5 (83.3) 43 (91.5) 74 (93.7) 11 (91.7) 4 (80) 1 (33.3) 37 (100) 53 (93)
Immunosuppressive therapy
Yes 0 (0) 0 (0) 0 (0) 1 (2.1) 1 (1.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
No 21 (100) 5 (100) 6 (100) 46 (97.9) 78 (98.7) 12 (100) 5 (100) 3 (100) 37 (100) 57 (100)
TST statusa
Positive 6 (75) 3 (75) 0 (0) 2 (18.2) 11 (44) 6 (100) 1 (100) 2 (100) 1 (14.3) 10 (62.5)
Negative 2 (25) 1 (25) 2 (100) 9 (81.8) 14 (56) 0 (0) 0 (0) 0 (0) 6 (85.7) 6 (37.5)
BCG scar
Yes 14 (93.3) 4 (100) 4 (66.7) 29 (80.6) 51 (83.6) 10 (100) 3 (75) 3 (100) 21 (67.7) 37 (77.1)
No 1 (6.7) 0 (0) 1 (16.7) 2 (5.6) 4 (6.6) 0 (0) 0 (0) 0 (0) 3 (9.7) 3 (6.3)
Unsure 0 (0) 0 (0) 1 (16.7) 5 (13.9) 6 (9.8) 0 (0) 1 (25) 0 (0) 7 (22.6) 8 (16.7)
BCG vaccinated
Yes 15 (71.4) 4 (80) 6 (100) 36 (76.6) 61 (77.2) 10 (83.3) 4 (80) 3 (100) 31 (83.8) 48 (84.2)
No 6 (28.6) 1 (20) 0 (0) 11 (23.4) 18 (22.8) 2 (16.7) 1 (20) 0 (0) 6 (16.2) 9 (15.8)
a Test positivity based on the stratified threshold.
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Appendix 13 Evaluations of tuberculin skin test
Diagnostic accuracy of tuberculin skin test at different thresholds
At induration thresholds of ≥ 5 mm, ≥ 10 mm and the stratified threshold (≥ 6 mm for unvaccinated and
≥ 15 mm for BCG vaccinated patients), the TST had sensitivities of 95.4% (95% CI 90.9% to 97.8%),
94.8% (95% CI 90.0% to 97.3%) and 93.5% (95% CI 88.4% to 96.4%) in culture-positive and highly
probable active TB patients (Table 76), respectively. In all non-active TB patients, the specificities for
thresholds of ≥ 5 mm, ≥ 10 mm and the stratified threshold were 50.3% (95% CI 42.4% to 58.3%),
55.7% (95% CI 47.7% to 63.4%) and 66.4% (95% CI 58.5% to 73.5%). The TST gave high NPVs at the
three thresholds; the NPV at the stratified threshold was 90.8% (95% CI 83.9% to 94.9%). Sensitivities
were higher for extrapulmonary TB than pulmonary TB. There were large differences in specificity when
analyses were restricted to category 4D non-active TB patients (Table 76), but there was very little change
in the sensitivities when the analyses were limited to culture-positive TB patients. For further results of
sensitivity analyses excluding highly probable (category 2) cases, see Table 77.
TABLE 76 Diagnostic accuracy of the TST at different thresholds
Test performance
Threshold
≥ 5mm ≥ 10mm threshold Stratifieda
n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
All TB 146/153 95.4 (90.9 to 97.8) 145/153 94.8 (90.0 to 97.3) 143/153 93.5 (88.4 to 96.4)
Culture-positive TB 98/104 94.2 (88.0 to 97.3) 98/104 94.2 (88.0 to 97.3) 96/104 92.3 (85.6 to 96.1)
Culture-negative TB 44/45 97.8 (88.4 to 99.6) 43/45 95.6 (85.2 to 98.8) 43/45 95.6 (85.2 to 98.8)
Smear-positive TB 23/26 88.5 (71.0 to 96.0) 23/26 88.5 (71.0 to 96.0) 23/26 88.5 (71.0 to 96.0)
Smear-negative TB 106/110 96.4 (91.0 to 98.6) 105/110 95.5 (89.9 to 98.0) 104/110 94.6 (88.6 to 97.5)
Pulmonary TB 42/47 89.4 (77.4 to 95.4) 42/47 89.4 (77.4 to 95.4) 40/47 85.1 (72.3 to 92.6)
Extrapulmonary TB 89/90 98.9 (93.8 to 99.8) 89/90 98.9 (94.0 to 99.8) 88/90 97.8 (92.3 to 99.4)
Specificity for a diagnosis of active TB
Active TB excluded 75/149 50.3 (42.4 to 58.3) 83/149 55.7 (47.7 to 63.4) 99/149 66.4 (58.5 to 73.5)
Active TB excluded,
TST negative, no
risk factors for LTBI
16/21 76.2 (54.9 to 89.4) 18/21 85.7 (65.4 to 95.0) 21/21 100.0 (84.5 to 100.0)
Predictive values
PPV 146/220 66.4 (59.9 to 72.3) 145/211 68.7 (62.2 to 74.6) 143/193 74.1 (67.5 to 79.8)
NPV 75/82 91.5 (83.4 to 95.8) 83/91 91.2 (83.6 to 95.5) 99/109 90.8 (83.9 to 94.9)
Likelihood ratios
Positive likelihood
ratio
– 1.92 (1.63 to 2.27) – 2.14 (1.78 to 2.57) – 2.79 (2.21 to 3.51)
Negative likelihood
ratio
– 0.09 (0.04 to 0.19) – 0.09 (0.05 to 0.19) – 0.10 (0.05 to 0.18)
a According to BCG vaccination status: ≥ 6 mm for unvaccinated and ≥ 15mm for vaccinated patients.
Note
Sensitivity, specificity and predictive values are presented as percentages.
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Combinations of tuberculin skin test and interferon gamma
release assays
The TST and T-SPOT.TB had a combined sensitivity of 97.7% (95% CI 93.5% to 99.2%) and specificity of
62.0% (95% CI 53.4% to 69.9%). Results were similar for the combination of the TST and QFT-GIT, with a
sensitivity of 96.9% (95% CI 92.4% to 98.8%) and specificity of 59.7% (95% CI 51.1% to 67.8%). Figure 16
shows sequential likelihood ratios for a testing strategy of a TST followed by either T-SPOT.TB or QFT-GIT.
A positive result for both the TST and IGRAs gave positive likelihood ratios of 5.80 (95% CI 3.90 to 10.0) for
TST followed by T-SPOT.TB and 4.77 (95% CI 3.25 to 8.16) for the TST followed by QFT-GIT. When both tests
in a combination were negative, the negative likelihood ratios were 0.04 (95% CI 0.01 to 0.09) for the TST
followed by T-SPOT.TB and 0.05 (95% CI 0.01 to 0 0.11) for the TST followed by QFT-GIT.
In sensitivity analyses excluding highly probable active TB cases (i.e. analyses of only culture-confirmed
active TB cases and all non-active TB cases), the sensitivities and specificities of the combinations were
largely unchanged. The TST and T-SPOT.TB had a combined sensitivity of 97.7% (95% CI 92.1% to
99.4%) and specificity of 62.0% (95% CI 53.4% to 69.9%). For the combination of a TST and QFT-GIT,
sensitivity was 96.6% (95% CI 90.5% to 98.8%) and specificity was 59.7% (95% CI 51.1% to 67.8%).
As can be seen in Figure 17, sequential likelihood ratios were generally similar to those from the analyses
including both cultured-confirmed and highly probable active TB cases (see Figure 16).
TABLE 77 Diagnostic accuracy of the TST: sensitivity analyses excluding highly probable (category 2) active TB cases
Test performance
Threshold
≥ 5mm ≥ 10mm Stratifieda
n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
Culture-positive TB 98/104 94.2 (88.0 to 97.3) 98/104 94.2 (88.0 to 97.3) 96/104 92.3 (85.6 to 96.1)
Smear-positive TB 21/24 87.5 (69.0 to 95.7) 21/24 87.5 (69.0 to 95.7) 21/24 87.5 (69.0 to 95.7)
Smear-negative TB 68/71 95.8 (88.3 to 98.6) 68/71 95.8 (88.3 to 98.6) 66/71 93.0 (84.6 to 97.0)
Pulmonary TB 36/42 85.7 (72.2 to 93.3) 36/40 90.0 (76.9 to 96.0) 34/40 85.0 (70.9 to 92.9)
Extrapulmonary TB 49/50 98.0 (89.5 to 99.6) 49/50 98.0 (89.5 to 99.6) 49/50 98.0 (89.5 to 99.6)
Specificity for a diagnosis of active TB
Active TB excluded 75/149 50.3 (42.4 to 58.3) 83/149 55.7 (47.7 to 63.4) 99/149 66.4 (58.5 to 73.5)
Active TB excluded,
TST negative, no
risk factors for LTBI
16/21 76.2 (54.9 to 89.4) 18/21 85.7 (65.4 to 95.0) 21/21 100.0 (84.5 to 100.0)
Predictive values
PPV 98/172 57.0 (50.0 to 64.1) 98/164 59.8 (52.1 to 67) 96/146 65.8 (57.7 to 73.0)
NPV 75/81 92.6 (84.8 to 96.6) 83/89 93.3 (86.1 to 96.9) 99/107 92.5 (85.9 to 96.2)
Likelihood ratios
Positive likelihood
ratio
– 1.90 (1.60 to 2.25) – 2.13 (1.77 to 2.56) – 2.75 (2.18 to 3.47)
Negative likelihood
ratio
– 0.12 (0.05 to 0.25) – 0.10 (0.05 to 0.23) – 0.12 (0.06 to 0.23)
a According to BCG vaccination status: ≥ 6 mm for unvaccinated and ≥ 15mm for vaccinated patients.
Notes
Sensitivity, specificity and predictive values are presented as percentages. Exclusion of category 2 active TB cases does not
affect estimation of specificities. Specificities were included in this table merely for completeness.
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T-SPOT.TB+
TST+ and T-SPOT.TB+
ATB
Not 
ATB
LR = 2.14 
(95% CI 1.59 to 3.19)
n = 131, LR = 5.80 
(95% CI 3.90 to 10.00)
TST+ T-SPOT.TB+ 112 19 131
LR = 2.71 
(95% CI 2.16 to 3.41)
T-SPOT.TB– 12 26 38
124 45 169 T-SPOT.TB–
TST+ and T-SPOT.TB–
ATB
Not 
ATB
LR = 0.17 
(95% CI 0.09 to 0.30)
n = 38, LR = 0.45 
(95% CI 0.23 to 0.83)
TST+ 124 45 169
TST– 7 84 91
131 129 260 T-SPOT.TB+
TST– and T-SPOT.TB+
ATB
Not 
ATB
LR = 12.00 
(95% CI 4.20 to 56.7)
n = 8, LR = 0.98 
(95% CI 0.10 to 6.00)
TST– T-SPOT.TB+ 4 4 8
LR = 0.08 
(95% CI 0.03 to 0.15)
T-SPOT.TB– 3 80 83
7 84 91 T-SPOT.TB–
TST– and T-SPOT.TB–
LR = 0.45 
(95% CI 0.15 to 0.81)
n = 83, LR = 0.04 
(95% CI 0.01 to 0.09)
(a)
FIGURE 16 Diagnostic performance of combinations of the TST with T-SPOT.TB or QFT-GIT. The analyses were based on 260 patients in whom results were available for both
the TST and T-SPOT.TB, and for both the TST and QFT-GIT. Those with indeterminate IGRA results were excluded from the analyses. The likelihood ratios are presented with
95% CIs. The stratified threshold was used to determine the positivity of the TST. (a) A sequence of testing in which T-SPOT.TB follows the TST; and (b) a sequence of testing
in which QFT-GIT follows the TST. The difference in the CI of the positive likelihood ratio for the TST is due to stochastic variation in the bootstrap method used for the
computation of the likelihood ratios. ATB, active tuberculosis; LR, likelihood ratio. (continued )
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QFT-IT+
(b) TST+ and QFT-IT+ 
ATB
Not 
ATB
LR = 1.76 
(95% CI 1.26 to 2.68) 
n = 111, LR = 4.77 
(95% CI 3.25 to 8.16)
TST+ QFT-IT+ 92 19 111
LR = 2.71 
(95% CI 2.15 to 3.50)
QFT-IT– 32 26 58
124 45 169 QFT-IT–
TST+ and QFT-IT –
ATB
Not 
ATB
LR = 0.45 
(95% CI 0.29 to 0.66)
n = 58, LR = 1.21 
(95% CI 0.78 to 2.02)
TST+ 124 45 169
TST– 7 84 91
131 129 260 QFT-IT+
TST– and QFT-IT+
ATB
Not 
ATB
LR = 5.14 
(95% CI 1.32 to 15.6) 
n = 10, LR = 0.42 
(95% CI 0.00 to 1.47)
TST– QFT-IT+ 3 7 10
LR = 0.08 
(95% CI 0.03 to 0.15)
QFT-IT– 4 77 81
7 84 91 QFT-IT–
TST– and QFT-IT–
LR = 0.62 
(95% CI 0.21 to 0.96) 
n = 81, LR = 0.05 
(95% CI 0.01 to 0.11)
FIGURE 16 Diagnostic performance of combinations of the TST with T-SPOT.TB or QFT-GIT. The analyses were based on 260 patients in whom results were available for both
the TST and T-SPOT.TB, and for both the TST and QFT-GIT. Those with indeterminate IGRA results were excluded from the analyses. The likelihood ratios are presented with
95% CIs. The stratified threshold was used to determine the positivity of the TST. (a) A sequence of testing in which T-SPOT.TB follows the TST; and (b) a sequence of testing
in which QFT-GIT follows the TST. The difference in the CI of the positive likelihood ratio for the TST is due to stochastic variation in the bootstrap method used for the
computation of the likelihood ratios. ATB, active tuberculosis; LR, likelihood ratio.
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T-SPOT.TB+
TST+ and T-SPOT.TB+
ATB
Not 
ATB
LR = 2.16 
(95% CI 1.60 to 3.33)
n = 94, LR = 5.79 
(95% CI 4.18 to 10.6)
TST+ T-SPOT.TB+ 75 19 94
LR = 2.67 
(95% CI 2.21 to 3.64)
T-SPOT.TB– 7 26 33
82 45 127 T-SPOT.TB–
TST+ and T-SPOT.TB–
ATB
Not 
ATB
LR = 0.15 
(95% CI 0.06 to 0.29)
n = 33, LR = 0.39 
(95% CI 0.15 to 0.80)
TST+ 82 45 127
TST– 6 84 90
88 129 217 T-SPOT.TB+
TST– and T-SPOT.TB+
ATB
Not 
ATB
LR = 14.00 
(95% CI 4.22 to 59.30)
n = 8, LR = 1.47 
(95% CI 0.25 to 7.42)
TST– T-SPOT.TB+ 4 4 8
LR = 0.10 
(95% CI 0.04 to 0.19)
T-SPOT.TB– 2 80 82
6 84 90 T-SPOT.TB–
TST– and T-SPOT.TB–
LR = 0.35 
(95% CI 0.13 to 0.72)
n = 82, LR = 0.04 
(95% CI 0.02 to 0.10)
(a)
FIGURE 17 Diagnostic performance of combinations of the TST with T-SPOT.TB or QFT-GIT: sensitivity analyses excluding highly probable TB cases. The analyses were based on
217 patients in whom results were available for both the TST and T-SPOT.TB, and for both the TST and QFT-GIT. Those with highly probable active TB were excluded from the
analyses. The likelihood ratios are presented with 95% CIs. The stratified threshold was used to determine the positivity of the TST. The difference in the CI of the positive
likelihood ratio for the TST is due to stochastic variation in the bootstrap method used for the computation of the likelihood ratios. (a) A sequence of testing in which
T-SPOT.TB follows the TST; and (b) a sequence of testing in which QFT-GIT follows the TST. (continued )
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QFT-IT+
(b) TST+ and QFT-IT+ 
ATB
Not 
ATB
LR = 1.70 
(95% CI 1.22 to 2.60) 
n = 78, LR = 4.55 
(95% CI 3.10 to 7.74)
TST+ QFT-IT+ 59 19 78
LR = 2.67 
(95% CI 2.14 to 3.53)
QFT-IT– 23 26 49
82 45 127 QFT-IT– TST+ and QFT-IT –
ATB
Not 
ATB
LR = 0.49 
(95% CI 0.31 to 0.75)
n = 49, LR = 1.30 
(95% CI 0.82 to 2.38)
TST+ 82 45 127
TST– 6 84 90
88 129 217 QFT-IT+ TST– and QFT-IT+
ATB
Not 
ATB
LR = 6.00 
(95% CI 1.69 to 19.40) 
n = 10, LR = 0.63 
(95% CI 0.00 to 2.12)
TST– QFT-IT+ 3 7 10
LR = 0.10 
(95% CI 0.04 to 0.19)
QFT-IT– 3 77 80
6 84 91 QFT-IT– TST– and QFT-IT–
LR = 0.55 
(95% CI 0.20 to 0.92) 
n = 80, LR = 0.05 
(95% CI 0.01 to 0.11)
FIGURE 17 Diagnostic performance of combinations of the TST with T-SPOT.TB or QFT-GIT: sensitivity analyses excluding highly probable TB cases. The analyses were based on
217 patients in whom results were available for both the TST and T-SPOT.TB, and for both the TST and QFT-GIT. Those with highly probable active TB were excluded from the
analyses. The likelihood ratios are presented with 95% CIs. The stratified threshold was used to determine the positivity of the TST. The difference in the CI of the positive
likelihood ratio for the TST is due to stochastic variation in the bootstrap method used for the computation of the likelihood ratios. (a) A sequence of testing in which
T-SPOT.TB follows the TST; and (b) a sequence of testing in which QFT-GIT follows the TST.
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Appendix 14 Additional results in the human
immunodeficiency virus-positive substudy cohort
TABLE 78 Hospital trusts performing T-SPOT.TB. The QFT-GIT and/or TST in the diagnostic workup of active TB in
the HIV-positive substudy cohort
Hospital trust
Number of tests performed Number of
patients
analysedaT-SPOT.TB QFT-GIT TST
Imperial College Healthcare NHS Trust 19 1 4 54
The Heart of England NHS Foundation Trust 3 0 0 6
Chelsea and Westminster Hospital NHS Foundation Trust 24 0 0 40
Royal Free London NHS Foundation Trust 6 3 5 53
St George’s University Hospitals NHS Foundation Trust 0 0 0 5
King’s College Hospital NHS Foundation Trust 0 0 0 2
University Hospitals of Leicester NHS Trust 0 2 0 23
London North West Healthcare NHS Trust 0 0 3 6
Oxford University Hospitals NHS Foundation Trust 0 0 0 4
Sandwell and West Birmingham Hospitals NHS Trust 0 0 0 1
Barts Health NHS Trust 3 0 0 7
Total 55 6 12 201
a Number of patients included from each centre in the analyses of the IDEA study.
TABLE 79 Cross-tabulation of T-SPOT.TB and QFT-GIT results in the HIV-positive substudy cohort
T-SPOT.TB, n (%)
Positive Negative Borderline Indeterminate Missing Total
QFT-GIT, n (%)
Positive 19 (65.5) 4 (3.6) 1 (10.0) 5 (11.1) 0 29 (14.4)
Negative 6 (20.7) 82 (73.9) 9 (90.0) 30 (66.7) 5 (83.3) 132 (65.7)
Indeterminate 4 (13.8) 24 (21.6) 0 10 (22.2) 1 (16.7) 39 (19.4)
Missing 0 1 (0.9) 0 0 0 1 (0.5)
Total 29 (100.0) 111 (100.0) 10 (100.0) 45 (100.0) 6 (100.0) 201 (100.0)
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TABLE 80 Diagnostic accuracy of T-SPOT.TB and QFT-GIT in the HIV-positive substudy cohort: sensitivity analyses
with indeterminate IGRA results included
Test performance
Test
T-SPOT.TB QFT-GIT
n/N Estimate (95% CI) n/N Estimate (95% CI)
Sensitivity for a diagnosis of active TB
All TB 23/31 74.2 (56.8 to 86.3) 19/32 59.4 (42.3 to 74.5)
Culture-positive TB 13/18 72.2 (49.1 to 87.5) 11/18 61.1 (38.6 to 79.7)
Culture-negative TB 10/13 76.9 (49.7 to 91.8) 8/13 61.5 (35.5 to 82.3)
Smear-positive TB 5/9 55.6 (26.7 to 81.1) 6/9 66.7 (35.4 to 87.9)
Smear-negative TB 14/18 77.8 (54.8 to 91.0) 10/19 52.6 (31.7 to 72.7)
Pulmonary TB 10/13 76.9 (49.7 to 91.8) 9/13 69.2 (42.4 to 87.3)
Extrapulmonary TB 11/14 78.6 (52.4 to 92.4) 7/15 46.7 (24.8 to 69.9)
Specificity for a diagnosis of active TB
Active TB excluded 101/160 63.1 (55.4 to 70.2) 117/164 71.3 (64.0 to 77.7)
Active TB excluded, TST
negative, no risk factors
for LTBI
42/66 63.6 (51.6 to 74.2) 54/67 80.6 (69.6 to 88.3)
Predictive value
PPV 23/82 28.0 (19.5 to 38.6) 19/66 28.8 (19.3 to 40.6)
NPV 101/109 92.3 (86.2 to 96.2) 117/130 90.0 (83.6 to 94.1)
Likelihood ratios
Positive likelihood ratio – 2.01 (1.51 to 2.69) – 2.07 (1.42 to 3.01)
Negative likelihood ratio – 0.41 (0.22 to 0.75) – 0.57 (0.37 to 0.88)
Note
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA results were included these
analyses as test positives.
TABLE 81 Comparison of T-SPOT.TB and QFT-GIT in the HIV-positive substudy cohort: sensitivity analysis with
indeterminate IGRA results included
Test
Number of
test resultsa Sensitivity (95% CI)
Number of
test resultsb Specificity (95% CI)
T-SPOT.TB 31 73.4 (55.4 to 86.0) 160 63.2 (55.4 to 70.3)
QFT-GIT 32 59.4 (41.6 to 75.0) 164 71.4 (64.0 to 77.8)
Ratio (95% CI);c p-value – 1.23 (0.94 to 1.63); 0.1 – 0.88 (0.77 to 1.03); 0.1
a Number of test results among those with active TB.
b Number of test results among those without active TB.
c The ratio of the sensitivity (or specificity) of T-SPOT.TB to that of QFT-GIT. The natural outputs from GEE models are
odds ratios. Ratios of sensitivities (relative sensitivity) and ratios of specificities (relative specificity) were computed post
estimation of the models. CIs were obtained using the delta method.
Note
Sensitivities and specificities are presented as percentages.
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